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Cancer 
(Under the direction of Cyrus Vaziri) 
 
Cancer cells rely on DNA damage tolerance pathways to cope with intrinsic 
oncogenic stresses and evade DNA-damaging environmental and therapeutic agents. 
However, the mechanisms by which neoplastic cells hijack tightly controlled DNA 
damage tolerance-signaling cascades to promote mutagenesis and chemoresistance 
are not understood. Thus, limitations in our knowledge of DNA damage tolerance and 
mutagenesis impede effective prevention and treatment of cancer. We have discovered 
two unique regulators of RAD18 and replication-associated DNA damage tolerance that 
are overexpressed in cancer: RNF168 (an apical mediator of double strand break 
signaling) and MAGEA4 (a cancer cell-specific protein with no known function). RNF168 
is mutated in human RIDDLE syndrome, a disease characterized by severe 
immunodeficiency, developmental defects, radiosensitivity and a predisposition to 
cancer. We show here that RNF168 is a novel component of the RAD18 complex, 
facilitating its recruitment to stalled replication forks and promoting damage tolerance 
following replication stress. We have also identified the cancer/testis antigen (CTA) 
MAGEA4 as a stabilizing binding partner of RAD18 that promotes trans-lesion DNA 
synthesis. Thus, the findings in this thesis offer neomorphic cancer cell-specific roles for 
regulators of DNA damage tolerance. 
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Identification of mechanisms of DNA damage tolerance that drive carcinogenesis 
and confer chemoresistance will allow for the development of more effective cancer 
treatment regimens. CTAs are absent from normal somatic cells but aberrantly 
overexpressed in many cancers. Interestingly, CTAs have been correlated with 
chemotherapeutic resistance and poor prognostic outcomes, though their contributions 
to carcinogenesis are not understood. We have found that depletion of several CTAs 
(MAGEA4, MAGEA10, or HORMAD1) sensitizes non-small cell lung cancer (NSCLC) 
cells to DNA-damaging therapies. These studies identify novel mechanisms by which 
NSCLC cells aberrantly overexpress germ cell proteins to alter genome maintenance, 
offering a cancer cell-specific mechanism by which neoplastic cells acquire 
chemoresistance and evade therapy. Accordingly, these CTAs are promising 
therapeutic targets whose inhibition should be innocuous to normal somatic cells while 
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CHAPTER 1: INTRODUCTION 
 
1.1  DNA damage 
Genome instability is a hallmark of cancer and the driving force behind the severe 
clinical phenotypes seen in many genetic diseases. Genome integrity is maintained 
cellular processes that process the tens of thousands of DNA damaging events each 
human cell is thought to experience daily1. Genome instability is caused Such DNA 
damage can be induced by exogenous agents including compounds in food items, 
chemical additives as well common pollutants such as polycyclic aromatic 
hydrocarbons, which are byproducts of combustion2. There are also several 
endogenously derived compounds such as formaldehyde or reactive oxygen species 
(ROS) that are produced during cellular metabolism, that can also have deleterious 
effects on DNA3-5.  
Not only are genotoxins derived from innumerable sources, they also induce a wide 
array of lesion types including but not limited to bulky adducts, double-stranded DNA 
breaks (DSBs) and inter-strand crosslinks (ICL), with each lesion repaired via a distinct 
mechanism. Briefly, bulky DNA adducts are tolerated through a low fidelity mechanism 
known as trans-lesion synthesis (TLS) which employs specialized polymerases to 
synthesize across the damaged template. Bulky lesions can also trigger an error-free 
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template-switching (TS) mechanism that utilizes information of a nascent sister 
chromatid as a replication template6, 7. 
Double strand breaks are the full cleavage of the sugar-phosphate backbone of 
double stranded DNA, yielding terminal DNA end structures which are primarily repaired 
by non-homologous end-joining (NHEJ) or by homologous recombination (HR). During 
NHEJ a Ku70/Ku80 heterodimer detects the break and is loaded onto each end, 
recruiting downstream repair proteins that ultimately result in the ligation of the two ends 
and restoration of genetic continuity8, 9. During HR DSB ends are recognized by the 
MRE11-RAD50-NBS1 (MRN) complex which activates a signaling cascade to initiate 
end resection and Rad51-mediated strand invasion. The undamaged sister chromatid or 
homologous allele is then used as a template for DNA synthesis10. Finally, ICLs activate 
the Fanconi Anemia (FA) pathway proteins, which detect, recruit and coordinate repair 
factors (including those involved in DSB repair) to ICL11. 
Of note, many repair mechanisms rely on information from an undamaged sister 
chromatid or homologous chromosome to perform high fidelity repair (TS, HR). Utilizing 
an undamaged template avoids aberrant alteration of the genetic information, however, 
undamaged templates are not always available. Thus, template-independent pathways 
(NHEJ, TLS) often coincide with mutagenesis.  
1.2  The DNA Damage Response  
1.2.1  DNA Damage Tolerance  
Accurate replication of DNA is crucial for cell survival and maintenance of genome 
stability. Cells have thus developed mechanisms to cope with frequent genotoxic 
injuries that interfere with DNA synthesis. During DNA replication the double helix must 
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be unwound to expose single stranded DNA (ssDNA), which is used as a template to 
synthesize daughter strands. DNA unwinding is carried out by a helicase (MCM2-7 
complex) and is strictly coupled with high fidelity replicative DNA polymerases (ε, δ, α) 
in order to avoid the generation of vulnerable, long stretches of ssDNA. Together these 
core components form a two-pronged fork structure termed the ‘replication fork.’ During 
normal conditions the replicative DNA polymerases (Polε on the leading strand, Polδ 
and Polα on the lagging strand) are able to rapidly duplicate DNA in an accurate 
manner. However, these polymerases are unable to bypass most DNA lesions, which 
can result in ‘replication fork stalling’. Left unresolved, fork stalling can lead to 
replication fork collapse and the formation of the most severe type of DNA lesion, DNA 
double stranded breaks. Lesions encountered during DNA replication are often tolerated 
by replication-associated DNA damage tolerance mechanisms. There are two 
predominant replication-associated DNA damage tolerance mechanisms pathways: 
error-prone TLS, which uses specialized polymerases to synthesizes across a lesion 
and TS, which uses a newly synthesized sister chromatid as a template for error-free 
bypass.  
1.2.1.1 Trans-lesion synthesis  
During normal DNA synthesis, cells utilize canonical replicative DNA polymerases 
that are able to rapidly duplicate DNA in an accurate and efficient manner. Damaged 
DNA, however, can act as a physical barrier that prevents bypass by replicative DNA 
polymerases. One the mechanisms used to tolerate this obstruction is TLS, which 
employs trans-lesion DNA polymerases to replicate damaged DNA templates. TLS is 
initiated when Proliferating Cell Nuclear Antigen (PCNA) is mono-ubiquitinated in 
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response to DNA damage. PCNA is a homotrimeric protein that acts as a sliding clamp 
and docking site for DNA polymerases12-14. Monoubiquitination (mub) of PCNA is carried 
out by one of multiple E3 ubiquitin ligases, although with regards to TLS activation, is 
thought to be predominantly catalyzed by RAD18. E3 ubiquitin ligase activity requires 
the cooperation of the appropriate E2 ubiquitin conjugating enzyme and a universally 
employed E1 ubiquitin activating enzyme15. Replication fork stalling causes uncoupling 
of the helicase and replicative DNA polymerase and generates long stretches of ssDNA. 
Replication Protein A (RPA) coats the ssDNA, activating the s-phase checkpoint and 
recruiting RAD18 to the lesion site. RAD18 works as a part of a heterotrimeric complex 
with its E2 ubiquitin conjugating enzyme RAD6 (RAD182:RAD61) to mub-PCNA and 
induce a ‘polymerase switch’ from the replicative polymerases to TLS polymerases 
(Polη, Polκ, Polι, Polζ and Rev1), which have a higher affinity for the mub-PCNA 
substrate16, 17. These TLS polymerases have enlarged catalytic sites that are able to 
accommodate bulky DNA lesions18.  
While TLS is inherently error-prone, trans-lesion polymerases are capable of high-
fidelity bypass of so-called ‘cognate lesions’. Polη, for example, is able to synthesize 
across helix-distorting thymine homodimers generated from UV radiation in an error-free 
manner, where Polκ would be error-prone. Benzo[a]pyrene, a product of combustion, is 
metabolically activated in cells to generate the DNA-adducting species BPDE, which 
Polκ, but not Polη, can bypass with high fidelity16, 19-28. 
1.2.1.2 Template switching 
Template switching is an error-free post-replication repair mechanism that utilizes a 
newly synthesized daughter strand as a template to bypass the DNA lesion. Initial work 
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on TS was generated from a series of studies in yeast showing that poly-ubiquitination 
of PCNA by RAD5 promoted replication between partially replicated sister chromatids 29-
34. In human, two RAD5 homologs have been identified: helicase-like transcription factor 
(HLTF) and SNF2 Histone-linker PHD-finger RING-finger Helicase (SHPRH), which can 
both poly-ubiquitinate PCNA in vitro35-38. Interestingly, damage-specific roles for HLTF 
and SHPRH have also been identified in the high fidelity tolerance of UV and MMS 
lesions, respectively. HLTF and SHPRH may also have acquired additional function in 
facilitating choosing correct TLS polymerase in response to various DNA damage39. 
Some studies have also suggested that HLTF translocase activity may contribute to 
template switching via a fork reversal mechanism in which newly-synthesized strands of 
DNA are annealed back together, forming a ‘chicken foot’ structure40-44. Fork reversal 
may also be mediated by ZRANB3, which utilizes poly-ubiquitinated PCNA to locate 
damage sites in vivo. ZRANB3 deficient cells are sensitive to methyl methanesulfonate 
(MMS), a potent chemotherapeutic and replication fork-stalling agent, but not 
Camptothecin, Hydroxyurea, H2O2 or UV45. 
It should be noted that the ubiquitin ligase RAD18, previously described as the 
activator of TLS, is also a key mediator of TS. RAD18 not only mub-PCNA, allowing for 
further extension of K63-linked poly-ubiquitin chains by the RAD5 homologs, but also 
mediates damage-specific responses of HLTF and SHPRH through direct binding39, 46. 
Importantly, RAD18 can exist in both ubiquitinated (non-active) and non-ubiquitinated 
(active) forms. Ubiquitinated RAD18 lacks the ability to interact with HLTF or SHPRH, is 
unable to ub-PCNA or form foci and can no longer prevent mutagenesis following 
exposure to DNA damaging agents47. RAD18 can additionally be regulated by 
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phosphorylation, stabilization and controlled expression, as well as sub-cellular 
distribution48-53. Thus may proteins can alter RAD18 function, significantly impacting 
DNA damage tolerance and cell fate.  
1.2.1.3 Fanconi Anemia pathway 
The FA pathway was identified through the investigation of a rare genetic instability 
disorder by the same name. Patients with FA usually have some combination of aplastic 
anemia, physical abnormalities and are at a 10-30% increased risk for cancer.  The 
heterogeneity of the disease caused by a defect in one of 19 associated FANC genes 
that regulate genome maintenance11.  
The first mechanistic details of FA pathway activation were characterized in its 
response to cross-linking agents. Briefly, FANCM-MHF1-MHF2 identifies the lesion and 
recruits the FA Core (FANCs A-C, E-G, L, M and associated proteins) and ID2 (FANCI, 
FANCD2) complexes. Monoubiquitination of the ID2 heterodimer by the core complex is 
considered an initiating event for FA pathway activation. This modification is catalyzed 
by the E3 ubiquitin ligase subunit FANCL and its E2 conjugating enzyme FANCT. 
Depending on the nature of the lesion, the FA can evoke the use of TLS polymerases, 
nucleotide excision repair, and/ or HR, and has been proposed to directly inhibit 
NHEJ11, 54.  
The E3 ubiquitin ligase RAD18, which was previously described as an activator of 
TLS (and TS) via ubiquitination of PCNA, also plays a role in FA pathway activation. 
RAD18-dependent mub-PCNA recruits FANCL, promotes its subsequent 
monoubiquitination of the ID2 complex, and has been shown to also recruit FANCD2 via 
a direct interaction55-57.   
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1.2.2 DNA Damage Repair  
Mechanisms for recognition and repair of DNA damage are crucial for maintenance 
of genomic stability and prevention of carcinogenesis.  Double strand breaks (DSBs), 
the most severe type of DNA damage, can occur in response to a variety of agents 
including environmental toxicants (e.g. reactive oxygen species formed from smog), and 
cancer therapies (e.g. ionizing radiation)58, 59.  Defects in DSB repair can cause 
diseases with severe clinical phenotypes, as is seen in RIDDLE syndrome, where 
mutations in the DSB repair signaling protein RNF168 generate severe 
immunodeficiency, developmental defects, radiosensitivity and a predisposition to 
cancer. Inability to correctly repair DSBs has also been linked to accelerated aging, 
infertility and abnormal development of the nervous and immune systems.  
Double strand breaks are primarily repaired by the HR and NHEJ pathways. Both 
HR and NHEJ engage complex signaling cascades, resulting in accumulation of repair 
proteins, BRCA1 and 53BP1, respectively, to the sites of damage59, 60. Upstream DSB 
repair signaling is initiated by ATM-dependent phosphorylation of histone 2A variant X 
(known as γH2AX), which binds with MDC1 at the lesion site. MDC1 acts as a DNA 
damage checkpoint activator and recruits the E3 ubiquitin ligase RNF8 to ubiquitinate 
γH2AX. Further poly-ubiquitination of γH2AX by RNF168 is needed for appropriate 
recruitment of BRCA1 or 53BP1 and is thought to potentially contribute to DSB repair 
pathway choice.  
In addition to post-translation modifications, repair pathway choice can be dictated 
by DNA end resection. End resection is a tightly controlled process that involves the 5’ 
to 3’ degradation of DSB ends, producing long stretches of 3’ ssDNA, and is initiated by 
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binding of the MRN complex to the DSB site. NBS1 recruits CtIP (required for MRE11 
nuclease activity) to the lesion site. MRE11 generates a nick in the DNA (via 
endonuclease activity) and subsequently generates short (25-50 nt)  3’ overhangs 
through exonucleolytic 3’-5’ degradation that are then engaged by more processive 
nucleases and helicases such as EXO1, DNA2, and BLM to generate ssDNA stretches 
spanning multiple kilobases. Negative regulation of end-resection is carried out by a 
series of proteins including 53BP1 and anti-resection factors10.  
1.2.2.1 Homologous recombination 
Homologous recombination is crucial for maintenance of genome integrity through 
its involvement in both DNA repair and meiotic chromosome segregation. In the context 
of DNA damage HR can respond to DNA gaps, inter-strand crosslinks and DSBs10. HR 
is a high-fidelity DSB repair mechanism that utilizes a sister chromatid or homologous 
chromosome as a template for repair. This template-dependence, however, restricts HR 
activity to the S and G2 phases of the cell cycle59.  
In HR, DSB ends are recognized by the MRN complex, which subsequently 
activates a signaling cascade to initiate end resection followed by Rad51 mediated 
strand invasion, D-loop formation, and DNA synthesis across lesion using the 
undamaged homologous allele as template. Replication intermediates are then resolved 
to restore the linkage flanking DSB61.  
Bunting et al. were amongst the first researchers to demonstrate the competitive 
nature between NHEJ and HR when they discovered that 53BP1 prevents HR in BRCA-
1 deficient cells by inhibiting resection62. Loss of 53BP1 is able to rescue HR defects in 
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BRCA1-null cells60. Similarly, studies have found that RAD18 promotes HR through 
inhibition of NHEJ, adding to the theory of competition between HR and NHEJ63, 64. 
1.2.2.2 Nonhomologous end-joining 
Unlike HR, NHEJ acts in a template-independent manner to ligate ends of the DSB. 
Since repair by NHEJ does not necessitate sequence homology at the break site, it is 
able to act during all stages of the cell cycle, but this temporal flexibility comes at the 
expense of repair fidelity. NHEJ is initiated when the Ku70/80 heterodimer is loaded 
onto the exposed ends of a DSB. Ku plays a multifunctional role in DSB repair- using 
lyase activity to remove damaged nucleotides in end-processing, and acting as a 
docking site for recruitment of other NHEJ proteins (e.g. DNA-PKcs)65, 66. DNA-PKcs-Ku 
binding marks the formation of DNA-PK holoenzyme which acts as a bridge to align 
broken ends of the DSB, and regulates binding of polymerases and nucleases at the 
lesion site. The DNA Ligase IV-XRCC4-XLF complex ligates the two ends of the DSB 
together. Use of NHEJ does not come without its limitations. Repair by NHEJ frequently 
results in small insertion and deletions that can give rise to mutations. NHEJ is also 
unable to repair collapsed replication fork lesions as collapsed forks represent a ‘one-
ended’ break and are not accessible to NHEJ67.  
1.2.2.3 Alternative end-joining 
Alternative end joining (Alt-EJ) (also, theta-mediated end-joining (TMEJ) or 
microhomology-mediated end-joining (MMEJ)) is a recently characterized DSB repair 
pathway. Although not a direct competitor with the canonical DSB repair pathways, 
alternative end-joining (alt-EJ) is thought to serve and important role in the repair of 
DSB in cells with defective NHEJ or HR. DNA polymerase theta (Polθ) is the primary 
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mediator of alt-EJ. Polθ utilizes resected ssDNA tails as a substrate for repair, 
catalyzing DNA synthesis from microhomologies (small patches of complementary 
sequence) at the lesion site. These ssDNA tails may result from inappropriately timed 
end-resection or aborted HR, and could describe the synthetic lethality seen with Polθ 
and factors that promote HR (e.g. BRCA1) or restrict end-resection (e.g. 53BP1)68-70.  
 
1.3  Role of the DNA damage response in cancer and disease  
Defects in DNA repair and genome maintenance are associated with a variety of 
diseases, including cancer, that often manifest with severe clinical phenotypes. For 
example, sunlight-induced skin cancer is increased in patients with xeroderma 
pigmentosum-Variant (XPV), caused by defects in the DNA polymerase Polη. In TLS 
can replicate DNA templates containing solar UV radiation-induced DNA lesions (i.e. 
Cyclobutane Pyrimidine Dimers). In-deficient XPV patients, failure to bypass CPDs can 
lead to replication fork collapse and cell death, or genome instability and cancer 71, 72. 
While genotoxic injury is generally negative, scientists have also capitalized on an 
understanding of mechanisms of DNA damage by using genotoxins such as ionizing 
radiation, platinating agents and other chemotherapeutics in the treatment of cancer67, 
73, 74. These agents cause a slew of lesion types including a variety of crosslinks, bulky 
DNA adducts, single-stranded DNA breaks (SSB), and the most severe type of lesion- 
DSB. As a whole, DNA damage tolerance is critical for multi-step carcinogenesis, 




1.3.1 Cancer/Testis Antigens 
Cancer testis antigens (CTAs) comprise a group of over 250 proteins that are 
normally germ cells restricted but aberrantly overexpressed in a wide array of cancers75, 
76. Expression of CTAs has been correlatively linked to chemotherapeutic resistance, 
tumorigenesis, metastasis, and poor patient prognoses, though the mechanisms by 
which CTAs contribute to carcinogenic outcomes are not known77-82.  
The first CTA, MAGEA1, was discovered nearly three decades ago when a patient 
with melanoma who was remarkably responsive to therapy was found to have cytotoxic 
T cells that recognized autologous cancer cells. MAGEA1 belongs to the Melanoma 
Antigen (MAGE) family of CTAs, a group of over 45 CTAs that share a MAGE 
Homology Domain (MHD), a region of ~170 amino acids with two structurally similar 
Winged Helix A and Winged Helix B motifs. A conserved di-leucine motif in the MHD is 
part of a partially hydrophobic region and participates in known MAGE protein-protein 
interactions81, 83. Outside of their tumorigenic link, MAGEs have been associated with a 
variety of cellular and developmental processes implicating them in neurodevelopmental 
and lung disorders84. 
Since the discovery of MAGEA1, several other types of CTAs have been identified, 
including HORMAD1. In mammalian germ cells, HORMAD1 has been shown to 
contribute to recombination and segregation during meiosis. Following the discoveries 
that HORMAD1 acts as a substrate of ATM that co-localizes with γH2AX and may 
interact with BRCA1, it has been suggested that HORMAD1 may play a role in DSB 
processing85-88. Identification of a role for HORMAD1 in recombinational repair in cancer 
cells could have huge implications for mechanisms of chemoresistance. In fact, many 
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CTAs are being aggressively pursued as targets for cancer treatment due to their 
absence in normal somatic tissue and association with various cancer endpoints. 
Our overall hypothesis is that cancer cells upregulate genome maintenance proteins 
to aberrantly tolerate endogenous, environmental and therapeutic DNA damaging 
agents to promote mutagenesis and chemoresistance. We have discovered two 
unique regulators of RAD18 and replication-associated DNA damage tolerance that 
are overexpressed in cancer: RNF168 (an apical mediator of double strand break 
signaling) and MAGEA4 (a cancer cell-specific protein with no known function). We 
show here that RNF168 is a novel component of the RAD18 complex, facilitating its 
recruitment to stalled replication forks and promoting damage tolerance following 
replication stress (Chapter 2). We have also identified the cancer/testis antigen (CTA) 
MAGEA4 as a stabilizing binding partner of RAD18 that promotes trans-lesion DNA 
synthesis (Chapter 3). Finally, we show that depletion of several CTAs (MAGEA4, 
MAGEA10, or HORMAD1) sensitizes non-small cell lung cancer (NSCLC) cells to DNA-
damaging therapies. These studies identify novel mechanisms by which NSCLC cells 
aberrantly overexpress germ cell proteins to alter genome maintenance, offering a 
cancer cell-specific mechanism by which neoplastic cells acquire chemoresistance and 
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Accurate DNA replication is crucial for cell survival and maintenance of genome 
stability. However, the double-stranded DNA that encodes our genetic information is 
constantly challenged by endogenous and environmental insults. Cells are particularly 
vulnerable to DNA damage incurred during DNA synthesis as it can impede replication 
and generate unstable structures that are prone to rearrangement1, 2.  
During DNA replication, duplex DNA is unwound by helicases and then primed and 
engaged by the replicative DNA polymerases (Pols ε, δ, and α). Together these core 
components form a two-pronged fork structure termed the ‘replication fork.’ This 
complex additionally includes many other components such as PCNA (proliferating cell 
nuclear antigen), a DNA sliding clamp protein that serves as a loading platform for 
replicative polymerases, synthesis initiation and elongation proteins, and fork-protection 
factors3. As the replication fork is progressing through DNA synthesis however, damage 
or difficult to replicate structures that are encountered must be addressed for faithful 
replication to proceed. 
Replication fork stalling can occur at fragile sites (e.g. stretches of nucleotide 
repeats), from polymerase-blocking lesions like those induced by methyl methane 
sulfonate (MMS, an alkylating chemotherapeutic agent) and ultraviolet (UV), via dNTP 
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pool depletion (e.g. mimicked by Hydroxyurea, a ribonucleotide reductase II inhibitor), 
and simulated by replication inhibitors (e.g. Aphidocholine, a Polα inhibitor)4-6. Failure to 
resolve stalled replisomes can result in replication fork collapse and the formation of a 
more severe type of DNA lesion, DNA double-stranded breaks (DSB). Cells have thus 
developed mechanisms for bypassing DNA damage encountered during replication. 
These mechanisms include error-prone trans-lesion synthesis (TLS), and error-free 
template switching (TS)/ fork regression to tolerate genotoxic insults and restore 
productive synthesis7.  
Post-translational modifications are critical components of the DNA damage 
response that can significantly alter cell fate. For example, distinct post-translational 
modifications, like ubiquitination, have been shown to dictate pathway choice in the 
response to DNA lesions as is observed with the E3 ubiquitin ligases RAD18 (TLS, TS, 
Fanconi Anemia pathway, homologous recombination), HLTF (TLS and TS), and 
RNF168 (DSB repair)8-14. 
Consistent with other well-described DNA damage response pathways, choice 
between TLS and TS is dictated ubiquitin modifications. Following replication fork 
stalling RAD18 is recruited to sites of RPA-coated single stranded (ss) DNA to mono-
ubiquitinate (mub) PCNA. In its homotrimeric ring state PCNA slides along the DNA, 
acting as a docking site for polymerases and other signaling molecules. 
Monoubiquitination of PCNA at K164 induces a  ‘polymerase switch’ from the replicative 
polymerases to TLS polymerases (η, κ, ι, ζ, and rev1), which have a higher affinity for 
the ubiquitinated form of PCNA4, 15. Unlike the replicative polymerases which have a 
strict requirement for undamaged bases, TLS polymerases are able to synthesize 
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across a damaged template and allow for resumption of replication, although 
mechanisms for damage-specific recruitment of TLS polymerases are not fully 
understood16, 17.  
In contrast, error-free TS uses the newly synthesized sister chromatid DNA as a 
template to accurately ‘bypass’ or ‘avoid’ lesions on the damaged template. Activation of 
TS in humans is thought to be mediated by poly-ubiquitination of PCNA by the RAD5 (in 
S. cerevisiae) homologs: helicase-like transcription factor (HLTF) and SNF2 Histone-
linker PHD-finger RING-finger Helicase (SHPRH)12, 13, 18-20. A study by Lin et al. 
identified damage-specific roles for HLTF and SHPRH in high fidelity tolerance of UV 
and MMS lesions, respectively8. This mode of DNA damage tolerance also involves 
RAD18, which contributes not only mono-ubiquitination of PCNA, allowing for further 
extension of K63-linked poly-ubiquitin chains by the RAD5 homologs, but also mediates 
damage-specific responses of HLTF and SHPRH through direct binding8, 21. Although 
recent publications have made headway in identifying novel regulators of DNA damage 
tolerance, including the influence of additional E3 ubiquitin ligases, but the exact 
mechanisms determining pathway choice and how it may influence genome instability 
diseases are not known22-26. 
Defects in genome maintenance mechanisms are responsible for a variety of severe 
clinical defects associated with many genetic diseases and cancer. Indeed, defects in 
the E3 ubiquitin ligase and DSB repair signaling protein, RNF168, are responsible for a 
rare genetic disease known as RIDDLE syndrome in which patients exhibit 
radiosensitivity, immunodeficiency and have a predisposition to cancer. Here we show 
that RNF168 localizes to replication factories in a noncanonical manner to promote DNA 
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synthesis following exposure to fork-stalling DNA damaging agents. RNF168 
additionally binds and recruits RAD18 to chromatin, facilitating ubiquitination of PCNA 
and conferring replication stress tolerance. 
 
2.2 Methods 
Cell culture and transfection 
hTERT-expressing normal human dermal fibroblasts (NHF) were provided by Dr. 
William Kaufmann (UNC Chapel Hill). RIDDLE hTERT fibroblast cells stably expressing 
vector or HA-RNf168, MRC5 and shRNF168- inducible U2OS were provided by Dr. 
Grant Stewart (University of Birmingham). Immortalized Cancer cell lines H1299, HeLa, 
U2OS, and 293T were purchased from the American Type Culture Collection (ATCC) 
and used for the described experiments without further authentication. H1299 RAD18-/- 
cells were generated by Dr. Yanzhe Gao and previously described22. U2OS RNF168 -/- 
and U2OS RNF8-/- cells were generated by Amélie Fradet-Turcotte and were a gift from 
the lab of Dr. Daniel Durocher. All cell lines were cultured in DMEM medium 
supplemented with 10% fetal bovine serum and penicillin–streptomycin (1%). Plasmid 
DNA and siRNA oligonucleotides were transfected using Lipofectamine 2000 
(Invitrogen) according to the manufacturer’s instructions, except that concentrations of 
plasmid DNA and Lipofectamine 2000 used in each transfection reaction were 
decreased by 50% to reduce toxicity. 
Immunoprecipitation and immunoblotting 
Lysates of cultured cells were washed three times in ice-cold PBS and lysed in 500 
µl of ice-cold cytoskeleton buffer (CSK buffer; 10 mM Pipes pH 6.8, 100 mM NaCl, 300 
 26 
mM sucrose, 3 mM MgCl2, 1 mM EGTA, 1 mM dithiothreitol, 0.1 mM ATP, 1 mM 
Na3VO4, 10 mM NaF and 0.1% Triton X-100) freshly supplemented with Protease 
Inhibitor Cocktail and Phostop (Roche). For subfractionation, lysates were centrifuged at 
4,000 RPM for 4 min at 4°C. The supernatant containing a mixture of cytosolic plus 
nucleosolic proteins was aliquoted and detergent-insoluble nuclear fractions were 
washed once with 1 ml of CSK buffer. Insoluble (chromatin) fractions were then 
resuspended in a minimal volume of CSK and sonicated to release chromatin before 
analysis by SDS–PAGE and immunoblotting.  
For all immunoprecipitation experiments, input samples were normalized for protein 
concentration. Sepharose or magnetic beads containing covalently conjugated 
antibodies against epitope tags were added to the extracts and incubations were 
performed overnight at 4°C using rotating racks. Immune complexes were recovered 
using magnetic stands (magnetic beads) or centrifugation (sepharose beads). The 
beads were washed five times with 1 ml CSK to remove nonspecifically-bound proteins. 
The washed immune complexes were boiled in Laemmli buffer for 10 min, to release 
and denature for SDS–PAGE.  
For immunoblotting, cell extracts or immunoprecipitates were separated by SDS-
PAGE, transferred to nitrocellulose membranes, blocked in 5% milk in TBST, and 
incubated overnight with the following primary antibodies: PCNA (sc-56), Chk1 (sc-
7898), β-actin (sc-130656), GAPDH (sc-32233), RNF8 (sc-271462), HA.F7 (sc-7392) 
and GST (sc-53909) from Santa Cruz Biotech; Polη (A301-231A), RAD6 (A300-281A), 
RAD18 (A301-340A), Polκ (A301-975A), and HLTF (A300-230A) from Bethyl; MYC-Tag 
(2276) from Cell Signaling; H2A (05-678), γH2AX (05-636), RNF168 (06-1130) from 
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Millipore; ORC4 (H83120) Transduction Labs; FLAGM2 (F1804) from Sigma-Aldrich; 
HA.11 (ENZ-ABS118) Enzo Life Sciences; DDDDK–tag magnetic beads (M185-9), MBL 
International; CldU, AbD Serotec; IdU, Becton Dickinson; BrdU (556028) BD 
Pharmingen; β-tubulin, AbCam. Antibody dilutions used for immunoblotting were 
1:1,000, with exceptions for the following antibodies: RNF168 (1:3000) PCNA (1:500), 
GAPDH (1:3,000) and γH2AX (1:5,000).  
Expression plasmids 
Mammalian expression vectors for HA- and MYC-tagged forms of RAD18 have been 
described previously15, 27. FLAG RNF168, GFP-RNF168 and FLAG-RNF8 constructs 
were provided by Dr. Grant Stewart have been described previously14. FLAG-HLTF 
expression vector was gifted by Dr. Karlene Cimprich. 
RNAi  
For transfection, two separate tubes were prepared, one containing siRNA and 
serum-free Optimem, and the other with Lipofectamine 2000 and serum-free Optimem. 
These separate mixtures were incubated for 5 min at room temperature in the dark 
before being combined and incubated for an additional 20min, according to Dharmacon 
and Lipofectamine manufacturer’s protocols. Cells were trypsinized and resuspended in 
antibiotic-free medium and plated directly into the siRNA/Optimem/Lipofectamine 
solution at 50% confluence to incubate overnight. The following morning media was 
changed to remove Lipofectamine. Cell lysates were harvested 48 hrs post-transfection. 
Sequences of siRNA oligonucleotides used here are as follows: control non-targeting 
siRNA, 5’-UAGCGACUAAACACAUCAA-3’ (Thermo Fisher Scientific); RAD18 3’-
untranslated region siRNA, 5’-UUAUAAAUGCCCAAGGAAAUU-3-; RNF168 siRNA #1, 
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siGENOME Smartpool Dharmacon (Cat# M-007152-03); RNF168 siRNA #2, 5’-GAGAA 
UAUGAAGAGGAAAUUU-3’; RNF168 siRNA #3, 5’-GAAGAGUCGUGCCUACUGAUU-
3’; and RNF8 siGENOME Smartpool Dharmacon (Cat# M-006900-01). 
Genotoxin treatment 
For UV treatment, culture medium was removed from cultured cells, which were then 
irradiated using a UV cross-linker (Stratagene) or left untreated for mock. The UV-C 
dose delivered to the cells was confirmed with an ultraviolet radiometer (UVP, Inc.). 
Media was replaced and plates were returned to the incubator and harvested 2 hrs 
later, unless otherwise indicated. For IR irradiation plates were placed in the Rad 
Source RS2000 for treatment with X-ray irradiation at the indicated dose and incubated 
for 1 hr before harvest unless otherwise indicated. The RS2000 machine is calibrated 
and maintained by the Lineberger Cancer Center. For cisplatin (CDDP) cells were 
treated with 20 µM CDDP and incubated for 6 hrs in the dark before harvest. For 
Mitomycin C (MMC) treatment cells were treated with 100nM MMC and incubated for 
2hrs prior to harvest. For Hydroxyurea (HU) treatment cells were treated with 2mM HU 
(immunoblotting) or 1mM (immunofluorescence) and incubated for 24 hrs prior to 
harvest. 
Fluorescence microscopy 
MRC5, U2OS WT, U2OS RNF168KO, RIDDLE + vector and RIDDLE +HA-RNF168 
cells were transfected with the indicated expression plasmids or siRNA and grown to 
~60% confluency on glass cover slips (Thermo Scientific #3422). Twenty-four hrs after 
plating, cells were treated with the indicated agent (or mock) and harvested at the 
indicate time points. Cells were pre-extracted, fixed and immunostained with anti-PCNA, 
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anti-HA, anti-CldU, anti-IdU or detected by click chemistry (EdU), and stained with DAPI 
(Vectashield). Imaging was done on the Zeiss 710 confocal microscope, in the UNC 
Microscopy Services Laboratory core facility, as described previously28.  
DNA fiber analysis 
DNA fiber analysis was carried out as was described previously 29, 30.  USOS cells 
transfected with the indicated siRNAs. Twenty-four hrs after treatment cells were plated 
on coverslips (Thermo Scientific #3422). Cells were pulsed with 250µM CldU for 30min, 
irradiated with 20J/m2 UV, and pulsed with 250µM IdU for 30min prior to harvest and 
fiber spreading. For quantification of replication structures, at least 300 structures were 
counted per experiment. The lengths of red or green labeled tracts were measured 
using ImageJ (National Institutes of Health; http://rsbweb.nih.gov/ij/) and arbitrary length 
values were converted into micrometers using the scale bars created by the 
microscope. 
ssDNA assay 
RIDDLE cells stably expressing vector or HA-RNF168 cells were pulsed with 250µM 
IdU for two days. Cells were then treated with mock or UV irradiation (40J/m2) and 8 hrs 
later were pulsed with 250µM CldU for 30min before harvest. IdU immunostaining was 
done under non-denaturing conditions and antibody was fixed prior to denaturing CldU 
processing. DNA was visualized with DAPI. Data represent mean ± SEM of three 
independent experiments. 
DNA synthesis assay 
H1299 cells were treated with siRNA targeting control, RAD18 or RNF168. 24 hours 
after transfection, cells were re-plated in wells of 24-well plates (in replicate) for 3H 
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thymidine incorporation and 10cm dishes for immunoblotting, for each time point 
replicate cultures for each time points. Wells were treated with mock or 5J/m2 UV 
irradiation. At the indicated time points cells were then pulsed with 0.5mCi/ml [3H]- 
methyl thymidine (Perkin Elmer) for 30min. At the indicated time points after re-plating, 
the amount of radiolabel incorporated into the trichloroacetic acid-insoluble genomic 
DNA fraction was determined using scintillation counting as described previously31, 32. 
Protein was harvested from the 10cm plates at corresponding times to evaluate relevant 
proteins. RIDDLE cell experiments were processed as H1299 with the exception of 
transfection.  
Flow cytometry  
Cells were labeled with 10 µM BrdU (5-Bromodeoxyuridine) 30 minutes before 
harvest. Cells were collected by trypsinization, fixed in 35% ethanol for 24 hrs, then 
stained with anti-BrdU and propidium iodide as previously described27. Stained nuclei 
were analyzed by flow cytometry on an Accuri C6 flow cytometer (BD, Oxford, UK) 
using the manufacturer’s software.  
Survival 
Replicate cultures of stably-expressing vector or HA-RNF168 RIDDLE patient cells 
were plated at low density in 6-well plates (3-wells per treatment). 24hrs post-plating 
cells were treated with UV radiation (0, 5, 10 Jm-2). After two weeks plates are washed 
with 1xPBS, and fixed and stained with crystal violet. Plates were scanned and the 




SupF mutagenesis assay 
Reporter plasmids harboring UV lesions were transfected into control, RAD18 and 
RNF168 over-expressing 293T cells, each in triplicate. After 48 hrs plasmids are 
recovered from cells, transformed into MBM7070 bacteria, and plated on agar 
containing IPTG and X-Gal. Mutation frequency is determined as the ratio of mutant 
(white) colonies to the total (white and blue) number of colonies as described 
previously22, 35. 
 
2.3 Results  
RNF168 localizes to replication fork sites. 
RNF168 ligase activity has been canonically associated with ubiquitination of 
histones H2A/H2AX in the signaling response to DSB. Recent studies suggest that 
RNF168-dependent chromatin modifications may play a role in altering other cell 
signaling processes1, 36, 37. Interestingly, a study by Raschle et al. found that RNF168 
chromatin recruitment was sensitive to inhibition of replication by geminin1. 
Furthermore, several other reports have suggested a role for histone ubiquitination in 
replication and replication stress38-41. To investigate whether RNF168 plays a role in 
replication-associated activities we wanted to determine if RNF168 was present at 
replication factories. We looked at co-localization of GFP-RNF168 with PCNA, a key 
replication fork component in untreated cells or those treated with ultraviolet radiation, 
which blocks synthesis via the formation of bulky DNA adducts, or HU, which depletes 
dNTPs in the cells, stalling replication forks. Mock treated cells exhibited minimal 
localization to sites of replication forks. However, upon treatment with an agent that 
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induces replication stress (UV or HU), RNF168 co-localized with PCNA foci (Fig 2.1A). 
Additionally, we found that GFP-RNF168 began to localize at early to mid s-phase 
PCNA foci at one hour after UV-C irradiation. This colocalization was maintained at 6 
and 24 hours, as damaged cells accumulated in late s-phase (Fig. 2.1B).  
To determine whether the colocalization of RNF168 with PCNA was indeed at sites 
of replication forks, we also measured focal localization of RNF168 with EdU (marking 
sites of newly synthesized DNA) in mock- and HU-treated stably complemented HA-
RNF168 h-TERT RIDDLE fibroblasts. Indeed RNF168 also localized at EdU foci 
following treatment with fork-stalling HU, further demonstrating that RNF168 is recruited 
to sites of DNA synthesis during replication stress (Fig. 2.9D). 
RNF168 associates with RAD18 and promotes its recruitment to chromatin. 
After identifying that RNF168 was recruited to replication forks following treatment 
with fork-stalling agents we next sought to determine whether it was interacting with any 
known DNA damage tolerance (DDT) components. Fractionated lysates from 
shRNF168 inducible U2OS cells that were mock or UV irradiated with 20J/m2 were 
probed for a series of DDT-associated proteins, including the E3 ubiquitin ligase RAD18 
(Fig. 2.2A). As expected, UV treatment increased the protein levels of RAD18 (both in 
total lysate and on the chromatin). Interestingly, however, shRNA-induced silencing of 
RNF168 diminished RAD18 recruitment to chromatin and abolished the induction of 
RAD18 on the chromatin usually observed following UV-treatment. RAD18 was instead 
sequestered in the soluble (cytosolic/ nucleosolic)-component of the harvested lysate.  
Consistent with these findings, H1299 lung adenocarcinoma cells treated with 
siRNAs targeting multiple regions of RNF168 were irradiated with mock or 20J/m2 UV. 
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RNF168-depleted cancer cells exhibited substantially decreased recruitment of RAD18 
to damaged chromatin. RNF8 (the E3 ubiquitin ligase that has been shown to influence 
RNF168 recruitment to damaged DNA) depletion reduced levels of both RNF168 and 
RAD18 on chromatin (Fig. 2.2B). Further, RNF168-depleted cancer cells, RIDDLE 
patients cells exhibited a similar diminished recruitment of RAD18 to chromatin, which 
was restored in RIDDLE cells stably-complemented with HA-RNF168(Fig. 2.2C).  
To determine whether or not RNF168 alters RAD18 distribution via direct interaction, 
H1299 cells expressing MYC-RAD18, FLAG-RNF168, or both were subjected to anti-
FLAG immunoprecipitation (IP). IP of RNF168 (co-expressed with RAD18) pulled down 
both RAD18 and its E2 ubiquitin-conjugating enzyme, RAD6 (Fig. 2.2D). Reciprocal IP 
of ectopically expressed RAD18 in 293T cells also resulted in RNF168 co-
immunoprecipitation (Fig. 2.8A). Additionally, size-exclusion chromatography from 
lysates of cultured cells revealed a ~500 kDa complex containing RAD18, RAD6 and 
RNF168 (Fig. 2.8E).  
RNF168 promotes replication fork progression. 
To determine whether RNF168 contributes to replication fork progression we 
examined rates of DNA synthesis using [3H] thymidine incorporation in RIDDLE patient 
cells following low-dose UV-treatment. RIDDLE patient cells displayed UV-induced 
inhibition of DNA synthesis when compared to the isogenic RNF168-complemented 
RIDDLE cells (Fig. 2.3A). Extending this observation, RNF168-depleted lung cancer 
cells phenocopied RAD18 depletion in defective recovery of DNA synthesis following 
UV-induced replication fork stalling (Fig. 2.3C). Chromatin-bound RAD18 is diminished 
in RNF168-defective cells correlating with defective DNA synthesis rates (Fig. 2.3A-D).  
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To further determine the impact of RNF168 on replication fork progression we 
performed DNA fiber analysis in U2OS cells treated with control or RNF168 siRNA, 
followed by mock or UV irradiation. RNF168-depleted cells showed elevated levels of 1st 
label termination structures, indicative of fork stalling, compared with control cells, and 
these were further augmented by UV treatment (Fig. 2.3E). Of note, RNF168 depletion 
by siRNA does not alter global DNA synthesis rates in U2OS cells as measured by 
BrdU/PI (Fig. 2.3F).  
Replication fork stalling triggers uncoupling of the helicases and replicative 
polymerases, generating stretches of vulnerable single stranded DNA (ssDNA). We 
used a thymidine analog ssDNA assay to determine whether or not prolonged fork 
stalling in the absence of RNF168 coincided with generation of ssDNA. RIDDLE and 
HA-RNF168 complemented RIDDLE cells were pulsed labeled with IdU two days prior 
to UV treatment and subsequent 30 minute CldU labeling before harvest. Non-
denaturing IdU immunostaining detects ssDNA whereas denaturing CldU 
immunostaining (following fixation) identifies replicating cells. The amount of single-
stranded DNA (ssDNA) generated in RIDDLE cells following UV treatment was 
significantly higher than that of the stably complemented HA-RNF168 RIDDLE cells, 
indicating that there were more stalled forks in these cells (Fig. 2.3G-H). 
RNF168 promotes ubiquitination of PCNA 
Ubiquitination of PCNA is a critical post-translational modification that alters cellular 
response (and pathway choice) following replication stress. RNF168 expression is able 
to promote ubiquitination (mono, bi and tri) of PCNA. To determine whether RNF168 
overexpression causes global DNA synthesis defects thus leading to mub (mono-
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ubiquitinated)-PCNA, we examined the cell cycle profiles of empty vector and FLAG-
RNF168 transfected H1299 lung adenocarcinoma cells. RNF168 over-expressing cells 
had no change in the s-phase population compared to the non-overexpressing cells 
measured by BrdU/PI (Fig. 2.4A). Previous reports have shown recombinant RNF8 was 
able to ubiquitinate PCNA in vitro, however, expression of RNF8 in cells was unable to 
promote ubiquitination of PCNA. As expected, ubiquitination of γH2AX was increased in 
RNF168 over-expressing cells, and ub-γH2AX following ionizing radiation was 
enhanced by both RNF168 and RNF8 overexpression, confirming that the expressed 
proteins were indeed functional42(Fig. 2.4B). 
To gain further insight into the function of RNF168 in the context of replication stress 
we made use of a series of RNF168 domain mutants. The catalytic RING (Really 
Interesting New Gene, zinc finger) domain mutants of RNF168 (ΔRING, C19S- point 
mutation that diminishes activity) are defective for ub-H2A and recruitment of 53BP1 
and BRCA1 following DSB. The MIU (Motif Interacting with Ubiquitin) domain mutants 
(ΔMIU1, ΔMIU2, ΔMIU 1+2 and A179G/A450G) are required for localization of RNF168 
binding to DSBs14. We look at the ability of GFP-RNF168 mutants (in U2OS RNF168 -/- 
cells) to localize at replication factories using PCNA as a replicative marker. 
Interestingly, the ΔMIU2 mutant, which fails to localize following IR was competent for 
colocalization with PCNA after UV suggesting a distinct, and novel mechanism for 
RNF168 recruitment to stalled forks. There also appeared to be some constitutive 




Separation of function RNF168  
We used FLAG-tagged RNF168 constructs with the same series of mutations to 
examine the impact on PCNA and RAD18. The contribution of RNF168 to damage 
tolerance was bifunctional: catalytically-inactive RNF168 (ΔRING, C19S) supported 
PCNA ubiquitination activity, however, was defective for RAD18 redistribution to 
chromatin (Fig. 2.5A, 2.5B, 2.8C). Additionally, point mutations in the UBZ (ubiquitin-
binding zinc finger) domain of RAD18 were unresponsive to RNF168 (Fig. 2.5C, D). 
Overall these results suggest that RAD18 recruitment to chromatin following replication 
stress is mediated by RNF168-dependent chromatin modification, and ub-PCNA is 
influenced by RNF168 binding to ubiquitinated substrates. 
Role for RNF168 in DNA damage tolerance 
To determine whether RNF168 directly impacts genome maintenance we a supF 
mutagenesis assay to measure mutation rates corresponding with lesion bypass of UV-
damaged pSP189 supF plasmid. Consistent with previous reports, we showed that 
ectopic expression of RAD18 suppressed UV-induced mutagenesis22. RNF168 was 
able to phenocopy RAD18 in suppressing mutagenesis of the UV-damaged supF 
reporter, influencing replicative bypass of ultraviolet-induced DNA lesions (Fig. 2.6A). 
As overexpression of RNF168 promoted ubiquitination of PCNA, we also asked 
whether cells lacking endogenous RAD18, the primary effector of ub-PCNA, would be 
affected by RNF168 overexpression. Somewhat surprisingly, H1299 RAD18 -/- 
overexpressing RNF168 displayed a moderate increase in mub-PCNA, as compared to 
control. This suggests both that RNF168 promotion of poly-ub-PCNA is primarily 
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moderated via RAD18 but may also impact RAD18-independent ub-PCNA (Fig. 2.5B, 
2.6B).  
In response to UV, HLTF binds to RAD18, promotes poly ub-PCNA and high-fidelity 
bypass of UV lesions8. Interestingly, RNF168 depletion decreased HLTF binding to 
chromatin in UV-damaged cells (Fig. 2.6C). The impact of RNF168 on HLTF was also 
observed in response to other fork-stalling agents and in RIDDLE cells (Fig. 2.10A-B). 
We additionally saw that RAD18-HLTF binding was severely reduced in U2OS RNF168 
-/- cells as compared to U2OS WT (Fig. 2.6D). Previously published work has shown 
that HLTF influence binding of RAD18 with trans-lesion polymerase η8. Pol η 
recruitment to chromatin after UV is also diminished following depletion of RNF168 (Fig. 
2.6E, 2.3D).  
Data from The Cancer Genome Atlas (TCGA) shows that many cancers, including 
lung squamous cell carcinoma’s have elevated levels of RNF168 (Fig. 2.6F). We found 
that RIDDLE patient cell lines expressing RNF168 exhibited enhanced survival following 
UV irradiation. Interestingly, levels of RNF168 in the complemented RIDDLE cells are 
much higher than those in normal human fibroblasts (NHF) (Fig. 2.6G). Taken together 
these results suggest a role for RNF168 in tolerance of UV-induced replication stress. 
 
2.4 Discussion 
RNF168 localizes to replication forks and mediates RAD18 redistribution 
Stalled replication forks elicit an elaborate signaling cascade that links cell cycle 
stage with recruitment of appropriate repair factors. Previous research has shown that 
depletion of ubiquitin interferes with replication-associated DNA repair without affecting 
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replication, suggesting that ubiquitination events play a key role in the assembly of DNA 
damage tolerance complexes at stalled replication forks1. Indeed, Vassilev et al. 
showed that there are not only higher levels of ub-H2A in proliferating cells than non-
proliferating but there is also partial co-localization of ub-H2A with PCNA-suggesting a 
role for ub-H2A in maintenance of DNA replication 41, 43. We have identified a 
noncanonical role for the E3 ubiquitin ligase and histone H2A modifier RNF168 in 
promoting replication-associated damage tolerance.  
Following exposure to fork-stalling agents, RNF168 localizes to sites of replication 
forks  (Fig. 2.1A, 2.9D). Additionally, we identified RNF168 as a novel component of 
RAD18 complexes (Fig 2.2D, Fig 2.8A)- RAD18 is a central regulator of pathway choice 
in replication-associated DNA damage tolerance. RNF168 depletion severely 
diminishes RAD18 re-localization to chromatin and abolishes the induction of RAD18 
normally observed following replication stress (Fig. 2.2A-C, 2.8B, 2.8D). RAD18 
depletion has also been shown to sensitize cells to DNA damage and increase mutation 
rates in cells9, 44, 45. Thus following genotoxic insult RNF168 may alter cellular response 
and mutagenesis in cells by altering RAD18-dependent signaling. 
RNF168 mediates replication fork progression following genotoxic injury 
Cells are particularly vulnerable to injury during S-phase of the cell cycle when 
unrepaired lesions can interfere with DNA synthesis and cell proliferation. We found that 
RNF168-deficiency impairs recovery from replication fork stalling and recapitulates 
hallmarks of defective DNA damage tolerance- namely persistent checkpoint signaling 
and decreased DNA synthesis28, 46-48. Both RIDDLE patient cells and H1299 lung 
adenocarcinoma cells depleted of RNF168 are defective in checkpoint recovery 
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following low-dose UV-treatment (Fig. 2.3A-D). RNF168-depleted cells showed elevated 
of fork stalling by DNA fiber analysis that was further augmented by UV treatment (Fig. 
2.3E). Additionally, the amount of vulnerable ssDNA generated in RIDDLE cells 
following UV treatment was significantly higher than that of the stably complemented 
HA-RNF168 RIDDLE cells (Fig. 2.3H). 
RNF168 promotes ubiquitination of PCNA 
Ubiquitination of PCNA is a critical post-translational modification that alters cellular 
response to replication stress. Interestingly, RNF168 overexpression massively induced 
ub-PCNA (Fig. 2.4A, 2.9A-C). Catalytically-inactive RNF168 (ΔRING, C19S), however, 
supported PCNA ubiquitination activity, suggesting that RNF168 is not a direct mediator 
of ub-PCNA when RAD18 is intact (Fig. 2.5B). Additionally, RNF168-depletion did not 
impact mub-PCNA following treatment with replication-stalling agents (data not shown), 
suggesting that RNF168-influenced ub-PCNA may favor poly-ubiquitination. Of note, 
mouse embryonic fibroblasts with a double knockout of SHPRH and HLTF (the E3 
ubiquitin ligases thought to be responsible for damage-associated poly-ub-PCNA) retain 
the ability to poly-ub-PCNA, thus it is possible that under extreme circumstances 
RNF168 may adopt PCNA as a substrate49. In fact RNF168 does contain a 
degenerative PCNA-interacting-protein (PIP) box motif (Fig. 2.9E) 28, 50, 51. An important 
avenue warranting further investigation is whether PCNA can act as a direct substrate 
of RNF168 (e.g. via PCNA K164R and ubiquitin K63R mutants)26. 
A previous publication showed that purified RNF8 (the E3 ubiquitin ligase that acts 
upstream of RNF168 in DSB repair signaling) induced ub-PCNA in vitro37. However, in 
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vitro ubiquitination models sometimes reveal activity that isn’t relevant in vivo and RNF8 
ub-PCNA does not appear to be recapitulated in a cell-based system (Fig. 2.4B)52. 
 
Response of RNF168 to replication stress is distinct from response to DSB 
RNF168 accumulation at sites of DSBs is dependent on its MIU domains 
(particularly MIU2), which recognize RNF8-catalyzed ub-H2A/H2AX14. When trying to 
determine the functional requirements for RNF168 in response to replication stress we 
expressed a series of GFP-RNF168 mutants in U2OS RNF168 -/- cells and looked at 
co-localization with PCNA with and without UV treatment. Interestingly, the ΔMIU2 
mutant, which fails to localize following IR, was competent for co-localization with PCNA 
after UV (Fig. 2.4C). This suggests that RNF168 recruitment following replication fork 
stalling is independent of its canonical recruitment in the context of DSB. None of the 
mutants on-hand exhibited severe deficiency in localizing to replication fork sites 
following UV irradiation (Fig. 2.5A). This suggests that RNF168 localization to 
replication factories following treatment with fork-stalling agents may be mediated 
through a third, UMI domain (UIM and MIU-related ubiquitin binding domain). Pinato et 
al. found that combined inactivation of all three RNF168 ubiquitin-binding domains 
rendered RNF168 unable to localize to DNA damage response foci and unable to form 
poly-ubiquitin chains53. Thus future studies should investigate a potential role for the 
UMI motif in directing RNF168 localization to replisomes following replication stress.  
Intriguingly, there appears to be some constitutive overlap between GFP-RNF168 
ΔRING and PCNA that is not seen with WT RNF168 (Fig. 2.4C). This could suggest that 
the ΔRING mutant is more stable for basal localization to replication factories or 
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possibly indicates the existence of a scaffold-like protein that recruits non-catalytic 
RNF168 to replisomes in a damage-free context.  
RAD18 localizes to stalled replication forks following RNF168-ubiquitination 
events 
We found that RNF168-dependent recruitment of RAD18 needed the RNF168 
catalytic RING domain, suggesting chromatin-modification facilitates RAD18 
redistribution (Fig. 2.5A, 2.5B, 2.8C). Indeed, point mutations in the UBZ (ubiquitin-
binding zinc finger) domain of RAD18 were unresponsive to RNF168 (Fig. 2.5C, 2.5D). 
Previous studies have demonstrated a role for RAD18 in DSB repair signaling, 
especially in promoting homologous recombination (HR) 10, 11, 54, 55. RAD18 recruitment 
to sites of DSB appears to be mediated through its UBZ domain, which recognizes ub-
H2A, a substrate of RNF168 and RNF8. Indeed RNF8/RNF168 have been shown to be 
necessary for RAD18/SLF1/SLF2 recruitment to DSB sites. However, SLF1/ SLF2 are 
not needed for ub-PCNA or polη recruitment, suggesting that the RAD18/SLF1/SLF2 
complex promotes function of SMC5/6 in HR and is not required for bypass of 
replication-blocking lesions1. Similarly, Hu et al. found that unlike RNF168, RAD18 
specifically competes with 53BP1 for recognition of ubiquitinated histone substrates. 
Furthermore, the RAD18 ligase activity that is needed for replication stress tolerance is 
dispensable for its role in HR11, 56. Finally, Panier et al. noted that in the DSB response, 
the ubiquitin-dependent recruitment of RNF168 and RAD18 is ‘temporally and 
genetically distinct’. This group added that the E3 ubiquitin ligase RNF169, a negative 
regulator of RNF168, was dispensable for the recruitment of RAD18 in the context of 
DSB. We, however, see that compared to RNF168, RNF169 diminishes recruitment of 
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RAD18 to chromatin following treatment with a fork-stalling agent57(Fig. 2.11). Our 
findings identify a new role for RNF168 in promoting redistribution of RAD18 to stalled 
replication forks. 
RNF168 promotes DNA damage tolerance 
Chromatin often serves as a loading platform for various DNA damage signaling, 
tolerance and repair proteins thus chromatin modifications can significantly alter 
response fate. We found that the ubiquitin ligase RNF168 is able to promote error-free 
bypass of UV induced DNA adducts, in a manner similar to RAD18, further cementing a 
novel role for RNF168 in tolerance of fork stalling lesions (Fig. 2.6A). 
Interestingly, RNF168 overexpression in H1299 RAD18-/- cells was able to promote 
ub-PCNA, although to a far less amount than when over-expressed in the presence of 
RAD18 (Fig. 2.6B). This suggests both that ub-PCNA promoted by RNF168 is primarily 
mediated through RAD18 but also that it may, to a lesser extent, contribute to RAD18-
independent ub-PCNA. RAD18-independent ub-PCNA could be mediated by 
CRL4/CDT2, a ubiquitin ligase that promotes degradation of PCNA-bound proteins, 
which was suggested to mub-PCNA26. However limitations in experimental design 
suggest that RAD18 could still mediate this ubiquitination activity. Another study by Lin 
et al. identified a role for HLTF-mediated mub-PCNA following UV irradiation that 
promoted recruitment of TLS polymerase η while inhibiting SHPRH function. 
Intriguingly, the RAD18 UBZ domain required for responsiveness to RNF168 is also 
required for RAD18-HLTF binding. We found that RNF168 depletion reduced chromatin-
bound HLTF and polymerase η, and that RNF168 -/- cells reduced HLTF-RAD18 
binding (Fig. 2.3D, 2.6C-E, 2.10A-B). RAD18 ligase activity is carried out in its 
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heterotrimeric state (RAD182:RAD6) and thus doesn’t necessitate competition between 
HLTF and RNF168 for the RAD18 UBZ9. 
In addition to its ligase activity, HLTF can also act as an annealing helicase and 
mediate fork reversal- a proposed mechanism for template switching that allows lesion 
bypass by providing access to a newly synthesized sister chromatid 2, 24. Further work 
by Cimprich group found that treatment with methyl methanesulfonate (MMS), a potent 
chemotherapeutic and replication fork-stalling agent, promotes HLTF degradation and 
SHPRH/RAD18 interaction with TLS polymerase κ8. Taking these studies into account, 
future experiments should explore roles for RNF168 in fork reversal as well as damage-
specific TLS polymerase recruitment and lesion tolerance that may ultimately contribute 
to the severe clinical manifestations seen in RIDDLE patients.  
Delicate balance of RNF168 and DNA damage tolerance 
In general, DNA damage tolerance pathways need to be tightly regulated. For 
example, RAD18 deficiency can increase mutation rates and induce DNA damage 
sensitivity. Overexpression of RAD18 can also be detrimental, disrupting recruitment of 
repair proteins and promoting error-prone TLS polymerases in the absence of DNA 
damage, that contribute to mutagenesis and cancer 48, 58-61. RNF168 regulation suffers a 
similar fate:  loss of RNF168 is responsible for the radiosensitivity, immunodeficiency 
and increased risk of cancer observed in RIDDLE syndrome patients, but RNF168 is 
also overexpressed in many cancers (Fig. 2.6F). RIDDLE patient cells complemented 
with RNF168 were shown to display enhanced tolerance of UV-radiation by cell survival 
assays, where levels of RNF168 are much higher than those in normal human 
fibroblasts (NHF) (Fig. 2.6G). This supports a gain-of-function role for RNF168 in 
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promoting DNA damage tolerance and carcinogenesis when it is over-expressed in 
cancer.  Taken together these results identify a role for RNF168 in tolerance of 
replication stress and enforce the delicate balance DNA damage tolerance pathways 







Figure 2.1 RNF168 localizes to replication forks 
 
(A) MRC5 cells expressing GFP-RNF168 were left untreated or treatment Hydroxyurea 
(1mM) or UV radiation (20J/m2). Cells were fixed and processed for GFP fluorescence 
and PCNA immunofluorescence. DNA was stained with DAPI.  
(B) MRC5 cells were either irradiated with 20J/m2 or mock treated. At the indicated time 
points cells were fixed and processed for GFP fluorescence and PCNA 
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Figure 1. RNF168 localizes to replication forks
(A) MRC5 cells expressing GFP-RNF168 were left untreated or treatment hydroxyurea (1mM) or UV radiation (20J/m2). Cells were fixed and processed 
for GFP fl o escence and PCNA immunofluorescence. DNA was stained with DAPI. 
(B) MRC5 cells were either irradiated with 20J/m2 or mock treated. At the indicated time points cells were fixed and processed for GFP fluorescence and 




Figure 2.2 RNF168 associates with RAD18 and facilitates its recruitment to 
chromatin 
 
(A) H1299 cells were transiently transfected with control empty vector (EV), Myc-
RAD18, FLAG-RNF168, or both. After 48 hrs FLAG-RNF168 was immunoprecipitated 
with anti-FLAG beads. Input and immunocomplexes were immunoblotted with the 
indicated antibodies. 
(B) U2OS cells were treated with vehicle or Doxycycline to induce shRNA silencing of 
RNF168. 72 hrs after induction cells were irradiated with 20J/m2  or mock treated and 
harvested for immunoblotting with the indicated antibodies.  
(C) H1299 cells were treated with the indicated siRNAs and 48 hrs after were subjected 
to 20J/m2  UV or mock irradiated, and harvested for immunoblotting with the indicated 
antibodies.  
(D) RIDDLE patient cells stably expressing vector or HA-RNF168 were subjected to 
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Figure 2. RNF168 associates with RAD18 and facilitates recruitment to chromatin
(A) H1299 cells were transiently transfected with ontrol mpty vector (EV), Myc-RAD18, Flag-RNF168, or both. Afte  48 hrs FLAG-RNF168 was 
immunoprecipitated with anti-FLAG beads. Input and immunocomplexes were immunoblotted with the indicated antibodies.
(B) U2OS cells were treated with vehicle or Doxycyclin to induce shRNA silencing of RNF168. 72 hrs after induction cells were irradiated with 20J/m2  or 
mock treated and harvested for immunoblotting with the indicated antibodies. 
(C) H1299 cells were treated with the indicated siRNAs and 48 hrs after were subjected to 20J/m2  UV or mock irradiated, and harvested for immunoblot-
ting with the indicated antibodies. 
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Figure 2. RNF168 associates with RAD18 and facilitat s recruitment to chromatin
(A) H1299 cells were transiently transfected with control empty vector (EV), Myc-RAD18, Flag-RNF168, or both. After 48 hrs FLAG-RNF168 was 
immuno recipitated with anti-FLAG beads. Input and immunocomplex s were immunoblotted with the indicated antibodies.
(B) U2OS cells w re treated with v hicle or Doxycycli  to induce shRNA silencing of RNF168. 72 hrs after induction cells were irradiated with 20J/m2  or 
mock tre ted and harvested for immunoblotting with the indic ted antibodies. 
(C) H1299 cells w re treated with the indicated siRNAs and 48 hrs aft r were subjected to 20J/m2  UV r mock rradiated, and harvested for immunoblot-
ting with the indic ted antibodies. 
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Figure 3. RNF168 promotes replication fork progression 
(A) RIDDLE cells stably expressing vector or HA-RNF168 were plated in triplicate for each time point and treated 5J/m2 UV. Cells were then pulsed with 
3H thymidine for 30min at each time point and harvested to measure rates of incorporation by scintillation counter.
(B) Time course immunoblot corresponding to samples in (A).
(C) H1299 cells were treated with the indicated siRNA and plated in triplicate for each time point. 48 hrs after siRNA treatment samples were then 
processed as in (A).
(D) Time course immunblot corresponding to samples in (C).
(E) Schematic of  treatment for replication fiber analysis (left). DNA fiber analysis of USOS cells transfected with the indicated siRNAs. Cells were pulsed 
with CldU, irradiated with 20J/m2 UV, and pulsed with IdU. The percentages of ongoing forks, first-label (bidirectional) origins, new origins (IdU-labelled 
only), first-label terminations (CldU-labelled only) and second label terminations were quantified using imageJ.
(F)
(G) Representative images of staining in RIDDLE fibroblasts used for analyzing the amount of s-phase cells with ssDNA.
(H) RIDDLE cells stably expressing vector or HA-RNF168 cells were pulsed with IdU for two days. Cells were then treated with mock or UV irradiation 
(40J/m2) and 8 hrs later were pulsed with CldU for 30min before harvest. IdU immunostaining was done under non-denaturing conditions and antibody 











Figure 2.3 RNF168 promotes replication fork progression  
 
(A) RIDDLE cells stably expressing vector or HA-RNF168 were plated in triplicate for 
each time point and treated 5J/m2 UV. Cells were then pulsed with 3H thymidine for 
30min at each time point and harvested to measure rates of incorporation by scintillation 
counter. 
(B) Time course immunoblot corresponding to samples in (A). 
(C) H1299 cells were treated with the indicated siRNA and plated in triplicate for each 
time point. 48 hrs after siRNA treatment samples were then processed as in (A). 
(D) Time course immunoblot corresponding to samples in (C). 
(E) Schematic of treatment for replication fiber analysis (left). DNA fiber analysis of 
USOS cells transfected with the indicated siRNAs. Cells were pulsed with CldU, 
irradiated with 20J/m2 UV, and pulsed with IdU. The percentages of ongoing forks, first-
label (bidirectional) origins, new origins (IdU-labeled only), first-label terminations (CldU-
labeled only) and second label terminations were quantified using imageJ (n=1). 
(F) U2OS cells treated with siControl or siRNF168 were pulse labeled with 10 µM BrdU 
for 30min and analyzed by flow cytometry to quantify S phase–positive populations. 
(G) Representative images of staining in RIDDLE fibroblasts used for analyzing the 
amount of s-phase cells with ssDNA. 
(H) RIDDLE cells stably expressing vector or HA-RNF168 cells were pulsed with IdU for 
two days. Cells were then treated with mock or UV irradiation (40J/m2) and 8 hrs later 
were pulsed with CldU for 30min before harvest. IdU immunostaining was done under 
non-denaturing conditions and antibody was fixed prior to denaturing CldU processing. 
DNA was with DAPI. Data represent mean ± SEM of three independent experiments. * 
indicates significant difference by one-way ANOVA with Bonferroni multiple 
comparisons test at 90% confidence (p<0.1).    
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Figure 2.4 RNF168 promotes ubiquitination of PCNA and its association with 





















































































Figure 4. RNF168 promotes ubiquitination of PCNA and its association with replication factories is distinct from its canonical 
role in DSBR.
(A) H1299 cells were transfected with EV and FLAG-RNF168 WT for 24 hr before harvest for immunoblot analysis with the indicated antibodies. One 
replicate plate was pulse labeled with 10 μM BrdU for 30min and analyzed by flow cytometry to quantify S phase–positive populations.
(B) H1299 cells were transfected  with EV, FLAG-RNF8 and FLAG-RNF168 for 24hr before mock, UV or IR irradiation. Lysates were harvested and 
anlayzed by immunblot with the indicated antibodies.
(C) U2OS RNF168 -/- cells transfected with the indicated GFP-RNF168 expression vectors were mock or UV-irradiated. 6 hrs post-irradiation cells were 
fixed and processed for GFP fluorescence and PCNA immunofluorescence. DNA was stained with DAPI.
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Figure 2.4 RNF168 promotes ubiquitination of PCNA and its association with 
replication factories is distinct from its canonical role in DSBR. 
(A) H1299 cells were transfected with EV and FLAG-RNF168 WT for 24 hrs before 
harvest for immunoblot analysis with the indicated antibodies. One replicate plate was 
pulse labeled with 10 µM BrdU for 30min and analyzed by flow cytometry to quantify S 
phase–positive populations. 
(B) H1299 cells were transfected with EV, FLAG-RNF8 and FLAG-RNF168 for 24hr 
before mock, UV or IR irradiation. Lysates were harvested and analyzed by immunoblot 
with the indicated antibodies. 
(C) U2OS RNF168 -/- cells transfected with the indicated GFP-RNF168 expression 
vectors were mock or UV-irradiated. 6 hrs post-irradiation cells were fixed and 









Figure 2.5 Separation of function for RNF168 
(A) Schematic of domains and point mutation mutants in RNF168 and RAD18 proteins. 
(B) H1299 WT cells were transfected with control plasmid or FLAG-RNF168 mutants. 
Samples were mock treated or irradiated with 30J/m2 UV and harvested for analysis by 
western blot with indicated antibodies. 
(C) H1299 RAD18 -/- cells were transfected with RAD18 WT or RAD18 C207F mutant 
plasmids and subsequently treated with siRNA targeting control or RNF168. Cells were 
harvested for analysis by western blot with indicated antibodies. 
(D) H1299 RAD18 -/- cells were transfected with RAD18 WT or RAD18 C207F mutant 











































































































Figure 5. Separation of function in RNF168
(A) Schematic of domains and point mutation mutants in RNF168 and RAD18 proteins.
(B) H1299 WT cells were transfected with control plasmid or FLAG-RNF168 mutants. Samples were mock treated or irradiated with 30J/m2 UV and 
harvested for analysis by western blot with indicated antibodies.
(C) H1299 RAD18 -/- cells were transfected with RAD18 WT or RAD18 C207F mutant plasmids and subsequently treated with siRNA targeting control or 
RNF168. Cells were harvested for analysis by western blot with indicated antibodies.
(D) H1299 RAD18 -/- cells were transfected with RAD18 WT or RAD18 C207F mutant plasmids and subsequently transfected with FLAG-RNF168 
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Figure 6. Role of RNF168 in DNA damage tolerance
(A) 293T cells were co-transfected with UV-treated pSP189 reporter plasmid and RAD18 or RNF168 expression vectors. Forty-eight hours later, 293T 
cell extracts were collected for validation of RAD18 and RNF168 expression by western blot (right). Recovered pSP189 plasmid was transformed into 
electro-competent MBM7070 bacteria and pSP189 mutation rates were determined by enumerating blue and white bacterial colonies. Data represent 
mean ± SEM of two independent experiments each performed in triplicate.  P-values were calculated using a two-tailed Student’s t-test. *p=0.0133
(B) H1299 WT or RAD18 -/- cells were transfected with EV, FLAG-RNF8, FLAG-RAD18 or FLAG-RNF168 plasmids as indicated. 24 hrs post-transfec-
tion samples were mock or UV irradiated (20J/m2) and harvested for analysis by western blot with indicated antibodies.
(C) H1299 WT cells were treated with control or RNF168 siRNA. 48 hrs post-transfection samples were mock or UV irradiated (20J/m2) and harvested as 
in (B). Relative levels of HLTF compared to total sample loaded were quantified by densitometry (right).
(D) 
(E) H1299 WT cells were treated with control, RAD18 or RNF168 siRNA. 48 hrs post-transfection samples were mock or UV irradiated (30J/m2) and 
harvested as in (B).
(F) Expression of RNF168 in normal and Lung Squamous Cell Carcinoma tumors from the TCGA data base. 
(G) RIDDLE + vector and RIDDLE + HA-RNF168 cells were plated at low density in 6-well plates (3-wells per treatment). 24h post-plating cells were 
damaged with UV and let to grow for two weeks before harvesting and staining with crystal violet .Data represent mean ± SEM of two independent 


























Figure 2.6 Role of RNF168 in DNA damage tolerance 
(A) 293T cells were co-transfected with UV-treated pSP189 reporter plasmid and 
RAD18 or RNF168 expression vectors. Forty-eight hours later, 293T cell extracts were 
collected for validation of RAD18 and RNF168 expression by western blot (right). 
Recovered pSP189 plasmid was transformed into electro-competent MBM7070 bacteria 
and pSP189 mutation rates were determined by enumerating blue and white bacterial 
colonies. Data represent mean ± SEM of two independent experiments each performed 
in triplicate.  P-values were calculated using a two-tailed Student’s t-test. *p=0.0133 
(B) H1299 WT or RAD18 -/- cells were transfected with EV, FLAG-RNF8, FLAG-RAD18 
or FLAG-RNF168 plasmids as indicated. 24 hrs post-transfection samples were mock or 
UV irradiated (20J/m2) and harvested for analysis by western blot with indicated 
antibodies. 
(C) H1299 WT cells were treated with control or RNF168 siRNA. 48 hrs post-
transfection samples were mock or UV irradiated (20J/m2) and harvested as in (B). 
Relative levels of HLTF compared to total sample loaded were quantified by 
densitometry. 
(D) U2OS WT and RNF168 -/- cells were transiently transfected with control empty 
vector (EV), HA-RAD18, FLAG-HLTF, or both, as indicated. After 24 hrs HA-RAD18 
was immunoprecipitated with anti-HA beads. Input and immunocomplexes were 
immunoblotted with the indicated antibodies.  
(E) H1299 WT cells were treated with control, RAD18 or RNF168 siRNA. 48 hrs post-
transfection samples were mock or UV irradiated (30J/m2) and harvested as in (B). 
(F) Expression of RNF168 in normal and Lung Squamous Cell Carcinoma tumors from 
the TCGA data base.  
(G) RIDDLE + vector and RIDDLE + HA-RNF168 cells were plated at low density in 6-
well plates (3-wells per treatment). 24h post-plating cells were damaged with UV and let 
to grow for two weeks before harvesting and staining with crystal violet .Data represent 
mean ± SEM of two independent experiments (left). NHF, RIDDLE + vector and 
RIDDLE + HA-RNF168 cells were mock or UV irradiated (20J/m2) and harvested to 
analyze relative levels of RNF168 (right). 
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Figure 2.8 Supplemental characterization of RNF168-RAD18 association 
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Figure 2.8 Supplemental characterization of RNF168-RAD18 association 
(A) 293T cells were transiently transfected with control empty vector (EV), HA-
RAD18, FLAG-RNF168, or both, as indicated. After 24 hrs HA-RAD18 was 
immunoprecipitated with anti-HA beads. Input and immunocomplexes were 
immunoblotted with the indicated antibodies. 
(B) U2OS WT and RNF168 -/- cells were mock or UV irradiated (20J/m2) and 
harvested for analysis by western blot at various time points with indicated 
antibodies. 
(C) U2OS RNF168-/- were transiently transfected with EV or FLAG-RNF168 WT or 
mutant constructs. 24 hrs post-transfection samples were UV irradiated (20J/m2) 
and harvested for analysis by western blot with indicated antibodies. 
(D) HeLa cells were transfected with control or RNF168 siRNAs. 48hrs post-
transfection cells were treated with the UV, Cisplatin, Hydroxyurea, Mitomycin C 
or mock treated and harvested for immunoblot with the indicated antibodies. 
(E) Size fractionation of RAD18, RAD6, and RNF168 complexes in cultured cells. 
Exponentially-growing cultures of 293T cells were lysed in 300 µl of CSK without 
sucrose and supplemented with 1 µg/ml (25,000 units/ml) of Benzonase. Lysates 
were incubated at room temperature for 15 minutes to digest chromatin, then 
centrifuged at 21,000g for 20 min. 250 µl of each clarified cell lysate (~2.0 mg) 
was loaded onto a 25ml Sephadex 200 gel filtration column. The column was 
eluted with sucrose-free CSK. 0.5 ml fractions were collected and 30 µl of each 
fraction was analyzed by SDS-PAGE and immunoblotting with antibodies against 





Figure 2.9 Supplemental characterization of RNF168-mediated ub-PCNA 
(A) U2OS RNF168-/- were transiently transfected with EV or FLAG-RNF168 WT or 
mutant constructs. 24 hrs post-transfection samples were UV irradiated with the 
indicated doses of UV and harvested for analysis by western blot with indicated 
antibodies. 
(B) H199 cells were treated with siControl or siRNF168. 24 hrs later cells were 
subsequently transfected with EV or siRNA-resistant FLAG-RNF168 for another 
24 hrs. Cells were then treated with UV and harvested for analysis by western 
blot with the indicated antibodies.  
(C) RIDDLE cells stably expressing vector or RNF168 were treated with UV and 
harvested for immunoblot with anti-RNF168 and anti-PCNA antibodies. 
Additional samples were pulse labeled with 10 µM BrdU for 30min and analyzed 
by flow cytometry to quantify S phase–positive populations. 
(D) Analysis of RNF168 amino acid sequence identifies a degenerative PIP Box 







Figure 2.10 RNF168 levels influence chromatin-bound HLTF  
(A) RIDDLE cells stably expressing vector or RNF168 were treated with the UV, 
Cisplatin, Hydroxyurea, Mitomycin C or mock treated and harvested for immunoblot with 
the indicated antibodies. 
(B) H1299 cells were transfected with EV, RNF168 or HLTF plasmids. 24 hrs after 
transfection, cells were treated with 20J/m2 UV and harvested for immunoblotting with 











































































Figure 2.11 Comparison of RNF168 and RNF169 on RAD18 recruitment and ub-
PCNA  
H1299 cells were transfected with FLAG-RNF168 or FLAG-RNF169. 24 hrs after 
transfection cells were treated with 20J/m2 UV and harvested for immunoblot analysis 
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Eukaryotic cells are exposed to many intrinsic and exogenous sources of DNA 
damage. The S-phase of the cell cycle is particularly vulnerable to genotoxins, because 
error-prone replication of damaged DNA can lead to mutagenesis, a ‘hallmark and 
enabling characteristic’ of cancer1. To mitigate the genome destabilizing consequences 
of DNA damage in S-phase, DNA replication forks that encounter lesions trigger a 
network of signal transduction pathways collectively termed the DNA damage response 
(DDR). The different effector arms of the DDR cooperate to facilitate S-phase recovery 
and resumption of normal cell cycle progression following genotoxic insult2. Failure to 
integrate DNA replication with DNA repair and cell cycle progression leads to reduced 
viability, compromised genome stability and a predisposition to cancer.  
Trans-lesion synthesis (TLS) is one of the main effector pathways of the DDR and is 
important for normal recovery from DNA replication fork stalling3. The conventional DNA 
polymerases that duplicate most of the genome every cell cycle cannot replicate DNA 
templates harboring bulky lesions. Therefore, following acquisition of DNA damage, a 
‘polymerase switch’ replaces replicative DNA polymerases at stalled replication forks 
with specialized TLS DNA polymerases that can accommodate bulky lesions. 
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The Y-family TLS polymerases include DNA polymerase eta (Polη), DNA 
polymerase kappa (Polκ), DNA polymerase iota (Polι) and REV13, 4. Collectively, Y-
family TLS polymerases enable cells to maintain DNA synthesis using damaged 
genomes. In TLS-deficient cells, checkpoint kinase signaling persists, leading to a 
protracted S-phase arrest and accumulation of DNA double-stranded breaks (DSBs)5-7.  
TLS can be error-free or error-prone depending on the nature of the DNA damage 
and the particular TLS polymerase(s) selected for lesion bypass3, 4. Polη is the default 
TLS polymerase recruited to stalled replication forks and performs error-free replication 
of DNA templates containing its cognate lesions (including ultraviolet-induced cyclo-
butane pyrimidine dimers), thereby suppressing mutagenesis. However, when Polη is 
absent, error-prone compensatory lesion bypass by other Y-family DNA polymerases 
leads to mutations8, a mechanism that explains the ultraviolet sensitivity and skin 
cancer propensity of Polη-deficient xeroderma pigmentosum-Variant patients9. TLS 
must be regulated strictly and used sparingly to ensure genomic stability.  
Mono-ubiquitination of the DNA polymerase processivity factor proliferating cell 
nuclear antigen (PCNA) is important for TLS activation and lesion bypass10, 11. In 
response to DNA damage, the E3 ubiquitin ligase RAD18 is recruited to stalled 
replication forks where it mono-ubiquitinates PCNA at the conserved residue K16412, 13. 
K164 mono-ubiquitination promotes interactions between PCNA and Y-family TLS 
polymerases (which possess ubiquitin-binding zinc fingers and ubiquitin-binding motifs) 
at stalled replication forks14.  
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RAD18 overexpression can increase PCNA mono-ubiquitination and promote 
recruitment of TLS polymerases to replication forks, even in the absence of DNA 
damage5. Conversely, in RAD18-deficient cells, Y-family TLS polymerases are not 
recruited efficiently to sites of DNA replication stalling5, 15, 16 and overall lesion bypass is 
reduced17. Moreover, RAD18 deficiency recapitulates the defective S-phase recovery 
phenotypes of Polη and Polκ-deficient cells after genotoxin exposure5, supporting a 
major role for RAD18 in TLS.  
Although RAD18 is important for TLS polymerase recruitment to stalled replication 
forks, the basis for lesion-specific selection of the correct TLS polymerase is not yet fully 
understood. All TLS polymerases preferentially associate with mono-ubiquitinated 
PCNA relative to unmodified species. Clearly, relative expression levels and activities of 
RAD18 and the Y-family DNA polymerases are likely to have an impact on the overall 
TLS capacity and accuracy, determining mutagenic outcomes. Recent sequencing 
efforts have demonstrated that cancer cell genomes contain tens to hundreds of 
thousands of nucleotide substitutions and other mutations18. Mutation rates of 
untransformed cells are insufficient to explain the large numbers of mutations found in 
cancer cells. Therefore, cancer may be associated with a ‘mutator phenotype’ that 
generates large numbers of driver and passenger mutations during tumor progression19, 
20. Owing to its pivotal role in error-prone DNA synthesis, RAD18-mediated TLS has the 
potential to contribute to the mutational burden of cancer genomes. Neoplastic cells 
experience various oncogene-induced forms of DNA damage and replication stress 
(including oxidative DNA damage from reactive oxygen species (ROS) and re-
replication) throughout tumor progression. The ATR/CHK1 branch of the DDR may help 
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pre-neoplastic cells endure oncogenic stress, thereby promoting tumorigenesis21. 
Similarly, the RAD18–TLS pathway is in essence a DNA-damage tolerance mechanism 
that could help maintain viability in the face of oncogene-induced replication stresses22. 
Therefore, RAD18–TLS has the potential to have an impact on tumorigenesis by 
promoting error-prone DNA synthesis and by conferring oncogenic stress tolerance. 
However, whether dysregulation of the TLS pathway has an impact on genome 
maintenance mechanisms and phenotypes of cancer cells is unknown. Most of our 
understanding of the mammalian RAD18–TLS signaling pathway stems from studies 
performed in cultured cancer cell lines. Remarkably, however, it is unknown whether 
RAD18 and TLS are differentially regulated in cancer cell lines and untransformed cells.  
In this report we identify a cancer cell-specific protein, the cancer/testes antigen 
(CTA) melanoma antigen-A4 (MAGE-A4), as a novel binding partner and stabilizing 
factor for RAD18. CTA proteins are ordinarily germ line restricted, yet can be aberrantly 
expressed at high levels in many cancers23. The MAGE represent a subclass of CTA24, 
some of which were recently shown to associate with and activate specific RING E3 
ubiquitin ligases25, thereby providing a new mechanism by which ubiquitin signaling is 
deregulated in cancer cells. Here we show that MAGE-A4 contributes to TLS pathway 
activation, DNA-damage tolerance and genome maintenance in cancer cells. These 
results suggest a mechanism by which cancer genomes are impacted via reprograming 






Cell culture and transfection 
hTERT-expressing human dermal fibroblasts were provided by Dr. William 
Kaufmann (UNC Chapel Hill). Primary mouse embryonic fibroblasts were derived from 
E13.5 embryos of WT C57/BL6 mice. Cancer cell lines H1299, A549, HeLa, U2OS, 
H157, H650, HCT116 and 293T were purchased from the American Type Culture 
Collection (ATCC) and used for the described experiments without further 
authentication. It is noteworthy that the H157 squamous cell lung carcinoma cell line is 
on the International Cell Line Authentication Committee (ICLAC) misidentified cell list. 
According to the ATCC, H157 is identical to the H1264 squamous cell lung carcinoma 
cell line. In the experiments shown in Fig. 3.13, H157 cells were used solely as one (of 
several) example of independent cancer cell lines in which RAD18 expression is MAGE-
A4 dependent. All cell lines tested negative for mycoplasma contamination using the 
ATCC Universal Mycoplasma Detection Kit (ATCC 301012K). All cell lines were 
cultured in DMEM medium supplemented with 10% fetal bovine serum and penicillin–
streptomycin (1%). Plasmid DNA and siRNA oligonucleotides were transfected using 
Lipofectamine 2000 (Invitrogen) according to the manufacturer’s instructions, except 
that concentrations of plasmid DNA and Lipofectamine 2000 were used in each 
transfection reaction were decreased by 50% to reduce toxicity. 
Adenovirus construction and infection 
Adenovirus construction, purification and infections were performed as described 
previously26, 27. H1299 cells were typically infected with 0.1-1.0 x 109 pfu ml-1 and 
titrated to achieve near-endogenous expression levels of RAD18 and other proteins.  
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Expression plasmids 
GST-RAD18, GST-RAD6 and GST-MAGE-A4 were expressed using the pGEX2T 
vector (GE Healthcare) and purified from BL21 (DE3) Escherichia coli (Invitrogen) as 
described previously26. Hexa-histidine tagged MAGE-A4 was expressed using the 
pRSET vector (Invitrogen V351-20) and purified from BL21 (DE3) E. coli bacteria. 
Mammalian expression vectors for HA- and MYC-tagged forms of RAD18 have been 
described previously26, 28. To generate MAGE-A4 expression vectors, the MAGE-A4 
open reading frame was PCR amplified from H1299 genomic DNA and subcloned into 
the pcDNA3.1(-) expression plasmid. MAGE-A4 mutants harboring internal deletions 
and individual nucleotide substitutions were derived by PCR using conventional 
methods. The primers used to make MAGE-A4 mutants are: 5’-F WT (5’-CGCGGATC 
CGCCACCATGTCTTCTGAGCAGAAGAGTCAGCAC-3’), 3’-R WT (5’-AACAAGCTTTC 
AGACTCCCTCTTCCTCCTCTAACAAAG-3’); 5’-F HelixB (5’-CGCGGATCCGCCACCA 
TGGATGGCCTGCTGGGTAATAATCAG-3’), 5’-F Helix A + B (5’-CGCGGATCCGCCAC 
CATGTCCTTGTTCCGAGAAGCACTCAGTAAC-3’); ΔWHA-F (5’-GCCTTTCCTATGGT 
CCAAGGGC-3’), ΔWHA-R (5’-GCCCTTGGACCATAGGAAAGGC-3’); ΔWHA-F (5’-TG 
ACGCAGAGGATGGCCTGC-3’), ΔWHA-R (5’-GCAGGCCATCCTCTGCGTCA-3’); 
ΔWHB-F (5’-GCCTTTCCTATGGTCCAAGGGC-3’), ΔWHB-R (5’GCCCTTGGACCATA 
GGAAAGGC-3’); ΔMage-F (5’-GACGCAGAGGGTCCAAGGGC-3’), ΔMage-R (5’-GCC 
CTTGGACCCTCTGCGTC-3’); L121/2A-F (5’-CTCATTTTGCGGCCCGCAAG-3’), L121/ 
2A-R (5’-CTTGCGGGCCGCAAAATGAG-3’); S90A-F (5’-GTTCCAGCGCCCAAGAAGA 
GG-3’), S90A-R (5’-CCTCTTCTTGGGCGCTGGAAC-3’); and S90D-F (5’-
GGGTTCCAGCGATCAAGAAGAGG-3’), S90D-R (5’-CCTCTTCTTGATCGCTGGAACC 
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C-3’). The identities of all complementary DNA inserts were confirmed by sequencing. 
MYC–TRIM69 was a gift from Dr. Angelique Whitehurst (UT Southwestern) and 
expression plasmids encoding FLAG-tagged MAGE-A4, MAGE-A12, MAGE-B10 and 
MAGE-A1 were obtained from the UNC Tissue Culture Core Facility Orfeome collection.  
RNA interference 
siRNAs were incubated with Lipofectamine 2000 and serum free Optimem for 15 
min at room temperature in the dark. Cells were then trypsinized and resuspended in 1 
ml of medium and plated directly into the siRNA/Optimem/Lipofectamine solution at 
50% confluence and incubated for 72 h. Sequences of siRNA oligonucleotides used 
here are as follows: control non-targeting siRNA, 5’-UAGCGACUAAACACAUCAA-3’ 
(Thermo Fisher Scientific); RAD18 3’-untranslated region siRNA, 5’-UUAUA 
AAUGCCCAAGGAAAUU-3-; MAGE-A4 siRNA #1, 5’-AGUGUGAAUUCACCGUGAA -
3’, MAGE-A4 siRNA #2 (targeting the 3’-untranslated region), 5’-GUGAAAUAGGU 
GAGAUAAAUU-3’; and USP7, 5’-AAGCGUCCCUUUAGCAUUAUU-3’. For MAGE-A4 
depletions, siRNA#1 was used unless otherwise indicated.  
Genotoxin treatment 
For ultraviolet C (UVC) treatment, growth medium was removed from cultured cells 
and replaced with PBS. The resulting culture dishes plates were irradiated using an 
ultraviolet cross-linker (Stratagene) or left untreated for control. The UVC dose delivered 
to the cells was confirmed with an ultraviolet radiometer (UVP, Inc.). Following 
ultraviolet or sham irradiation, cells were re-fed with complete growth medium and 
returned to the incubator. For CPT treatments, cells were treated with 2 µM CPT and 
incubated for 2 h.  
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Fluorescence microscopy  
H1299 cells were grown to ~60% confluency on glass bottom plates (Mat-tek) and 
then transfected with a CFP-RAD18-WT expression plasmid. Twenty hours after 
transfection, cells were ultraviolet irradiated (20 Jm-2) or sham treated and fixed 6 h later 
for staining with anti-MAGE-A4 and fixed-cell imaging on a Zeiss 710 confocal 
microscope, in the UNC Microscopy Services Laboratory core facility, as described 
previously29.  
Immunoprecipitation and immunoblotting 
To prepare extracts containing soluble and chromatin-associated proteins, 
monolayers of cultured cells typically in 60 mm plates were washed three times in ice-
cold PBS and lysed in 500 µl of ice-cold cytoskeleton buffer (CSK buffer; 10 mM Pipes 
pH 6.8, 100 mM NaCl, 300 mM sucrose, 3 mM MgCl2, 1 mM EGTA, 1 mM dithiothreitol, 
0.1 mM ATP, 1 mM Na3VO4, 10 mM NaF and 0.1% Triton X-100) freshly supplemented 
with Protease Inhibitor Cocktail and Phostop (Roche). Lysates were centrifuged at 
1,000 g for 2 min, to remove the CSK-insoluble nuclei. Supernatants were removed and 
further centrifuged at 10,000 g for 10 min, to obtain a clarified fraction containing a 
mixture of cytosolic plus nucleosolic proteins. The detergent-insoluble nuclear fractions 
were washed once with 1 ml of CSK buffer and then resuspended in a minimal volume 
of CSK before analysis by SDS–PAGE and immunoblotting.  
For all immunoprecipitation experiments, input samples were normalized for protein 
concentration. Magnetic beads containing covalently conjugated antibodies against 
epitope tags were added to the extracts and incubations were performed overnight at 
4°C using rotating racks.  
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Immune complexes were recovered using magnetic stands. The beads were 
washed five times with 1 ml CSK (5–10 min per wash), to remove nonspecifically 
associated proteins. The washed immune complexes were boiled in protein loading 
buffer for 10 min, to release and denature for SDS–PAGE.  
For immunoblotting, cell extracts or immunoprecipitates were separated by SDS-
PAGE, transferred to nitrocellulose membranes, and incubated overnight with the 
following primary antibodies: PCNA (sc-56), Chk1 (sc-7898), β-actin (sc-130656), cyclin 
E (sc-198), GAPDH (sc-32233), MAGE-A4 (sc-292429), Pan-MAGE-A (sc71537) and 
GST (sc-53909) from Santa Cruz Biotech (Santa Cruz, CA); Polη (A301-231A), Polι 
(A301-304A), RAD6 (A300-281A), RAD18 (A301-340A) and USP7 (A300-033A) from 
Bethyl Laboratories (Montgomery, TX); p42 MAPK (9107) and MYC-Tag (2276) from 
Cell Signaling; γH2AX (05-636) from Millipore; and Cdc45 rat monoclonal antibody as 
previously described30. Antibody dilutions used for immunoblotting were 1:1,000, with 
exceptions for the following antibodies: PCNA (1:500), GAPDH (1:2,000) and γH2AX 
(1:2,000).  
In vitro protein-binding assays with lysate 
Mammalian cells were transfected with 2 µg of plasmid and incubated for 48 h. Cell 
lysate was collected in CSK buffer and centrifuged at 13,300 r.p.m. to clear lysate. 
Recombinant GST–RAD18 fragments (100 ng) were incubated in 1 ml CSK with 100 µg 
cleared lysate for 2 h at 4°C. Fifty microlitres of Glutathione Sepharose beads (GE 
Healthcare 17-0756-01) was added to the solution and incubated for 2 h more at 4°C. 
Beads and complexes were collected by centrifugation and washed three times in CSK 
+ 1% BSA, then resuspended in water and 4 x Laemmli buffer and boiled for 10 min.  
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In vitro RAD18–MAGE-A4 recombinant protein binding assay 
Recombinant 6 x His–MAGE-A4 (1 µg) was incubated in 1 ml of CSK + 1% BSA with 
either GST or GST–RAD18 (0.3 µg) for 2 h at 4°C. Fifty microlitres of Glutathione 
sepharose beads (GE Healthcare 17-0756-01) was added to the solution and incubated 
for 2 h more at 4°C. Beads and complexes were collected by centrifugation and washed 
three times in CSK + 1% BSA, then resuspended in water and 4 x Laemmli buffer and 
boiled for 10 min.  
In vitro degradation of RAD18 
HA–RAD18 was expressed alone or in combination with MAGE-A4 in 293T cells. 
Cells were collected using CSK buffer. HA–RAD18 complexes were isolated by 
immunoprecipitation using anti-HA magnetic beads (MBL Intl M-1329) for 2 h at 4°C. 
Beads were washed with CSK and incubated for 1 h at 37°C in 2 mM MgCl2, 1 mM 
creatine phosphate, 25 U ml-1 creatine phosphokinase (FisherSci, ICN10050990), PBS 
and 1 mg ml-1 of rabbit reticulocyte lysate, untreated (L4151), from Promega, as a 
source of ubiquitination factors and proteasome activity, as described by Hernandez-
Pigeon et al.31.  
Flow cytometry 
Cells were labeled with 10 µM BrdU immediately before harvest. Cells were 
collected by trypsinization, fixed in 35% ethanol for 24 h, then stained with anti-BrdU 
and propidium iodide as previously described26. Stained nuclei were analyzed by flow 




In vitro PCNA ubiquitination assay 
Recombinant RAD18–RAD6 complex was purified from baculovirus-infected Sf9 
cells and incubated with recombinant PCNA in the presence of E1, ubiquitin and an 
ATP-regenerating system as described previously32.  
SupF mutagenesis assay 
293T cells were co-transfected with a ultraviolet-irradiated (500 Jm-2) pSP189 
reporter plasmid33 and control, RAD18 or MAGE-A4 expression vectors using 
Lipofectamine 2000. Forty-eight hours later, pSP189 was recovered from the 293T cells 
using a DNA miniprep kit (Qiagen, Hilden, Germany). Purified plasmid DNA was DpnI 
digested and electroporated into the MBM7070 bacterial strain. The mutation frequency 
in the supF coding region was determined by enumerating the ratios of blue (WT) and 
white (mutant) colonies.  
Mass spectrometry  
PBS-washed cell pellets from HA-RAD18-expressing (and control) cells were lysed 
with CSK and digested with 1,000 U ml-1 of RNasefree DNase I (Roche) at 25°C for 30 
min. The resulting mixtures were sonicated to dissociate the nuclei. Insoluble material 
was removed by centrifugation at 10,000 g for 10 min. The resulting supernatant 
(containing cytosol, nucleosol and solubilized chromatin proteins) was used for 
immunoprecipitation of RAD18 complexes.  
Anti-HA-conjugated magnetic beads (MBL Intl, M-1329) were incubated with HA–
RAD18-containing supernatant for 4°C for 3 h. Following incubation, beads were 
washed in CSK. The protein complexes were digested directly off of the beads using 
FASP Protein Digestion Kit (Protein Discovery #44250).  
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Peptides were separated by reversed-phase nano-high-performance liquid 
chromatography with a nanoAquity UPLC system (Waters Corp.). Peptides were first 
trapped in a 2-cm trapping column (75-µm inside diameter (ID), Michom Magic C18 
beads of 5.0-µm particle size, 200-Å pore size) and then separated on a self-packed 25-
cm column (75-µm ID, Michom Magic C18 beads of 5.0-µm particle size, 100-Å pore 
size) at room temperature. The flow rate was 350 nl min-1 over a gradient of 1% buffer B 
(0.1% formic acid in acetonitrile) to 30% buffer B in 200 min. Next, a following wash 
raised buffer B to 70%. The identity of the eluted peptides was determined with an in-
line LTQ-Orbitrap Velos mass spectrometer (Thermo Scientific). The ion source was 
operated at 2.0–2.4 kV with the ion transfer tube temperature set at 250°C. Full MS 
scan (300 to 2,000 m/z) was acquired in Orbitrap at 60,000 resolution setting; 
datadependent MS2 spectra were acquired in LTQ by collision-induced dissociation with 
the 15 most intense ions. Precursor ions were selected on the basis of charge states (2 
or 3) and intensity thresholds (above 5,000) from the full scan; dynamic exclusion (one 
repeat every 30 s, with a 60-s exclusion time window) was also taken into account. The 
polysiloxane lock mass of 445.120030 was used throughout spectral acquisition.  
Protein identification, quantification and filtering. Raw data were analyzed using 
Sorcerer-SEQUEST (build 5.1.1, SageN Research) and the Transproteomic Pipeline 
(TPP v4.7.1). MS/MS spectra were searched against the human UniProtKB/ Swiss-Prot 
sequence database (downloaded February 2015) supplemented with common 
contaminants, that is, porcine (Swiss-Prot P00761) and bovine (P00760) trypsin, and 
further concatenated with its reversed copy as a decoy. Search parameters used were a 
precursor mass between 400 and 4,500 amu, up to 2 missed cleavages, precursor-ion 
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tolerance of 3 amu, accurate mass binning within PeptideProphet, semi-tryptic 
digestion, a static carbamidomethyl cysteine modification and variable methionine 
oxidation. False discovery rates were determined by ProteinProphet and minimum 
protein probability cutoffs resulting in a 1% false discovery rate were selected 
individually for each experiment. The resulting spectral count data from controls and 
HA–RAD18-WT APMS experiment were input into the Spotlite web application using 
SAINTexpress (version 3.1.0), to determine protein–protein interaction probabilities by 
modeling the expected spectral count distribution of true and false interactions. In 
addition, raw data were re-searched and signal intensity was quantified using the 
MaxQuant LFQ algorithm with the identical sequence database and search parameters, 
except a 20-p.p.m. precursor mass tolerance, fully tryptic digestion and match between 
runs were used.  
 
3.3 Results 
MAGE-A4 is a component of the RAD18–RAD6 complex.  
To identify new regulators of the TLS pathway we defined the RAD18 protein 
interaction network in H1299 adenocarcinoma cells using label-free affinity purification 
and shotgun mass spectrometry (APMS). As a control we also investigated the protein 
interaction network of a TLS-compromised RAD18 Δ402-444 mutant, which lacks a 
domain involved in mediating binding to Polη26, 28 and other partners34 (Fig. 1a). RAD18 
interaction networks were defined for HA–RAD18 wild type (WT) and HA–RAD18 Δ402-
444 complexes isolated from undamaged cells and from genotoxin (ultraviolet or 
Camptothecin (CPT))-treated cultures.  
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Co-complexed proteins were separated from background contaminants and false 
positives using the SAINT (significance analysis of interactome) algorithm. Top-scoring 
proteins included well-known RAD18 interactors such as RAD6A and RAD6B (E2 
ubiquitin-conjugating enzymes), PCNA (a RAD18 substrate) and MSH2, a reported 
regulator of RAD18 (35; Fig. 3.1B). As expected from previous work29, PCNA binding to 
RAD18 Δ402-444 was decreased or undetectable (Fig. 3.1C). One of the highest 
confidence and abundant novel RAD18 interactors we identified was the CTA MAGE-A4 
(Fig. 3.1C).  
The presence of MAGE-A4 in the RAD18 complexes was unaffected by ultraviolet or 
CPT, genotoxins that activate the distinct TLS and DSB repair effector pathways of 
RAD18, respectively. Comparison of relative MAGE-A4 abundance between RAD18 
WT and RAD18 Δ402-444 APMS revealed that MAGE-A4 association does not depend 
on the Polη-binding domain of RAD18.  
As the association of RAD18 with MAGE-A4 provided a potentially important new 
relationship between DNA-damage tolerance and cancer, we validated and further 
characterized the RAD18–MAGE-A4 interaction. First, we confirmed the RAD18– 
MAGE-A4 interaction in H1299 cells by performing independent co-immunoprecipitation 
(co-IP) and immunoblotting experiments (Fig. 3.1D).  
A genome-wide screen previously detected MAGE-A4 as a binding partner of the E3 
ubiquitin ligase TRIM6936, a mitotic regulator37. For the purpose of comparison with a 
known MAGE-A4 partner, we expressed MYC epitope-tagged RAD18 and TRIM69 at 
similar levels in H1299 cells and examined levels of MAGE-A4 associated with each E3 
ligase by co-IP. In a side-by-side comparison, RAD18 immune complexes contained 
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more MAGE-A4 than was present in TRIM69 immunoprecipitates (Fig. 3.1E). Other E3 
ubiquitin ligases we tested (HLTF1, SHPRH, RNF8 and RNF168) failed to co-IP with 
MAGE-A4 (not shown). We conclude that MAGE-A4 is a specific and constitutive 
component of the RAD18 complex in H1299 lung carcinoma cells. 
 MAGE-A4 associates with the RAD6-binding domain of RAD18.  
E3 ubiquitin ligases share many common sequence motifs. However, for the known 
MAGE-interacting RING-domain E3 ligases, no single consensus sequence or domain 
of the E3 is sufficient to mediate MAGE binding24, 25. Therefore, we performed 
experiments to map the MAGE-A4-interacting domain of RAD18. We expressed the 
different functional domains of the RAD18 protein as individual in-frame fusions with 
glutathione S-transferase (GST) (Fig. 3.2A), then performed ‘pull-down’ assays to 
identify the MAGE-A4-binding domain(s) of RAD18. As shown in Fig. 3.2B, the GST–
RAD18 267-402 fragment, specifically recovered MAGE-A4 from H1299 cell lysates. In 
reciprocal ‘pull-down’ experiments, GST–MAGE-A4 also recovered RAD18 from H1299 
and 293T cell lysates (Fig. 3.2C).  
Interestingly, GST–RAD18 (267–402) contains the RAD6- binding domain (amino 
acids 340–395) previously defined by Watanabe et al.28. Similar to MAGE-A4, RAD6 
was only recovered from cell lysates with GST–RAD18 (267–402) (Fig. 3.2B). To 
determine whether the RAD6-binding domain is also involved in RAD18–MAGE-A4 
complex formation in cells, we determined the effect of internal deletion of amino acids 
340–395 on the RAD18–MAGE-A4 association. Using transient transfection, HA–
RAD18 (WT) and HA–RAD18 D340–395 (Fig. 3.2D) were expressed at similar levels in 
H1299 cells (Fig. 3.2E). However, in co-IP and immunoblotting experiments, MAGE-A4 
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and RAD6 only associated with WT RAD18 (Fig. 3.2E). We conclude that the RAD6-
binding domain is necessary for RAD18–MAGE-A4 interactions in vitro and in cells.  
We considered the possibility that the association of MAGE-A4 with RAD18 might be 
indirect and mediated via RAD6. However, in pull-down experiments recombinant GST–
RAD6 did not recover MAGE-A4 from H1299 cell lysates (Fig. 3.2F). To more carefully 
evaluate a role for RAD6 (or other factors) in mediating the RAD18–MAGE-A4 
interaction, we performed binding studies using purified MAGE-A4 and GST–RAD18 
(267–402). As shown in Fig. 3.2G, we detected specific association of RAD18 (267–
402) with MAGE-A4 in the absence of RAD6. Using AlphaScreen-based protein 
proximity assays38, we validated the association of isolated MAGE-A4 (and of RAD6) 
with RAD18 (267–402) (Fig. 3.8). Interestingly, recombinant unlabeled RAD6 competed 
with epitope-tagged MAGE-A4 for RAD18 binding both in vitro and in cells (Fig. 3.8A–
D). However, gel filtration chromatography experiments show that most of the cellular 
RAD6 is free and monomeric (Fig 3.8E–H). Moreover, from quantitative immunoblotting, 
RAD6 levels in H1299 cells exceed MAGE-A4 by 28-fold and exceed RAD18 levels by 
114-fold (Fig. 3.9). Therefore, MAGE-A4 is not sufficiently abundant in H1299 cells to 
outcompete RAD6 for RAD18 association. We conclude that MAGE-A4 is a specific 
binding partner of RAD18 and associates with the RAD6-binding domain (as also 
reported for p95/NBS1)39.  
MAGE-A4 promotes RAD18 stability.  
Reportedly, several MAGE family members directly activate their partner E3 ligases 
to promote substrate ubiquitination25. Therefore, we performed in vitro ubiquitin ligase 
assays using recombinant proteins, to determine the effect of MAGE-A4 on RAD18-
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directed PCNA mono-ubiquitination. As shown in Fig. 3.3A, recombinant MAGE-A4 did 
not stimulate RAD18-dependent PCNA mono-ubiquitination under experimental 
conditions where other MAGE proteins stimulate catalytic activities of their cognate E3 
ligases25. Interestingly, MAGE-A4 was ubiquitinated by RAD18 (Fig. 3.3A). High molar 
ratios of MAGE-A4:RAD18 led to decreased PCNA mono-ubiquitination in vitro (Fig. 
3.3A). The apparent mild inhibition of PCNA mono-ubiquitination by MAGE-A4 in vitro 
results from substrate competition when MAGE-A4 is in vast excess of PCNA (Fig. 
3.3A, lanes 9–12).  
The major substrate and distal effector of RAD18-mediated ubiquitination in DNA 
damage tolerance is the sliding clamp PCNA, which is present on replicating chromatin 
in the nucleus.  
Although PCNA and RAD18 were present in both chromatin and soluble fractions, 
MAGE-A4 was primarily soluble (Fig. 3.3B). Moreover, in ultraviolet-irradiated H1299 
cells, RAD18 but not MAGE-A4 redistributed to nuclear foci representing sites of DNA 
replication stalling (Fig. 3.3C). Taken together, the results of Fig. 3.3A-C suggest that 
MAGE-A4 may not function as an allosteric activator of RAD18 or respond directly to 
replication fork stalling. Accordingly, we investigated alternative roles for MAGE-A4 in 
RAD18 regulation.  
Proteins often stabilize their binding partners. Therefore, we determined the effect of 
MAGE-A4 depletion on RAD18 levels. As shown in Fig. 3.3D, we attained ~90% 
depletion of MAGE-A4 in H1299 cells using two independent transiently transfected 
small interfering RNAs (siRNAs). Interestingly, both MAGE-A4- directed siRNAs led to 
substantial (92% and 73% decreases in RAD18 expression in H1299 cells). Neither 
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MAGE-A4-directed siRNA affected RAD18 levels in 293T cells, which lack detectable 
MAGE-A4 expression (Fig. 3.3D). Using cycloheximide treatment to block new protein 
synthesis, we measured RAD18 decay rates in control and MAGE-A4-depleted cultures. 
In control (MAGE-A4 replete) H1299 cells, RAD18 was stable for at least 24 hrs (the 
duration of this experiment, see Fig. 3.3E). In MAGEA4-depleted cells, RAD18 
expression was reduced and its half-life decreased when compared with MAGE-A4-
replete cells (Fig. 3.3E). RAD18 depletion did not affect the half-life of MAGE-A4 (Fig. 
3.3F). However, we note that MAGE-A4 levels exceed those of RAD18 by ~3-fold in 
H1299 cells (Fig. 3.9). Moreover, most of the cellular MAGE-A4 is not nuclear (Fig. 
3.3C) or in the same complex as RAD18 (Fig. 3.8f–h), explaining why RAD18 does not 
influence the overall MAGE-A4 pool.  
Figure 3.3D–F suggested that MAGE-A4 stabilizes RAD18. In previous work, 
proteasomal degradation of RAD18 (in USP7-depleted cells) was partially prevented by 
treatment with the proteasome inhibitor MG13240. Therefore, we determined the effect 
of MG132 treatments on RAD18 stability in control (MAGE-A4 replete), MAGE-A4-
depleted and USP7-depleted H1299 cells. RAD18 levels were unaffected by MG132 in 
MAGE-A4-replete H1299 cells in which RAD18 is stable and has a half-life (t1/2) 
exceeding 24 hrs (Fig. 3.3E). However, the reduced RAD18 stability in USP7- or 
MAGE-A4-depeleted H1299 cells was partially rescued by MG132 treatment (Fig. 4.4A). 
MG132-induced poly-ubiquitin laddering of RAD18 was also decreased by ectopically 
expressed MAGE-A4 in 293T cells, which lack endogenous MAGE-A4 (Fig. 3.10). To 
further test the effect of MAGE-A4 on RAD18 stability, we reconstituted the ubiquitin-
coupled proteolysis of RAD18 in a cell-free rabbit reticulocyte lysate and compared the 
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degradation of immunopurified HA–RAD18 complexes from control and MAGE-A4-
expressing cells. As shown in Fig. 3.4B, HA–RAD18 derived from MAGE-A4 co-
expressing 293T cells was degraded less efficiently when compared with RAD18 from 
control cultures lacking endogenous MAGE-A4. Taken together Figs 3.3A–F and 3.4A,B 
show that MAGE-A4 protects RAD18 from ubiquitin-coupled proteolysis.  
The results of Fig. 3.2 suggest that MAGE-A4 increases RAD18 expression via 
direct binding. Therefore, we compared the stabilizing effects of co-transfected MAGE-
A4 on HA–RAD18 WT and the MAGE-A4-interaction-deficient HA–RAD18 Δ340–395 
mutant. As shown in Fig. 3.4C, levels of HA–RAD18 WT were increased by co-
expressed MAGE-A4. HA–RAD18 Δ402–444 (which is defective for Polη interaction but 
binds MAGE-A4) was also stabilized by co-expressed MAGE-A4. However, levels of 
HA–RAD18 Δ340–395 (indicated by the white arrowhead in Fig. 3.4C) were insensitive 
to MAGE-A4.   
The MAGE-A4-interaction-deficient RAD18 mutant also lacks RAD6-binding activity. 
Therefore, we considered the possibility that failure of MAGE-A4 to stabilize RAD18 
Δ340–395 was secondary to impaired ubiquitin ligase activity. However, a catalytically 
inactive RAD18 C28F mutant was stabilized by co-expressed MAGE-A4 (Fig. 3.4C). We 
conclude that MAGE-A4 stabilizes RAD18 via direct interactions with the RAD6-binding 
motif and independently of RAD18 E3 ligase activity.  
Next we asked whether stabilization of associated E3 ligases represents a general 
mechanism for modulation of ubiquitin signaling by MAGE-A4. We determined the effect 
of MAGE-A4 expression on TRIM69 levels. As shown in Fig. 3.4D, MAGE-A4 
expression was inversely correlated with TRIM69 levels. Therefore, the stabilizing effect 
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of MAGE-A4 on RAD18 expression is relatively specific. Other MAGE-A4-associated E3 
ligases have not been identified but eventually it will be interesting to elucidate the basis 
for the differential effects of MAGE-A4 on stability of its (putative) other E3 ligase 
partners. 
Structural basis for MAGE-induced RAD18 stability.  
Previous investigators have used deletion and truncation mutants to isolate 
separable functional domains of MAGE proteins (albeit for effectors other than 
RAD18)41, 42. Therefore, we performed structure–function analyses to define MAGE-A4 
residues and domains that are important for stabilizing RAD18. We generated MAGE-
A4 deletion mutants lacking or retaining the winged-helix (WH)-A and WH-B regions of 
the MAGE-homology domain, as illustrated in Fig. 3.5A. In addition, we generated a 
MAGE-A4 LL4AA mutant harboring alanine substitutions in a di-Leucine motif (L121 and 
L122) that is conserved between MAGE proteins and is generally necessary for their 
interactions with E3 ubiquitin ligase partners. We also generated a MAGE-A4 mutant 
with an alanine substitution at Serine 90, a phosphorylated residue present in RAD18-
associated MAGE-A4. In transient transfections, the MAGE-A4 mutants were expressed 
with different efficiencies in 293T cells. Most notably, mutants lacking the WH-A and 
WH-B domains expressed poorly when compared with full-length MAGE-A4 (Fig. 3.5B 
and Fig. 3.11). We compared the various MAGE-A4 mutants for RAD18-stabilizing 
activity. As expected, WT MAGEA4 extended the half-life of RAD18 from ~24 to >50 h 
in 293T cells (Fig. 3.5C,D). MAGE-A4 S90A retained RAD18-stabilizing activity, 
indicating that MAGE-A4 S90 phosphorylation is dispensable for regulating RAD18 
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expression levels (Fig. 3.11). MAGE-A4 LL4AA did not affect RAD18 levels, suggesting 
that MAGE-A4–RAD18 interactions are necessary for MAGE-A4 to stabilize RAD18.  
All MAGE-A4 deletion mutants (including MAGE-A4 mutant AB, which retains a pro-
apoptotic carboxy-terminal domain of MAGE-A4 previously shown to bind gankyrin41, 42) 
failed to stabilize RAD18. We conclude that the individual WH-A or WH-B domains, or 
the entire MAGE-homology domain and its flanking sequences alone are insufficient to 
confer RAD18 stability. Instead, it is most likely to be that multiple regions of the MAGE-
A4 protein act in a concerted non-separable manner to stabilize RAD18.  
The MAGE family members are highly conserved and may, in some cases, have 
overlapping functions in activating their E3 ligase partners25. It was of interest to 
determine the extent to which other MAGE family members stabilized RAD18. We were 
able to ectopically express MAGE-A12, MAGE-B10 and MAGE-A1 in 293T cells (Fig. 
3.6A) and therefore these particular CTAs were tested for RAD18-stabilizing activity. 
Unexpectedly, despite the high conservation of primary sequences and domains 
between different MAGE family members, only MAGE-A4 stabilized RAD18 (Fig. 
3.6B,C). Interestingly, these cycloheximide stability experiments also showed that 
MAGE-A4 has a long half-life (>48 hrs) when compared with MAGE-B10, MAGE-A1 and 
MAGE-A12. Therefore, MAGE-A4 is highly stable compared with other MAGE family 
members and specifically stabilizes RAD18. 
MAGE-A4 promotes PCNA mono-ubiquitination and TLS.  
Increased expression of RAD18 can substantially enhance both basal and 
genotoxin-induced PCNA mono-ubiquitination5. Therefore, we determined whether 
MAGE-A4 contributes to RAD18-dependent TLS pathway activation in cancer cells. As 
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shown in Fig. 3.7A and Fig. 3.12, siRNA-mediated MAGE-A4 knockdown in H1299 cells 
led to an attenuation of ultraviolet-inducible PCNA mono-ubiquitination. The reduced 
PCNA ubiquitination of MAGE-depleted cells was rescued by co-transfection of siRNA-
resistant MAGE-A4 (Fig. 3.7A). 5-Bromodeoxyuridine (BrdU) labeling and fluorescence 
activated cell sorting analyses revealed no effect of MAGE-A4 depletion on DNA 
synthesis or cell cycle parameters (Fig. 3.7B). Therefore, the reduced PCNA mono-
ubiquitination of MAGEA4-depleted cells was not secondary to cell cycle changes.  
As MAGE-A4 depletion led to reduced PCNA monoubiquitination in H1299 cells, we 
also asked whether forced expression of MAGE-A4 in cells lacking the protein 
endogenously was sufficient to induce PCNA mono-ubiquitination. As shown in Fig. 
3.7C, ectopic overexpression of MAGE-A4 in A549 cells enhanced PCNA mono-
ubiquitination in response to low ultraviolet doses. Overexpressed MAGE-A4 did not 
affect PCNA mono-ubiquitination in H1299 cells (which already express high levels of 
endogenous MAGE-A4). MAGE-A4 also induced PCNA mono-ubiquitination when 
ectopically expressed in non-transformed mouse embryonic fibroblasts and human 
dermal fibroblasts. MAGE-A4 expression did not induce PCNA monoubiquitination in 
RAD18 -/- cells, demonstrating that the stimulatory effect of MAGE-A4 on PCNA mono-
ubiquitination was RAD18 dependent.  
As MAGE-A4 promotes RAD18-mediated PCNA monoubiquitination (Fig. 3.7A–C), 
we determined the potential contribution of MAGE-A4 to replication of damaged DNA. 
RAD18-depleted cells fail to recover appropriately from DNA damage-induced inhibition 
of DNA synthesis5. Interestingly, MAGE-A4 depletion partially phenocopied the 
defective S-phase recovery of RAD18-depleted H1299 cells from ultraviolet induced 
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replication arrest (Fig. 3.7D). Moreover, co-depletion of RAD18 and MAGE-A4 did not 
have additive inhibitory effects on S-phase recovery after ultraviolet treatment (Fig. 
3.7D). Similar to phenotypes described in RAD18-depleted cells, the defective recovery 
of MAGE-A4-depleted cells from S-phase arrest was associated with persistence of 
γH2AX (Fig. 3.7E). RAD18 expression was also MAGE-A4 dependent in H157 and 
H650 adenocarcinoma cells and in U2OS osteosarcoma cells (which express 
endogenous MAGE-A4; see Fig. 3.13A,B). Similar to H1299 cells, MAGE-A4 depletion 
led to an attenuation of PCNA mono-ubiquitination and increased γH2AX after 
ultraviolet treatment in U2OS cells (Fig. 3.13C). Taken together, the results of Fig. 
3.7C–E indicate a role for MAGEA4 in facilitating TLS and recovery from DNA damage-
induced replication fork stalling.  
To determine whether MAGE-A4 impacts RAD18-mediated genome maintenance 
we used an established assay in which RAD18 promotes error-free bypass of an 
ultraviolet-damaged pSP189 reporter plasmid, thereby suppressing mutagenesis43. As 
shown in Fig. 3.7F, ectopic expression of RAD18 in 293T cells suppressed mutagenesis 
of the ultraviolet-damaged supF reporter by 40%, consistent with previous reports43. 
Interestingly, MAGE-A4 expression alone led to a 31% decrease in mutagenesis. When 
co-expressed with RAD18, MAGE-A4 further enhanced the suppressive effect of 
RAD18 on mutagenesis. As expected, MAGE-A4 induced the expression of 
endogenous and ectopically co-expressed RAD18 coincident with suppression of 
mutagenesis (Fig. 3.7F). MAGE-A4 overexpression did not affect DNA synthesis rates 
or ultraviolet-checkpoint recovery of 293T cells (Fig. 3.14). Therefore, MAGE-A4 can 
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specifically influence replicative bypass of ultraviolet-induced DNA lesions, further 
consistent with its novel role in regulating RAD18 levels and TLS activity in cancer cells. 
 
3.4 Discussion 
Potts and colleagues25 made the seminal discovery that many MAGE proteins bind 
and activate E3 ubiquitin ligases, contributing to deregulated ubiquitin signaling in 
cancer cells. Our work identifies RAD18 as a target of MAGE-A4 and provides a new 
potential mechanism by which genome maintenance and genome stability can be 
altered in cancer cells.  
There are interesting similarities and differences in the relationship between MAGE-
A4 and RAD18 when compared with previously described MAGE-E3 ligase 
associations. For example, the conserved di-leucine motif required by other MAGE 
family members to activate their cognate E3 ligases25 is also necessary for MAGE-A4 to 
stabilize RAD18. However, although other MAGEs are allosteric activators of their 
associated E3 ligases25, MAGE-A4 does not stimulate catalytic activity of purified 
recombinant RAD18 under defined in vitro conditions. Instead MAGE-A4 stabilizes 
RAD18 to confer increased PCNA mono-ubiquitination and TLS. Therefore, this study 
provides a new paradigm for MAGE induced reprograming of ubiquitin signaling via 
altered E3 ligase stability in cancer cells.  
It is possible that MAGE-A4–RAD18 signaling also occurs during normal mammalian 
development and in non-pathological situations. Similar to MAGE proteins, Rad18 is 
expressed at high levels in germ cells and male rad18-/- mice have impaired 
spermatogenesis and fertility44. However, in preliminary experiments we have not 
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detected Mage-A4 (or other Mage proteins) in anti-RAD18 immunoprecipitates from 
mouse testes extracts. Therefore, we favor the hypothesis that RAD18 binding is a 
‘neomorphic’ activity of aberrantly expressed MAGE-A4 in cancer cells.  
Remarkably, although several MAGE-E3 ubiquitin ligase complexes have been 
characterized25, no conserved sequence motifs (on MAGE-A4 family member or E3 
ligases) mediate these protein–protein associations. Thus, the mechanism of 
association appears to be different for every MAGE-E3 ligase complex. Our structure–
function analyses show that MAGE-A4 binds and stabilizes RAD18 via the RAD6-
binding domain. Reportedly, p95/NBS1 also associates with the RAD6-binding domain 
of RAD1839. Physiologically, RAD18 exists as an asymmetric hetero-trimer comprising 
two RAD18 molecules in complex with one molecule of RAD645. Therefore, we 
hypothesize that one RAD18 molecule in the [RAD18]2–RAD6 heterotrimer has a ‘free’ 
RAD6-binding domain that is available to interface with MAGE-A4, p95 and perhaps 
additional proteins. This hypothesis predicts that MAGE-A4 and p95 (or other proteins) 
may compete for RAD18 binding in cancer cells, and that such competition may have 
an impact on genome maintenance events involving RAD18–p95 associations. MAGE-
A4 lacks the RAD6-like β-sheet and therefore interacts with RAD18 via a distinct 
mechanism. Clearly, biophysical and crystallographic studies will be necessary to fully 
characterize the putative [RAD18]2–RAD6–MAGE-A4 complex that exists in cancer 
cells.  
The only other documented E3 ligase-binding partner of MAGE-A4 is TRIM69 and 
the mechanism of MAGE-A4– TRIM69 association has not been studied. Other known 
effectors of MAGE-A4 are the transcription factor Miz142 and the liver oncoprotein 
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gankyrin41, which both bind a C-terminal region of MAGE-A4. We show here that the 
minimal MAGE-A4 C-terminal region (AB) that regulates Miz1 and gankyrin is 
insufficient to stabilize RAD18. Indeed, none of the major conserved MAGE-A4 domains 
retain RAD18-stabilizing activity in isolation. Therefore, RAD18 binding is probably not a 
modular interaction mediated by individual MAGE-A4 domains. Instead, the overall 
tertiary structure adopted by MAGE-A4 is likely to be involved in the formation of the 
MAGE-A4–[RAD18]2–RAD6 complex. The finding that all MAGE-A4 mutants failed to 
stabilize RAD18 may further support the idea that multiple regions of the MAGE-A4 are 
required for its RAD18 association. Other MAGE family members with a MAGE-A4-
related domain organization do not share RAD18-stabilizing activity, further suggesting 
that unique or specific tertiary structural determinants are required for MAGE-A4 to bind 
and stabilize RAD18.  
Regardless of the mechanism of MAGE-A4–RAD18 interaction, we show here that 
endogenous MAGE-A4 confers RAD18 stability and expression in cancer cells. TLS is 
generally assumed to be a housekeeping genome maintenance mechanism and it has 
not been suggested that expression or activities of core TLS pathway components are 
significantly different between cell types. However, expression levels of RAD18 and 
other TLS proteins (including Polη, Polι and PCNA) vary greatly between different 
cultured cell lines (Fig. 3.15). What then are the possible consequences of variable 
RAD18 and TLS polymerase expression on genome stability and carcinogenesis? 
RAD18-deficient cells do not recruit TLS polymerases to replication forks5, 16 and exhibit 
reduced lesion bypass activity17. Conversely, RAD18 overexpression stimulates PCNA 
ubiquitination, recruits Y-family polymerases to replication forks, promoting TLS5, 46. 
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Therefore, the repertoire of Y-family DNA polymerases and the degree to which 
different TLS polymerases respond to RAD18 and PCNA monoubiquitination may have 
enormous impact on genome stability when RAD18 is present at aberrantly high levels. 
For example, HeLa cells express unusually high levels of Polι compared with H1299 
cells (Fig. 3.15). Polι has exceptionally low fidelity, misincorporating dGTP more 
frequently than the correct dATP across ‘T’ on undamaged templates47. Therefore, 
increased RAD18 expression in a cell with aberrantly high Polι levels cell will probably 
have a severe effect on replication fidelity. Polk overexpression in cultured cells leads to 
insertions and deletions48. Consequently, Polk activation in response to aberrant RAD18 
overexpression might cause elevated frequency of indel mutations. Moreover, TLS 
polymerases have low processivity compared with replicative DNA polymerases. 
Therefore, elevated RAD18 expression and PCNA monoubiquitination could lead to 
rampant recruitment of Y-family polymerases to undamaged DNA, causing replication 
fork slowdown and/or other defects that result in ‘fork collapse’ and compromise 
genome stability due to DSB formation. A potential role for MAGE-A4–RAD18 as a 
mutagenic driver or source of genomic instability in cancer cells owing to inappropriate 
TLS polymerase activation is highly likely.  
Maiorano and colleagues46 recently showed that ectopic RAD18 overexpression can 
lead to DNA damage tolerance. Potentially, MAGE-A4-induced RAD18 expression 
might contribute to tumorigenesis by enhancing DNA-damage tolerance via TLS (and 
perhaps additional RAD18-mediated DNA repair pathways such as homologous 
recombination49 and cross-link repair34). Neoplastic cells must endure endogenous 
stresses including ROS-induced DNA damage and other forms of DNA replication 
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stress50. Collectively, TLS polymerases can perform bypass of oxidative lesions (such 
as 8-oxo-dG and AP sites) potentially conferring tolerance of oncogene-induced ROS. 
In addition, TLS polymerases can facilitate ongoing DNA synthesis in cells undergoing 
oncogene-induced re-replication22 (one of the earliest responses to oncogene activation 
in untransformed cells51). Therefore, increased TLS capacity afforded by MAGE-A4–
RAD18 may contribute to tolerance of spontaneously arising DNA damage and 
replication stress, thereby facilitating neoplastic cell survival and tumor progression.  
Clearly, future experiments are necessary to determine the potential contribution of 
MAGE-A4 and RAD18 to genome destabilization and tolerance of oncogenic stress. In 
addition to promoting tolerance of intrinsic oncogene-induced sources of stress (such as 
ROS and re-replication), RAD18 confers tolerance of chemo/radiotherapy52, 53. 
Therefore, the MAGE-A4–RAD18 signaling axis may represent an attractive therapeutic 
target that, when inhibited, could be innocuous to normal cells but selectively sensitize 






Figure 3.1: MAGE-A4 is a novel component of the RAD18 complex in cancer cells  
 
(A) Domain organization of full-length RAD18 and RAD18 Δ402-444 (which harbors an 
internal deletion removing the Polη-binding domain). (B) Spectral counts and estimated 
probability of true interaction by SAINT analysis for selected proteins identified HA-
RAD18-WT and Control (HA) APMS experiments. (C) Total protein signal intensity 
versus relative abundance between HA-RAD18-WT and HA-RAD18 Δ402-444 APMS. 
Signal intensity was normalized to the corresponding experiment’s bait intensity (x axis). 
(D) H1299 cells were infected with adenoviruses encoding WT HA-RAD, HA-RAD18 
Δ402-444 or with an ‘empty’ control adenovirus. Infected cells were treated with CPT (2 
µM) or UVC (20 Jm-2). Two hours (h) later, cell extracts were prepared and 
immunoprecipitated with anti-HA antibody- conjugated magnetic beads. The resulting 
immune complexes and input fractions were analyzed by immunoblotting with anti-HA 
and anti-MAGE-A4 antibodies. (E) Expression vectors encoding MYC–RAD18, MYC–
TRIM69 or green fluorescent protein (GFP) (for control plasmid) were transiently 
transfected into H1299 cells. Extracts from the resulting cells were immunoprecipitated 
with an anti-MYC antibody and the resulting immune complexes (or input fractions) 
were analyzed by immunoblotting with antibodies against MAGE-A4 and MYC.  
 
  
undetectable (Fig. 1c and Supplementary Note 1). The complete
list of proteins detected in RAD18 complexes is available in
Supplementary Data 1. One of the highest confidence and
abundant novel RAD18 interactors we identified was the CTA
MAGE-A4 (Fig. 1c).
The presence of E-A4 in the RAD18 complexes wa
unaffected by ultraviolet or CPT, genotoxins that activate the
distinct TLS and DSB repair effector pathways of RAD18,
respectively. Comparison of relative MAGE-A4 abundance
between RAD18 WT and RAD18 D402-444 APMS revealed that
MAGE-A4 association does not depend on the PolZ-binding
domain of RAD18.
As the association of RAD18 with MAGE-A4 provided a
potentially important new relationship between DNA-damage
tolerance and cancer, we validated and further characterized the
RAD18–MAGE-A4 interaction. First, we confirmed the RAD18–
MAGE-A4 interaction in H1299 cells by performing independent
co-immunoprecipitation (co-IP) and immunoblotting experi-
ments (Fig. 1d).
A genome-wide screen previously detected MAGE-A4 as a
binding partner of the E3 ubiquitin ligase TRIM69 (ref. 31), a
mitotic regulator32. For the purpose of comparison with a known
MAGE-A4 partner, we expressed MYC epitope-tagged RAD18
and TRIM69 at similar levels in H1299 cells and examined levels
of MAGE-A4 associated with each E3 ligase by co-IP. In a side-
by-side comparison, RAD18 immune complexes contained more
MAGE-A4 than was present in TRIM69 immunoprecipitates
(Fig. 1e). Other E3 ubiquitin ligases we tested (HLTF1, SHPRH,
RNF8 and RNF168) failed to co-IP with MAGE-A4 (not shown).
We conclude that MAGE-A4 is a specific and constitutive
component of the RAD18 complex in H1299 lung carcinoma
cells.
MAGE-A4 associates with the RAD6-binding domain of RAD18.
E3 ubiquitin ligases share many common sequence motifs.
However, for the known MAGE-interacting RING-domain
E3 ligases, no single consensus sequence or domain of the
E3 is sufficient to mediate MAGE binding24,25. Therefore, we
performed experiments to map the MAGE-A4-interacting
domain of RAD18. We expressed the different functional
domains of the RAD18 protein as individual in-frame fusions
with glutathione S-transferase (GST) (Fig. 2a), then performed
‘pull-down’ assays to identify the MAGE-A4-binding domain(s)
of RAD18. As shown in Fig. 2b, the GST–RAD18 267-402






































































































































































Figure 1 | MAGE-A4 is a novel component of the RAD18 complex in cancer cells. (a) Domain organization of full-length RAD18 and RAD18 D402–444
(which harbours an internal deletion removing the PolZ-binding domain). (b ) Spectral counts and estimated probability of true interaction by SAINT
analysis for selected proteins identified in HA–RAD18-WTand Control (HA) APMS experiments. (c) Total protein signal intensity versus relative abundance
between HA–RAD18-WT and HA–RAD18 D402–444 APMS. Signal intensity was normalized to the corresponding experiment’s bait intensity (x axis).
(d) H1299 cells were infected with adenoviruses encoding WT HA–RAD18, HA–RAD18 D402–444 or with an ‘empty’ control adenovirus. Infected cells
were treated with CPT (2mM) or UVC (20 J m! 2). Two hours (h) later, cell extracts were prepared and immunoprecipitated with anti-HA antibody-
conjugated magnetic beads. The resulting immune complexes and input fractions were analysed by immunoblotting with anti-HA and anti-MAGE-A4
antibodies. (e) Expression vectors encoding MYC–RAD18, MYC–TRIM69 or green fluorescent protein (GFP) (for control plasmid) were transiently
transfected into H1299 cells. Extracts from the resulting cells were immunoprecipitated with an an i-MYC antibody and the resulting immune complexes
(or input fractions) were analysed by immunoblotting with antibodies against MAGE-A4 and MYC.
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Figure 3.2: MAGE-A4 associates with the RAD6-binding domain of RAD18.  
 
  
lysates. In reciprocal ‘pull-down’ experiments, GST–MAGE-A4
also recovered RAD18 from H1299 and 293T cell lysates
(Fig. 2c).
Interestingly, GST–RAD18 (267–402) contains the RAD6-
binding domain (amino acids 340–395) previously defined by
Watanabe et al.26. Similar to MAGE-A4, RAD6 was only
recovered from cell lysates with GST–RAD18 (267–402)
(Fig. 2b). To determine whether the RAD6-binding domain is
also involved in RAD18–MAGE-A4 complex formation in cells,
we determined the effect of internal deletion of amino acids
340–395 on the RAD18–MAGE-A4 association. Using transient
transfection, HA–RAD18 (WT) and HA–RAD18 D340–395
(Fig. 2d) were expressed at similar levels in H1299 cells
(Fig. 2e). However, in co-IP and immunoblotting experiments,
MAGE-A4 and RAD6 only associated with WT RAD18 (Fig. 2e).
We conclude that the RAD6-binding domain is necessary for
RAD18–MAGE-A4 interactions in vitro and in cells.
We considered the possibility that the association of
MAGE-A4 with RAD18 might be indirect and mediated via
RAD6. However, in pull-down experiments recombinant
GST–RAD6 did not recover MAGE-A4 from H1299 cell lysates
(Fig. 2f). To more carefully evaluate a role for RAD6 (or other
factors) in mediating the RAD18–MAGE-A4 interaction, we
performed binding studies using purified MAGE-A4 and
GST–RAD18 (267–402). As shown in Fig. 2g, we detected
specific association of RAD18 (267–402) with MAGE-A4 in the
absence of RAD6. Using ALPHAscreen-based protein proximity
assays33, we independently validated the association of
isolated MAGE-A4 (and of RAD6) with RAD18 (267–402)



































































































































































Figure 2 | MAGE-A4 associates with the RAD6-binding domain of RAD18. (a) The indicated RAD18 fragments were expressed as GST fusions in E. coli.
The RAD6-binding domain spanning residues 267–402 is highlighted in red. (b) GST–RAD18 fragments were incubated with H1299 cell extracts. After
‘pull-down’ with GSH-sepharose beads, the recovered GST–RAD18 fusions and 5% of ‘input’ H1299 cell lysate were analysed by immunoblotting with
antibodies against GST, MAGE-A4 and RAD6. (c) GST–MAGE-A4 or GST was incubated with extracts from H1299 or 293T cells. After pulldown with
GSH-sepharose beads, the recovered GST proteins (and 5% of input cell extract) were analysed by immunoblotting with antibodies against GST and
RAD18. (d) Domain organization of full-length RAD18 and the RAD18 D340–395 (DR6BD) mutant harbouring an internal deletion that removes the
RAD6-binding domain. (e) H1299 cells were transiently transfected with expression plasmids encoding HA–RAD18 and HA–RAD18 D340–395 (DR6BD) or
with an empty vector control. Lysates from the resulting cells were immunoprecipitated with anti-HA antibodies. Anti-HA immune complexes and
inputs (20mg) were analysed by immunoblotting with antibodies against RAD18, MAGE-A4 and RAD6. (f) Recombinant GST, GST–RAD18 267–402 or
GST–RAD6 were incubated with H1299 cell extracts then pulled down with GSH-sepharose beads. The recovered GST proteins were analysed by
immunoblotting with antibodies against MAGE-A4 and GST. (g) Recombinant GST and GST–RAD18 267–402 were incubated with full-length recombinant
Hexa-histidine-tagged MAGE-A4 (His-MAGE-A4). GST proteins were recovered using GSH-sepharose beads. Recovered GST proteins (and 5% of input)
were analysed by immunoblotting with antibodies against GST and MAGE-A4.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms12105
4 NATURE COMMUNICATIONS | 7:12105 | DOI: 10.1038/ncomms12105 | www.nature.com/naturecommunications
 97 
Figure 3.2: MAGE-A4 associates with the RAD6-binding domain of RAD18. 
(A) The indicated RAD18 fragments were expressed as GST fusions in E. coli. The 
RAD6-binding domain spanning residues 267–402 is highlighted in red. (B) GST–
RAD18 fragments were incubated with H1299 cell extracts. After ‘pull-down’ with GSH-
sepharose beads, the recovered GST–RAD18 fusions and 5% of ‘input’ H1299 cell 
lysate were analyzed by immunoblotting with antibodies against GST, MAGE-A4 and 
RAD6. (C) GST–MAGE-A4 or GST was incubated with extracts from H1299 or 293T 
cells. After pulldown with GSH-sepharose beads, the recovered GST proteins (and 5% 
of input cell extract) were analyzed by immunoblotting with antibodies against GST and 
RAD18. (D) Domain organization of full-length RAD18 and the RAD18 D340–395 
(ΔR6BD) mutant harboring an internal deletion that removes the RAD6-binding domain. 
(E) H1299 cells were transiently transfected with expression plasmids encoding HA–
RAD18 and HA–RAD18 D340–395 (ΔR6BD) or with an empty vector control. Lysates 
from the resulting cells were immunoprecipitated with anti-HA antibodies. Anti-HA 
immune complexes and inputs (20 mg) were analyzed by immunoblotting with 
antibodies against RAD18, MAGE-A4 and RAD6. (F) Recombinant GST, GST–RAD18 
267–402 or GST–RAD6 were incubated with H1299 cell extracts then pulled down with 
GSH-sepharose beads. The recovered GST proteins were analyzed by immunoblotting 
with antibodies against MAGE-A4 and GST. (G) Recombinant GST and GST–RAD18 
267–402 were incubated with full-length recombinant Hexa-histidine-tagged MAGE-A4 
(His-MAGE-A4). GST proteins were recovered using GSH-sepharose beads. 
Recovered GST proteins (and 5% of input) were analyzed by immunoblotting with 




Figure 3.3 MAGE-A4 promotes RAD18 stability.  
 
  
RAD6 competed with epitope-tagged MAGE-A4 for RAD18
binding both in vitro and in cells (Supplementary Fig. 1a–d).
However, gel filtration chromatography experiments show that
most of the cellular RAD6 is free and monomeric (Supplementary
Fig 1e–h). Moreover, from quantitative immunoblotting, RAD6
levels in H1299 cells exceed MAGE-A4 by 28-fold and exceed
RAD18 levels by 114-fold (Supplementary Fig. 2). Therefore,
MAGE-A4 is not sufficiently abundant in H1299 cells to
outcompete RAD6 for RAD18 association. We conclude that
MAGE-A4 is a specific binding partner of RAD18 and associates
with the RAD6-binding domain (as also reported for p95/NBS1)34.
MAGE-A4 promotes RAD18 stability. Reportedly, several
MAGE family members directly activate their partner E3 ligases
to promote substrate ubiquitination25. Therefore, we performed
in vitro ubiquitin ligase assays using recombinant proteins, to
determine the effect of MAGE-A4 on RAD18-directed PCNA
mono-ubiquitination. As shown in Fig. 3a, recombinant
MAGE-A4 did not stimulate RAD18-dependent PCNA
mono-ubiquitination under experimental conditions where
other MAGE proteins stimulate catalytic activities of their
cognate E3 ligases25. Interestingly, MAGE-A4 was ubiquitinated
by RAD18 (Fig. 3a). High molar ratios of MAGE-A4:RAD18 led
to decreased PCNA mono-ubiquitination in vitro (Fig. 3a). The
apparent mild inhibition of PCNA mono-ubiquitination by
MAGE-A4 in vitro results from substrate competition when
MAGE-A4 is in vast excess of PCNA (Fig. 3a, lanes 9–12).
The major substrate and distal effector of RAD18-mediated
ubiquitination in DNA damage tolerance is the sliding clamp
PCNA, which is present on replicating chromatin in the nucleus.
Although PCNA and RAD18 were present in both chromatin
and soluble fractions, MAGE-A4 was primarily soluble (Fig. 3b).
Moreover, in ultraviolet-irradiated H1299 cells, RAD18 but not
MAGE-A4 redistributed to nuclear foci representing sites of DNA
replication stalling (Fig. 3c and Supplementary Fig. 3). Taken
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Figure 3 | MAGE-A4 promotes RAD18 stability. (a) Rec mbinant RAD18–RAD6 complex (0, 0.27, 0.54 and 0.82 mM) was incubated with E1, ubiquitin
and purified PCNA. Reaction products were analysed by immunoblotting with antibodies against the indicated proteins. (b) Soluble and chromatin fractions
from H1299 cells were analysed by SDS–PAGE (20 mg per lane) and immunoblotting with antibodies against the indicated proteins. (c) H1299 cells were
transiently transfected with an expression plasmid encoding CFP-RAD18 (or empty vector for control), ultraviolet irradiated (20 J m! 2) and processed for
immunofluorescence microscopy after 6 h. Scale bar, 10mm. (d) H1299 and 293T cells were transfected with two independent siRNAs targeting MAGE-A4
or with control non-targeting siRNA oligonucleotides. After 72 h, extracts from the siRNA-transfected cells were analysed by immunoblotting with
antibodies against the indicated proteins. (e,f) H1299 cells were transfected with siRNA oligonucleotides against MAGE-A4, RAD18 or control non-
targeting siRNA as indicated. Forty eight hours later, cells were treated with cycloheximide (CHX, 100mg ml! 1) and collected at different time points for
immunoblot analysis.
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Figure 3.3 MAGE-A4 promotes RAD18 stability.  
 
(A) Recombinant RAD18–RAD6 complex (0, 0.27, 0.54 and 0.82 µM) was incubated 
with E1, ubiquitin and purified PCNA. Reaction products were analyzed by 
immunoblotting with antibodies against the indicated proteins. (B) Soluble and 
chromatin fractions from H1299 cells were analyzed by SDS–PAGE (20 µg per lane) 
and immunoblotting with antibodies against the indicated proteins. (C) H1299 cells were 
transiently transfected with an expression plasmid encoding CFP-RAD18 (or empty 
vector for control), ultraviolet irradiated (20 J m-2) and processed for 
immunofluorescence microscopy after 6 h. Scale bar, 10 µm. (D) H1299 and 293T cells 
were transfected with two independent siRNAs targeting MAGE-A4 or with control non-
targeting siRNA oligonucleotides. After 72 h, extracts from the siRNA-transfected cells 
were analyzed by immunoblotting with antibodies against the indicated proteins. (E,F) 
H1299 cells were transfected with siRNA oligonucleotides against MAGE-A4, RAD18 or 
control non-targeting siRNA as indicated. Forty-eight hours later, cells were treated with 






Figure 3.4 MAGE-A4 protects RAD18 from ubiquitin-mediated proteolysis.  
 
(A) Replicate plates of H1299 cells were transfected with siRNA against MAGE-A4, 
USP7 or with non-targeting control siRNA. After 48 h, one plate of each replicate was 
treated with 10 µM MG132 for 16 h. Extracts from control and MG132-treated cells were 
analyzed by immunoblotting with antibodies against the indicated proteins. (B) 293T 
cells were co-transfected with an HA–RAD18 expression vector in combination with a 
CMV-MAGE-A4 plasmid or an empty vector for control. After 48 h, RAD18 complexes 
were immunoprecipitated with anti-HA antibodies. The resulting immune complexes 
were incubated in a rabbit reticulocyte lysate (RRL) to reconstitute ubiquitin-coupled 
proteolysis in vitro. Relative levels of RAD18 and MAGE-A4 were determined by 
immunoblotting and quantified using densitometry. (C) H1299 cells were transiently co-
transfected with WT or mutant HA–RAD18 expression plasmids in combination with a 
MAGE-A4 expression vector (or empty vector control). Forty-eight hours later, cells 
were harvested for immunoblot analysis of RAD18 and MAGE-A4. The white arrowhead 
indicates the RAD18Δ340–395 mutant protein band that is insensitive to MAGE-A4. (D) 
Replicate cultures of H1299 cells were transfected with an expression vector encoding 
MYC–TRIM69 or with an empty vector plasmid for control. Sixteen hours later, the cells 
were transfected with siRNA against MAGE-A4 or with a scrambled control siRNA and 
incubated for an additional 48 h before immunoblot analysis.  
  
together, the results of Fig. 3a–c suggest that MAGE-A4 may not
function as an allosteric activator of RAD18 or respond directly to
replication fork stalling. Accordingly, we investigated alternative
roles for MAGE-A4 in RAD18 regulation.
Proteins often stabilize their binding partners. Therefore, we
determined the effect of MAGE-A4 depletion on RAD18 levels.
As shown in Fig. 3d, we attained B90% depletion of MAGE-A4
in H1299 cells using two independent transiently transfected
small interfering RNAs (siRNAs). Interestingly, both MAGE-A4-
directed siRNAs led to substantial (92% and 73% decreases in
RAD18 expression in H1299 cells). Neither MAGE-A4-directed
siRNA affected RAD18 levels in 293T cells, which lack detectable
MAGE-A4 expression (Fig. 3d). Using cycloheximide treatment
to block new protein synthesis, we measured RAD18 decay
rates in control and MAGE-A4-depleted cultures. In control
(MAGE-A4 replete) H1299 cells, RAD18 was stable for at least
24 h (the duration of this experiment, see Fig. 3e). In MAGE-
A4-depleted cells, RAD18 expression was reduced and its half-life
decreased when compared with MAGE-A4-replete cells (Fig. 3e).
RAD18 depletion did not affect the half-life of MAGE-A4
(Fig. 3f). However, we note that MAGE-A4 levels exceed those of
RAD18 by B3-fold in H1299 cells (Supplementary Fig. 2).
Moreover, most of the cellular MAGE-A4 is not nuclear (Fig. 3c)
or in the same complex as RAD18 (Supplementary Fig. 1f–h),
explaining why RAD18 does not influence the overall MAGE-A4
pool.
Figure 3d–f suggested that MAGE-A4 stabilizes RAD18.
In previous work, proteasomal degradation of RAD18
(in USP7-depleted cells) was partially prevented by treatment
with the proteasome inhibitor MG132 (ref. 35). Therefore, we
determined the effect of MG132 treatments on RAD18 stability
in control (MAGE-A4 replete), MAGE-A4-depleted and
USP7-depleted H1299 cells. RAD18 levels were unaffected by
MG132 in MAGE-A4-replete H1299 cells in which RAD18 is
stable and has a half-life (t1/2) exceeding 24 h (Fig. 3e). However,
the reduced RAD18 stability in USP7- or MAGE-A4-depeleted
H1299 cells was partially rescued by MG132 treatment (Fig. 4a).
MG132-induced poly-ubiquitin laddering of RAD18 was also
decreased by ectopically expressed MAGE-A4 in 293T cells,
which lack endogenous MAGE-A4 (Supplementary Fig. 4). To
further test the effect of MAGE-A4 on RAD18 stability, we
reconstituted the ubiquitin-coupled proteolysis of RAD18 in a
cell-free rabbit reticulocyte lysate and compared the degradation
of immunopurified HA–RAD18 complexes from control and
MAGE-A4-expressing cells. As shown in Fig. 4b, HA–RAD18
derived from MAGE-A4 co-expressing 293T cells was degraded
less efficiently when compared with RAD18 from control cultures
lacking endogenous MAGE-A4. Taken together Figs 3a–f
and 4a,b show that MAGE-A4 protects RAD18 from ubiquitin-
coupled proteolysis.
The results of Fig. 2 suggest that MAGE-A4 increases RAD18
expression via direct binding. Therefore, we compared the stabi-
lizing effects of co-transfected MAGE-A4 on HA–RAD18 WT
and the MAGE-A4-interaction-deficient HA–RAD18 D340–395
mutant. As shown in Fig. 4c, levels of HA–RAD18 WT were
increased by co-expressed MAGE-A4. HA–RAD18 D402–444
(which is defective for PolZ interaction but binds MAGE-A4)
was also stabilized by co-expressed MAGE-A4. However, levels of
HA–RAD18 D340–395 (indicated by the white arrowhead in
Fig. 4c) were insensitive to MAGE-A4.
The MAGE-A4-interaction-deficient RAD18 mutant also lacks
RAD6-binding activity. Therefore, we considered the possibility
that failure of MAGE-A4 to stabilize RAD18 D340–395 was
secondary to impaired ubiquitin ligase activity. However, a
catalytically inactive RAD18 C28F mutant was stabilized by







































































Figure 4 | MAGE-A4 protects RAD18 from ubiquitin-mediated proteolysis. (a) Replicate plates of H1299 cells were transfected with siRNA against
MAGE-A4, USP7 or with non-ta geting control siRNA. Af r 48 h, one plate of each replicate was treated with 10mM MG132 for 16 h. Extracts from control
and MG132-treated cells were analysed by immunoblotting with antibodies against the indicated proteins. (b) 293T cells were co-transfected with
an HA–RAD18 expression vector in ombination with a CMV-MAGE-A4 pl smid or an empty vector for control. After 48 h, RAD18 complexes were
immunoprecipitated with anti-HA antibodies. The resulting immune complexes were incubated in a rabbit reticulo yte lys te (RRL) to reconstitute
ubiquitin-coupled proteolysis in vitro. Relative levels of RAD18 and MAGE-A4 were determined by immunoblotting and quantified using densitometry.
(c) H1299 cells were transiently co-transfected with WT or mutant HA–RAD18 expression plasmids in c mbination with a MAGE-A4 expression vector
(or empty vector control). Forty eight hours later, cells were harvested for immunoblot analysis of RAD18 and MAGE-A4. The white arrowhead indicates
the RAD18D340–395 mutant protein band that is insensitive to MAGE-A4. (d) Replicate cultures of H1299 cells were transfected with an expression
vector encoding MYC–TRIM69 or with an empty vector plasmid for control. Sixteen hours later, the cells were transfected with siRNA against MAGE-A4 or
with a scrambled control siRNA and incubated for an additional 48 h before immunoblot analysis.
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Figure 3.5: Mutational analyses to define structural requirements for MAGE-A4-
induced RAD18 stabilization.  
ultraviolet-checkpoint recovery of 293T cells (Supplementary
Fig. 8). Therefore, MAGE-A4 can specifically influence repli-
cative bypass of ultraviolet-induced DNA lesions, further
consistent with its novel role in regulating RAD18 levels and
TLS activity in cancer cells.
Discussion
Potts and colleagues25 made the seminal discovery that many
MAGE proteins bind and activate E3 ubiquitin ligases,
contributing to deregulated ubiquitin signalling in cancer cells.
Our work identifies RAD18 as a target of MAGE-A4 and provides
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Figure 5 | Mutational analyses to define structural requirements for MAGE-A4-induced RAD18 stabilization. (a) Domain structure of full-length
MAGE-A4 and MAGE-A4 mutants used in this study. The MAGE-homology domain (MHD) is conserved between MAGE family members and comprises
juxtaposed WH-A and WH-B regions. (b) 293T cells were transiently transfected with expression vectors encoding the MAGE-A4 mutants shown in a or
with an empty vector (EV). After 48 h, extracts from the resulting cells were analysed by immunoblotting with anti-Pan-MAGE-A (which recognizes an
epitope in the WH-B domain) or with anti-MAGE-A4 (which recognizes a C-terminal epitope of MAGE-A4 in residues 275–317). (c) Replicate plates of
293T cells were transiently transfected with expression vectors encoding WT or mutant forms of MAGE-A4. Forty-eight hours post transfection, cells were
treated with cycloheximide (CHX) and then harvested at different times post CHX. Cell extracts were analysed by immunoblotting with antibodies against
RAD18, MAGE-A4 and actin. (d) RAD18 levels in each lane of immunoblots in c were quantified by densitometry with ImageJ software. The graph indicates
the levels of RAD18 remaining at each time point following CHX treatment in control and MAGE-A4-expressing cells.
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Figure 5: Mutational analyses to define structural requirements for MAGE-A4-
induced RAD18 stabilization. 
 
(A) Domain structure of full-length MAGE-A4 and MAGE-A4 mutants used in this study. 
The MAGE-homology domain (MHD) is conserved between MAGE family members and 
comprises juxtaposed WH-A and WH-B regions. (B) 293T cells were transiently 
transfected with expression vectors encoding the MAGE-A4 mutants shown in A or with 
an empty vector (EV). After 48 h, extracts from the resulting cells were analyzed by 
immunoblotting with anti-Pan-MAGE-A (which recognizes an epitope in the WH-B 
domain) or with anti-MAGE-A4 (which recognizes a C-terminal epitope of MAGE-A4 in 
residues 275–317). (C) Replicate plates of 293T cells were transiently transfected with 
expression vectors encoding WT or mutant forms of MAGE-A4. Forty-eight hours post 
transfection, cells were treated with cycloheximide (CHX) and then harvested at 
different times post CHX. Cell extracts were analyzed by immunoblotting with antibodies 
against RAD18, MAGE-A4 and actin. (D) RAD18 levels in each lane of immunoblots in c 
were quantified by densitometry with ImageJ software. The graph indicates the levels of 
RAD18 remaining at each time point following CHX treatment in control and MAGE-A4-




Figure 3.6: Effect of MAGE family members on RAD18 stability.  
a new potential mechanism by which genome maintenance and
genome stability can be altered in cancer cells.
There are interesting similarities and differences in the
relationship between MAGE-A4 and RAD18 when compared
with previously described MAGE-E3 ligase associations. For
example, the conserved di-leucine motif required by other
MAGE family members to activate their cognate E3 ligases25 is
also necessary for MAGE-A4 to stabilize RAD18. However,
although other MAGEs are allosteric activators of their
associated E3 ligases25, MAGE-A4 does not stimulate catalytic
activity of purified recombinant RAD18 under defined
in vitro conditions. Instead MAGE-A4 stabilizes RAD18 to
confer increased PCNA mono-ubiquitination and TLS.
Therefore, this study provides a new paradigm for MAGE-
induced reprograming of ubiquitin signalling via altered E3
ligase stability in cancer cells.
It is possible that MAGE-A4–RAD18 signalling also occurs
during normal mammalian development and in non-pathological
situations. Similar to MAGE proteins, Rad18 is expressed at high
levels in germ cells and male rad18! /!mice have impaired
spermatogenesis and fertility39. However, in preliminary
experiments we have not detected Mage-a4 (or other Mage
proteins) in anti-RAD18 immunoprecipitates from mouse testes
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Figure 6 | Effect of MAGE family members on RAD18 stability. (a) 293T cells were transfected with expression vectors encoding FLAG-tagged forms of
WT MAGE-A4, MAGE-A4 AB (see Fig. 5a), MAGE-A12, MAGE-B10 and MAGE-A1. After 48 h, extracts were prepared from the transfected cells and
analysed by immunoblotting with anti-Pan-MAGE and anti-FLAG antibodies. (b) Replicate plates of 293T cells were transiently transfected with expression
vectors encoding WT MAGE-A4, MAGE-A4 AB, MAGE-A12, MAGE-B10 and MAGE-A1. Forty-eight hours post transfection, cells were treated with
cycloheximide (CHX) and then harvested at different times post CHX. Cell extracts were analysed by immunoblotting with antibodies against RAD18, FLAG
and actin. (c) RAD18 levels in each lane of immunoblots in b were quantified by densitometry with ImageJ software. The graph indicates the levels of
RAD18 remaining at each time point following CHX treatment in control and MAGE-expressing cells.
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Figure 3.6: Effect of MAGE family members on RAD18 stability. 
 
(A) 293T cells were transfected with expression vectors encoding FLAG-tagged forms 
of WT MAGE-A4, MAGE-A4 AB (see Fig. 5a), MAGE-A12, MAGE-B10 and MAGE-A1. 
After 48 h, extracts were prepared from the transfected cells and analyzed by 
immunoblotting with anti-Pan-MAGE and anti-FLAG antibodies. (B) Replicate plates of 
293T cells were transiently transfected with expression vectors encoding WT MAGE-A4, 
MAGE-A4 AB, MAGE-A12, MAGE-B10 and MAGE-A1. Forty-eight hours post 
transfection, cells were treated with cycloheximide (CHX) and then harvested at 
different times post CHX. Cell extracts were analyzed by immunoblotting with antibodies 
against RAD18, FLAG and actin. (C) RAD18 levels in each lane of immunoblots in b 
were quantified by densitometry with ImageJ software. The graph indicates the levels of 
RAD18 remaining at each time point following CHX treatment in control and MAGE-




Figure 3.7 MAGE-A4 promotes TLS and DNA-damage tolerance.  
 
  
is a ‘neomorphic’ activity of aberrantly expressed MAGE-A4 in
cancer cells.
Remarkably, although several MAGE-E3 ubiquitin ligase
complexes have been characterized25, no conserved sequence
motifs (on MAGE-A4 family member or E3 ligases) mediate these
protein–protein associations. Thus, the mechanism of association
appears to be different for every MAGE-E3 ligase complex. Our
structure–function analyses show that MAGE-A4 binds and
stabilizes RAD18 via the RAD6-binding domain. Reportedly,
p95/NBS1 also associates with the RAD6-binding domain of
RAD1834. Physiologically, RAD18 exists as an asymmetric
hetero-trimer comprising two RAD18 molecules in complex
with one molecule of RAD6 (ref. 40). Therefore, we hypothesize
that one RAD18 molecule in the [RAD18]2–RAD6 heterotrimer
has a ‘free’ RAD6-binding domain that is available to interface
with MAGE-A4, p95 and perhaps additional proteins. This
hypothesis predicts that MAGE-A4 and p95 (or other proteins)
may compete for RAD18 binding in cancer cells, and that such
competition may have an impact on genome maintenance
events involving RAD18–p95 associations. MAGE-A4 lacks the
RAD6-like b-sheet and therefore interacts with RAD18 via a
distinct mechanism. Clearly, biophysical and crystallographic
studies will be necessary to fully characterize the putative
[RAD18]2–RAD6–MAGE-A4 complex that exists in cancer cells.
The only other documented E3 ligase-binding partner of
MAGE-A4 is TRIM69 and the mechanism of MAGE-A4–
TRIM69 association has not been studied. Other known effectors
of MAGE-A4 are the transcription factor Miz1 (ref. 37) and the
liver oncoprotein gankyrin36, which both bind a C-terminal
region of MAGE-A4. We show here that the minimal MAGE-A4
C-terminal region (AB) that regulates Miz1 and gankyrin is
insufficient to stabilize RAD18. Indeed, none of the major
conserved MAGE-A4 domains retain RAD18-stabilizing activity





























































































































































































Figure 7 | MAGE-A4 promotes TLS and DN -damage t lerance. (a) H1299 cells were transiently transfected with MAGE-A4 or non-targeting siRNAs.
After 16 h, cells were transfected with a siRNA-resistant MAGE-A4 expression plasmid (or empty vector control). Forty-eight hours later, cells were sham
or ultraviolet irradiated (20 J m! 2) and harvested for immunoblot analysis after 2 h. (b ) H1299 cells were transfected with siRNA against RAD18,
MAGE-A4 or non-targeting siRNA. Forty-eight hours later, cells were pulsed labelled with BrdU (10 mM) for 1 h and collected for flow cytometry. (c) H1299,
A549 or mouse embryonic fibroblast (MEF) cells were transfected with a MAGE-A4 expression plasmid or empty vector. After 48 h, cells were sham or
ultraviolet irradiated (20 J m! 2) and extracted 2 h later for immunoblotting. Human dermal fibroblasts (HDFs) stably transduced with a pINDUCER-MAGE-
A4 were treated with indicated doxycycline concentrations for 48 h and then collected for immunoblotting. (d) H1299 cells were transfected with siRNA
against RAD18 and MAGE-A4 (or with non-targeting oligonucleotides). Twenty-four hours post transfection, cells were re-plated in 24-well dishes and
ultraviolet irradiated (5 J m! 2) 48 h later. DNA synthesis rates were measured immediately before and at different times after ultraviolet treatment.
(e) H1299 cells were transfected with siRNA against MAGE-A4 or with non-targeting siRNA. Seventy-two hours post transfection, cells were sham or
ultraviolet irradiated (5 J m! 2) and harvested at different times for immunoblotting. (f) 293T cells were co-transfected with ultraviolet-damaged pSP189
reporter plasmid and MAGE-A4 or RAD18 expression vectors. Forty-eight hours later, 293T cell extracts were collected for immunoblot analysis of
MAGE-A4 and RAD18 (right). Recovered pSP189 plasmid was transformed into electro-competent MBM7070 bacteria and pSP189 mutation rates were
determined by enumerating blue and white bacterial colonies. Data represent means±s.e.m. of four independent experiments each performed in triplicate.
P-values were calculated using a two-tailed Student’s t-test. Baseline mutation rates for the experiments ranged from 5.6 to 9.6%.
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Figure 3.7 MAGE-A4 promotes TLS and DNA-damage tolerance. 
 
(A) H1299 cells were transiently transfected with MAGE-A4 or non-targeting siRNAs. 
After 16 h, cells were transfected with a siRNA-resistant MAGE-A4 expression plasmid 
(or empty vector control). Forty-eight hours later, cells were sham or ultraviolet 
irradiated (20 Jm-2) and harvested for immunoblot analysis after 2 h. (B) H1299 cells 
were transfected with siRNA against RAD18, MAGE-A4 or non-targeting siRNA. Forty-
eight hours later, cells were pulsed labeled with BrdU (10 µM) for 1 h and collected for 
flow cytometry. (C) H1299, A549 or mouse embryonic fibroblast (MEF) cells were 
transfected with a MAGE-A4 expression plasmid or empty vector. After 48 h, cells were 
sham or ultraviolet irradiated (20 Jm-2) and extracted 2 h later for immunoblotting. 
Human dermal fibroblasts (HDFs) stably transduced with a pINDUCER-MAGE- A4 were 
treated with indicated doxycycline concentrations for 48 h and then collected for 
immunoblotting. (D) H1299 cells were transfected with siRNA against RAD18 and 
MAGE-A4 (or with non-targeting oligonucleotides). Twenty-four hours post transfection, 
cells were re-plated in 24-well dishes and ultraviolet irradiated (5 Jm-2) 48 h later. DNA 
synthesis rates were measured immediately before and at different times after 
ultraviolet treatment. (E) H1299 cells were transfected with siRNA against MAGE-A4 or 
with non-targeting siRNA. Seventy-two hours post transfection, cells were sham or 
ultraviolet irradiated (5 Jm-2) and harvested at different times for immunoblotting. (F) 
293T cells were co-transfected with ultraviolet-damaged pSP189 reporter plasmid and 
MAGE-A4 or RAD18 expression vectors. Forty-eight hours later, 293T cell extracts were 
collected for immunoblot analysis of MAGE-A4 and RAD18 (right). Recovered pSP189 
plasmid was transformed into electro-competent MBM7070 bacteria and pSP189 
mutation rates were determined by enumerating blue and white bacterial colonies. Data 
represent means ± s.e.m. of four independent experiments each performed in triplicate. 
P-values were calculated using a two-tailed Student’s t-test. Baseline mutation rates for 
the experiments ranged from 5.6 to 9.6%.  
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Supplementary Fig. 1 RAD6 and MAGE-A4 associate with the RAD6-binding domain of 
RAD18. 
 
(a)  Amplified Luminescent Proximity Homogeneous Assay (ALPHA) screen assay showing 
association of RAD18 and RAD6.  The indicated concentrations of purified recombinant GST-
RAD18 335-400 and His-tagged full-length RAD6 were incubated in 384-well plates (16 
replicate wells for each experimental condition) in a reaction volume of 6 Pl for 1 h at room 
temperature in the dark.  Next, 3 Pl of nickel chelate acceptor beads (Perkin Elmer 6760619C) 
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Figure 3.8 RAD6 and MAGE-A4 associate with the RAD6-binding domain of 
RAD18.  
 
 (A) Amplified Luminescent Proximity Homogeneous Assay AlphaScreen assay 
showing association of RAD18 and RAD6. The indicated concentrations of purified 
recombinant GST- RAD18 335-400 and His-tagged full-length RAD6 were incubated in 
384-well plates (16 replicate wells for each experimental condition) in a reaction volume 
of 6 µl for 1 hr at room temperature in the dark. Next, 3 µl of nickel chelate acceptor 
beads (Perkin Elmer 6760619C) were added to give a concentration of 20 µg/ml and 
incubations were continued for 1 hr. Finally 3 µl of glutathione donor beads (Perkin 
Elmer 6765300) were added (20 µg/ml final concentration) and incubations were 
continued for one more hour. Plates were analyzed using the Perkin Elmer Envision 
plate reader to excite at 680 nm and detect fluorescence at 520 nm.  
(B) The AlphaScreen assay was used to detect the association of GST-RAD18 335-400 
with His-tagged full-length MAGE-A4, exactly as described for RAD18-RAD6 
association in (A) above. Note that the binding curves in (A) and (B) cannot be 
compared directly because in AlphaScreen assays the magnitude of signal for each 
unique protein-protein interaction is determined by specific protein conformations and 
tag proximities.  
(C) AlphaScreen assay was used to detect competition between RAD6 and MAGE-A4 
for RAD18-binding. In separate reactions His-RAD6 (25 nM) or His-MAGE-A4 (200 nM) 
were incubated with equimolar GST-RAD18 in the presence of different concentrations 
(0-200 nM) of untagged competitor RAD6 (or BSA for control). Donor and acceptor 
beads were added to the reactions and plates were analyzed as described in (A) above. 
To plot the data, the effect of untagged RAD6 (or BSA) on fluorescence was normalized 
to emission signals obtained in the RAD18/His-RAD6 and RAD18/His-MAGE-A4 
reactions without added protein. Error bars represent the mean of 16 replicate wells +/- 
SEM for each experimental condition.  
(D) Effect of MAGE-A4 expression on RAD18-associated RAD6 in cultured cells. 293T 
cells were transfected with expression vectors encoding MYC-RAD18 and MAGE-A4 (or 
empty vector for control). Cell lysates were prepared 48 hrs after transfection, and 
RAD18 was immunoprecipitated using anti-MYC beads. Levels of RAD18-associated 
RAD6 were determined by SDS-PAGE and immunoblotting. Note that in this 
experiment, levels of ectopically-expressed RAD18 were very high and no longer 
sensitive to co-expressed MAGE- A4.  
(E)-(H) Size fractionation of RAD18, RAD6 and MAGE-A4 complexes in cultured cells. 
Exponentially-growing cultures of 293T cells were transfected with empty vector, CMV-
GFP, or with a CMV-MAGE-A4 expression plasmid. 48 hrs later GFP fluorescence was 
used to confirm efficient (~90%) transfection efficiency. Cells were lysed in 300 µl of 
CSK without sucrose and supplemented with 1 µg/ml (25,000 units/ml) of Benzonase. 
Lysates were incubated at room temperature for 15 minutes to digest chromatin, then 
centrifuged at 21,000g for 20 min. 250 µl of each clarified cell lysate (~2.0 mg) was 
loaded onto a 25ml Sephadex 200 gel filtration column that was calibrated with 
appropriate molecular weight markers (E). The column was eluted with sucrose-free 
CSK. 0.5 ml fractions were collected and 30 µl of each  
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Figure 3.8 RAD6 and MAGE-A4 associate with the RAD6-binding domain of 
RAD18.  
fraction was analyzed by SDS-PAGE and immunoblotting with antibodies against 
RAD18, RAD6 and MAGE-A4 (F). Relative levels of RAD18, RAD6 and MAGE-A4 
between different fractions were determined by densitometry and are plotted in panels 
(G) and (H). The fractions containing the ~160 kDa [RAD18]2-RAD6 complex predicted 
by biophysical studies and a previously undescribed ~530 kDa RAD18 and RAD6-







Figure 3.9 Quantitative immunoblot analysis of RAD18, RAD6 and MAGE-A4 
expression levels in H1299 cells.  
 
The indicated amounts of H1299 whole cell lysate, recombinant RAD18-RAD6 (A), and 
MAGE- A4 (B) proteins were analyzed by SDS-PAGE and immunoblotting. By 
comparing expression levels of proteins in cell lysates with defined quantities of purified 
protein standards we estimate that 1 µg of H1299 cell lysate contains 41 pg (0.74 fmol) 
of RAD18, 719 pg (42 fmol) of RAD6, and 88 pg (2.5 fmol) of MAGE-A4. Therefore, the 
































Supplementary Fig. 2  Quantitative immunoblot analysis of RAD18, RAD6 and MAGE-A4 
expression levels in H1299 cells. 
 
The indicated amounts of H1299 whole cell lysate, recombinant RAD18-RAD6 (a), and MAGE-
A4 (b) proteins were analyzed by SDS-PAGE and immunoblotting.   By comparing expression 
levels of proteins in cell lysates with defined quantities of purified protein standards we estimate 
that 1 Pg of H1299 cell lysate contains 41 pg (0.74 fmol) of RAD18, 719 pg (42 fmol) of RAD6, 
and 88 pg (2.5 fmol) of MAGE-A4.  Therefore, the RAD18:RAD6:MAGE-A4 stoichiometry in 













Figure 3.10 Effect of MAGE-A4 on MG132-induced ubiquitin laddering of RAD18 in 
293T cells.  
 
Replicate cultures of exponentially-growing 293T cells were co-transfected with 
expression vectors encoding HA-RAD18 and MAGE-A4 (WT or LL>AA mutant). 48 hrs 
later the resulting cultures were treated with MG132 (20 µM) for 4 hrs. Cell lysates were 

































Supplementary Fig. 4  Effe t of MAGE-A4 on MG132-induced ubiquitin laddering of 
RAD18 in 293T cells. 
 
Replicate cultures of exponentially-growing 293T cells were co-transfected with expression 
vectors encoding HA-RAD18 and MAGE-A4 (WT or LL>AA mutant).  48 h later the resulting 
cultures were treated with MG132 (20 PM) for 4 h.  Cell lysates were analyzed by 















Figure 3.11 Effect of different MAGE-A4 mutants on RAD18 stability.  
 
Replicate plates of 293T cells were transiently transfected with expression vectors 
encoding wild-type or mutant forms of MAGE-A4. 48 hrs post-transfection cells were 
treated with CHX and then harvested at different times post-CHX. Cell extracts were 




































Supplementary Fig. 5  Effect of differe t MAGE-A4 mutants on RAD18 stability. 
 
Replicate plates of 293T cells were transiently transfected with expression vectors encoding 
wild-type or mutant forms of MAGE-A4.  48 h post-transfection cells were treated with CHX 
and then harvested at different times post-CHX.  Cell extracts were analyzed by immunoblotting 








Figure 3.12 MAGE-A4-depletion leads to reduced RAD18 expression and 
decreased PCNA mono-ubiquitination.  
 
RAD18-/- H1299 cells were transfected with MAGE-A4-directed siRNA or with a non-
targeting siRNA control. 24 hrs post-transfection cells were complemented with 
adenovirally-encoded HA- RAD18. 24 hrs later, cells were UV-irradiated (20 J/m2), or 
sham-treated for controls. 4 hrs after UV-treatment cells were lysed and extracts were 
























Supplementary Fig. 6  MAGE-A4-depletion leads to reduced RAD18  expression and 
decreased PCNA mono-ubiquitination. 
 
RAD18-/- H1299 cells were transfected with MAGE-A4-directed siRNA or with a non-targeting 
siRNA control.  24 h post-transfection cells were complemented with adenovirally-encoded HA-
RAD18.  24 h later, cells were UV-irradiated (20 J/m2), or sham-treated for controls.  4 h after 
UV-treatment cells were lysed and extracts were analyzed by SDS-PAGE and immunoblotting 



















Figure 3.13 Fig. 7 Effect of MAGE-A4 depletion on RAD18 expression in H157, 








































Supplementary Fig. 7  Effect of MAGE-A4 depletion on RAD18 expression in H157, H650 
and U2OS cells. 
 
(a) Exponentially-growing H157 and H650 cells were transfected with siMAGE-A4 or non-
targeting control (siCon) siRNAs.  48 h later cells were lysed and extracts were analyzed by 
SDS-PAGE and immunoblotting with the indicated antibodies. 
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Figure 3.13 Effect of MAGE-A4 depletion on RAD18 expression in H157, H650 and 
U2OS cells.  
 
(A) Exponentially-growing H157 and H650 cells were transfected with siMAGE-A4 or 
non- targeting control (siCon) siRNAs. 48 hrs later cells were lysed and extracts were 
analyzed by SDS-PAGE and immunoblotting with the indicated antibodies.  
(B)-(C) Replicate plates of exponentially-growing U2OS cells were transfected with 
siMAGE-A4 or non-targeting control (siCon) siRNAs. 48 hrs later, some cultures were 
treated with Cycloheximide (CHX, 100 g/ml) to block new protein synthesis. At indicated 
times after CHX treatment, control and MAGE-A4-depleted cells were analyzed by 
SDS-PAGE and immunoblotting with antibodies against RAD18 and MAGE-A4 (B). 
Other replicate cultures were irradiated with UV-irradiated (5 J/m2), or sham-treated for 
controls. At different times after UV-treatment, cells were harvested and analyzed by 





Figure 3.14 MAGE-A4 expression in 293T cells does not affect inhibition or 
recovery of DNA synthesis after UV-irradiation.  
 
(Α) Duplicate 10 cm plates of 293T cells were transfected with MAGE-A4 expression 
plasmid (CMV-MAGE-A4) or an empty vector for control. 24 hrs later the transfected 
cells were re-plated in 60 mm tissue culture dishes (for protein analysis) or 24-well 
plates (for DNA synthesis assays). The cells were UV-irradiated (5 J/m2) or sham-
treated and rates of DNA synthesis at various times post-UV were determined by 
measurements of [3H]-thymidine incorporation. For each time point, rates of DNA 
synthesis were measured in triplicate and are normalized to DNA synthesis rates 
immediately prior to irradiation. Each data point represents the mean of the triplicate 
determinations and the error bars represent the range. (B) Coincident with UV- 
treatments, the 60 mm plates were used to prepare cell extracts for SDS-PAGE and 































Supplementary Fig. 8  MAGE-A4 expression in 293T cells does not affect inhibition or 
recovery of DNA synthesis after UV-irradiation. 
 
(a)  Duplicate 10 cm plates f 293T cells w re transfected with MAGE-A4 expression plasmid 
(CMV-MAGE-A4) or an e pty vector for control.  24 h later the transfected cells were re-plated 
in 60 mm tissue cultur  dishes (for protein analysis) or 24-well plates for DNA synt esis 
assays).  The c lls were UV-irradiated (5 J/m2) or sham-treated and rat s of DNA synthesis at 
various times p st-UV were determi ed by measurements of [3H]-thymidine incorporation.  For 
each time point, rates of DNA synthesis were measured in triplicate and are normalized to DNA 
synthesis rates immediately prior to irra iation.  Each data point represents the mean of the 
triplicate determinations and the error bars represent the range.  (b) Coincident with UV-
treatments, the 60 mm plates were used to prepare cell extracts for SDS-PAGE and 









Figure 3.15 Heterogeneous expression of MAGE-A4 and TLS proteins in 
commonly-studied cell lines.  
 
Extracts from different cell lines were subject to immunoblot analysis using antibodies 

































Supplementary Fig. 9  Heterogeneous expression of MAGE-A4 and TLS proteins in 
commonly-studied cell lines. 
 
Extracts from different cell lines were subject to immunoblot analysis using antibodies against 
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CHAPTER 4: CANCER TESTIS ANTIGENS PROMOTE RESISTANCE TO 
CANCER THERAPIES THROUGH GENOME MAINTENANCE 
 
4.1 Introduction 
Lung cancer is the deadliest form of cancer worldwide. Non-small cell lung cancer 
(NSCLC) constitutes over 80% of lung cancer cases, for which most current treatments 
are ineffective1. Major limitations of existing pharmaceutical agents used in lung cancer 
treatment include the development of chemoresistance and unintentional toxicity in 
normal tissue2. Traditional treatment regimens for many lung cancer patients involve 
poly-therapies that utilize a combination of surgical intervention, ionizing radiation and 
chemotherapeutics, including platinum-based crosslinking agents (e.g. cisplatin) and 
DNA topoisomerase (topo) inhibitors (e.g. Camptothecin analogs, Etoposide and 
doxorubicin). Ionizing radiation and the aforementioned chemotherapeutics work by 
inducing DNA damage and limiting cell proliferation. These therapies are particularly 
toxic in cancer cells, where cell growth is aberrantly up-regulated (e.g. cancer cells)3-5. 
Cells undergoing carcinogenesis use DNA damage repair to not only survive intrinsic 
oncogenic stresses and environmental carcinogenic exposures, but also to evade 
damage induced by genotoxic pharmaceutical agents6-8. Thus, neoplastic cells may 
acquire chemoresistance through use of highly adapted DNA repair mechanisms that 
allow them to tolerate therapy-induced DNA damage (Fig. 4.1). However, the 
mechanisms determining how cancer cells use DNA damage repair pathways to adapt
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 and resist chemotherapies are not known. Elucidating mechanisms of DNA damage 
tolerance and repair will allow us to improve the efficacy of cancer treatment while 
limiting off target toxicities.  
Ionizing radiation (IR) therapy as a cancer treatment is mediated through its ability to 
damage DNA, both directly and indirectly via the generation of free radicals. IR 
produces a wide variety of lesions types including damaged bases, crosslinks and the 
most severe type of lesion, a DNA double stranded break (DSB)9. Many 
chemotherapeutics also induce DSBs as their mechanism of action. The 
topoisomerase-I inhibiting Camptothecins prevent re-ligation of nicked DNA generated 
during coil relaxation via a covalently trapped DNA:topo adduct and induce DSBs during 
subsequent attempts to replicate through the damage10, 11. Similarly, Etoposide and 
doxorubicin prevent re-ligation of DNA strands by complexing with type II 
topoisomerases, leading to the formation of DSB. While the antitumor activity of 
cisplatin is generally attributed to the formation of DNA crosslinks, repair of cisplatin-
induced lesions is thought to primarily be done through a combination of nucleotide 
excision repair and a DSB repair pathway known as homologous recombination12-14. 
Thus, competent DSB repair may contribute to the high rates of chemoresistance 
observed in lung cancer patients.  
DSB repair is primarily mediated through error-free homologous recombination (HR) 
and error-prone nonhomologous end joining (NHEJ). Although high fidelity repair of 
DSB is preferred, the dependence of HR on the availability of a sister chromatid limits 
its activity to S and G2 phases of the cell cycle. NHEJ, however, is capable of acting 
throughout the cell cycle. A third pathway termed alternative end-joining (alt-EJ), is 
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thought to primarily act as a ‘back-up’ for HR and NHEJ, and is preferentially repairs 
DSB lesions through the use of microhomology found between the broken ends (Fig. 
4.2). 
Interestingly, several recent publications have implicated a group of proteins known 
as cancer/testis antigens (CTAs) in resistance to common chemotherapeutics including 
Cisplatin, Etoposide and Doxorubicin15-17. CTAs comprise a group of over 200 proteins 
that are ordinarily germline-restricted and absent from normal somatic cells but 
aberrantly overexpressed in many different cancers18<< citation from ch1>>. The first 
CTA, MAGEA1, was discovered in the 1990s when a patient with melanoma who was 
remarkably responsive to therapy was found to have cytotoxic T cells that recognized 
autologous cancer cells. MAGEA1 belongs to the Melanoma Antigen (MAGE) family of 
CTAs, a group of over 45 CTAs that share a high degree structure and sequence 
similarity, indicative of common biological functions19, 20. MAGE proteins have since 
been found to be aberrantly overexpressed in many other cancers, including NSCLC, 
and linked to the promotion of tumorigenesis and metastasis 21-25. The biological 
function of MAGE proteins is largely unknown, however, recent studies have identified a 
link between CTAs and E3 ubiquitin ligases, suggesting CTAs may reprogram ubiquitin 
signaling networks in cancer cells19, 26, 27. Interestingly, E3 ubiquitin ligases mediate a 
wide array of DNA damage signaling pathways.  
Based on our recent discovery that MAGEA4 promotes DNA damage tolerance via 
TLS, we postulated that other CTAs may also promote DNA damage tolerance in 
cancer cells26.  We considered the CTA HORMAD1 as a candidate DNA repair mediator 
in cancer cells because in mouse germ cells mHormad1 is an ATM substrate, co-
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localizes with gH2AX and facilitates DSB processing28, 29. We show here that depletion 
of HORMAD1 sensitizes NSCLC cells, but not triple negative breast cancer cells, to 
ionizing radiation. HORMAD1 forms irradiation-induced foci that co-localize with γH2AX, 
which we also identified as a novel binding partner. We also found that HORMAD1 loss 
reduces rates of recombination by DR-GFP while also diminishing recruitment of 
RAD51 to DSB.  
 
4.2 Methods 
Cell culture and transfection 
Cancer cell lines H1299, U2OS, and H358 were purchased from the American Type 
Culture Collection (ATCC) and used for the described experiments without further 
authentication. H1299 RAD18-/- cells were generated by Dr. Yanzhe Gao26. 
MDAMB436 and MDAMB468 were provided by the lab of Dr. Carey Anders. All cell 
lines (except MDAMB468) were cultured in DMEM medium supplemented with 10% 
fetal bovine serum and penicillin–streptomycin (1%). MDAMB468 cells were cultured in 
RPMI1640 supplemented with 10% FBS and maintained in non-vented flasks without 
aeration. Plasmid DNA and siRNA oligonucleotides were transfected using 
Lipofectamine 2000 (Invitrogen) according to the manufacturer’s instructions, except 
that concentrations of plasmid DNA and Lipofectamine 2000 used in each transfection 
reaction were decreased by 50% to reduce toxicity. 
Expression plasmids and RNAi 
HA-HORMAD1 was a gift from Dr. Angelique Whitehurst (UT Southwestern). 
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Sequences of siRNA oligonucleotides used here are as follows: control non-targeting 
siRNA, (5’-UAGCGACUAAACACAUCAA-3’) (Thermo Fisher Scientific); siMAGEA4 
(targeting the 3’-untranslated region); Smartpool siGENOME siHORMAD1 (Dharmacon 
CAT# M-018596-02); siMAGEA10 (GGUCAAAAGCU GUGGGACAUU); Smartpool 
siGENOME siBRCA1 (Cat# M-003461-02); Smartpool siGENOME siBRCA2 (Cat# M-
003462-01). 
For transfection, two separate tubes were prepared, one containing siRNA and 
serum-free Optimem, and the other with Lipofectamine 2000 and serum-free Optimem. 
These separate mixtures were incubated for 5 min at room temperature in the dark 
before being combined and incubated for an additional 20min, according to Dharmacon 
and Lipofectamine manufacturer’s protocols. For plasmid transfection, the transfection 
mixture was plated directly onto cells (in antibiotic-free). For siRNA transfection cells 
were trypsinized and resuspended in antibiotic-free medium and plated directly into the 
siRNA/Optimem/Lipofectamine solution at 50% confluence to incubate overnight. The 
following morning cells were then trypsinized and plated in 6-well plates (24 hrs prior to 
genotoxin treatment). 
Fluorescence microscopy  
In experiments with siRNA H1299 cells were treated with siControl or siHORMAD1. 
Twenty-four hrs post transfection/ (or plating in non-siRNA experiments) cells were 
irradiated (10 Gy) or sham treated and fixed 1 hr later for staining with indicated 
antibodies. Fixed-cell imaging was done on a Zeiss 710 confocal microscope, in the 
UNC Microscopy Services Laboratory core facility, as described previously26.  
 
 127 
Immunoprecipitation and immunoblotting 
Lysates of cultured cells were washed three times in ice-cold PBS and lysed in 500 
µl of ice-cold cytoskeleton buffer (CSK buffer; 10 mM Pipes pH 6.8, 100 mM NaCl, 300 
mM sucrose, 3 mM MgCl2, 1 mM EGTA, 1 mM dithiothreitol, 0.1 mM ATP, 1 mM 
Na3VO4, 10 mM NaF and 0.1% Triton X-100) freshly supplemented with Protease 
Inhibitor Cocktail and Phostop (Roche). For subfractionation, lysates were centrifuged at 
4,000 RPM for 4 min at 4°C. The supernatant containing a mixture of cytosolic plus 
nucleosolic proteins was aliquoted and detergent-insoluble nuclear fractions were 
washed once with 1 ml of CSK buffer. Insoluble (chromatin) fractions were then 
resuspended in a minimal volume of CSK and sonicated to release chromatin before 
analysis by SDS–PAGE and immunoblotting.  
For all immunoprecipitation experiments, input samples were normalized for protein 
concentration. Magnetic beads containing covalently conjugated antibodies against 
epitope tags were added to the extracts and incubations were performed overnight at 
4°C using rotating racks. Immune complexes were recovered using magnetic stands. 
The beads were washed five times with 1 ml CSK to remove nonspecifically bound 
proteins. The washed immune complexes were boiled in Laemmli buffer for 10 min, to 
release and denature for SDS–PAGE.  
For immunoblotting, cell extracts or immunoprecipitates were separated by SDS-
PAGE, transferred to nitrocellulose membranes, and incubated overnight with the 
following primary antibodies: GAPDH (sc-32233), HA.F7 (sc-7392) for IP, MAGEA4 (sc-
292429), BRCA1 (sc-6954), RAD51 (sc-8349) from Santa Cruz Biotech; RAD18 (A301-
340A) from Bethyl; H2A (05-678), γH2AX (05-636) from Millipore; ORC4 (H83120) 
 128 
Transduction Labs; FlagM2 (F1804) from Sigma-Aldrich; HA.11 (ENZ-ABS118) for IB 
Enzo Life Sciences; and FANCD2 Epitomics (2986). Antibody dilutions used for 
immunoblotting were 1:1,000, with exceptions for the following antibodies: FANCD2 
(1:3000), GAPDH (1:3,000) and γH2AX (1:5,000).  
GFP Reporter and Survival Assays 
H1299 cells stably integrated with DR-GFP (or EJ2-5) were treated with ISCE1 to 
simulate DSB, and carried out as described by Pierce et al.30. DNA damage tolerance 
was measured using survival assays, which have been used extensively to reveal the 
phenotypes resulting from genotoxic insult19, 31. Replicate plates cells treated with the 
indicated siRNAs were transfected as described above and plated at low density ~200-
1000 cells (depending on cell line). Cells were treated with genotoxic agent 24 hrs post-
plating and exposed to chemotherapeutics for 24 hrs; cisplatin (in H2O), Camptothecin 
(in DMSO), Etoposide (in DMSO), Paclitaxel (Sigma T7402) (in DMSO), Doxorubicin  
(Sigma D1515) (in H2O). Two weeks after genotoxin treatment plates were fixed and 
stained with crystal violet. Plates were scanned and the Image J colony counter plugin 
was used to quantify density32, 33.  
 
4.3 Results 
MAGE-A members promote resistance to DSB-inducing therapeutics in NSCLC 
cells  
 Analysis of The Cancer Genome Atlas (TCGA) data shows enhanced expression of 
MAGEA4 in lung adenocarcinoma tumors as compared with non-malignant tissue (Fig. 
4.3). Given our recent finding that MAGEA4 participates in DNA damage tolerance 
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through trans-lesion synthesis and the abundance of literature implicating a role for 
CTAs in chemoresistance we decided to investigate if there was a role for MAGEA4 in 
mediating tolerance to commonly used DNA-damaging chemotherapeutics. H1299 lung 
adenocarcinoma cells depleted of MAGEA4 exhibit increased sensitivity to ionizing 
radiation in addition to a variety of DNA-damaging chemotherapeutics (Fig. 4.4A-E). 
Treatment with ionizing radiation, Camptothecin, Etoposide, doxorubicin and cisplatin 
activates DSB repair pathways in cells. Thus, MAGEA4 may promote resistance to DNA 
damaging anti-cancer agents in NSCLC via promotion of DSB repair. Of note, survival 
following treatment with paclitaxel, a mitotic spindle poison that prevents normal 
progression of mitosis was unaffected by MAGEA4 status (Fig. 4.4F)34. Combined, 
these results indicate that MAGEA4 may specifically promote therapeutic resistance in 
NSCLC through activation of DSB repair pathways. 
 We recently identified MAGEA4 as a novel binding partner and stabilizer of 
RAD1826. RAD18 participates in many facets of DNA damage tolerance repair including 
trans-lesion synthesis, the Fanconi Anemia pathway and DSB repair35-38. H1299 
RAD18-/- cells treated with Camptothecin and Cisplatin (agents that activate the 
Fanconi Anemia pathway) exhibit similar sensitivity, as do MAGEA4-depleted H1299 
cells (Fig. 4.5A-B). In fact, H1299 cells with reduced MAGEA4 levels were defective in 
recruitment of a key regulator in Fanconi Anemia Pathway activation, FANCD2, 
following Camptothecin treatment (Fig. 4.5C). Thus, part of MAGEA4-dependent 
chemoresistance may be mediated through RAD18-dependent DNA damage tolerance 
mechanisms (Fig. 4.5D). However, not all MAGEA4-mediated resistance to DSB cancer 
therapeutics is through RAD18, as is exhibited by the compounded sensitivity in H1299 
 130 
RAD18-/- cells depleted of MAGEA4 and exposed to ionizing radiation (Fig. 4.6). 
Additionally the MAGE family CTA MAGEA10, which was absent from the RAD18 
interaction network we previously published, was also capable of sensitizing lung 
adenocarcinoma cells to topoisomerase II inhibitors and ionizing radiation26 (Fig. 4.7A-
C). This suggests that while the RAD18-MAGEA4 complex may contribute to 
chemoresistance, MAGEA members can more generally contribute to resistance of 
DSB-inducing chemotherapeutics in a RAD18-independent manner.  
To determine whether MAGEA-mediated NSCLC chemoresistance is indeed 
mediated through enhanced DSB repair we measured rates of recombination via a 
reporter assay that is indicative of HR activity. The DR-GFP HR reporter assay utilizes a 
stably integrated DR-GFP vector to initiate recombination activity following ISceI-
induced DSBs30, 39, 40. BRCA1, an established HR protein, was used as a control. 
Interestingly, both MAGEA4 and MAGEA10 depletion increased homologous 
recombination activity, suggesting that these two proteins could be promoting DSB 
repair through a pathway that is competitive with HR (e.g. NHEJ or alt-EJ) (Fig. 4.8).  
HORMAD1 promotes homologous recombination and radioresistance 
Analysis of TCGA gene expression data from over 450 NSCLC revealed that 
HORMAD1 mRNA is highly expressed in lung cancer relative to non-malignant tissues 
(Fig. 4.9A).  Genes affiliated with HORMAD1 meiotic DSB processing (HORMAD2, 
SPO11, SYCE1, SYCP1-3) were not overexpressed in NSLC (Fig. 4.9B), suggesting 
that HORMAD1 activity in cancer cells may be distinct from its known role in meiosis.  
A previous report from Watkins et al. suggested a role for HORMAD1 in suppressing 
RAD51-dependent HR in triple negative breast cancer41. To investigate a potential role 
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for HORMAD1 in DSB repair in the lung cancer we depleted HORMAD1 in H1299 lung 
adenocarcinoma cells to look at clonogenic survival following treatment with ionizing 
radiation. Contrary to the previous report, we saw diminished survival after IR where in 
cells with reduced HORMAD1 protein levels, suggesting instead that HORMAD1 
contributes to radioresistance (Fig. 4.9C). Similar results were seen in another NSCLC 
cell line, H358 (bronchoalveolar carcinoma) (Fig 4.9D). However, HORMAD1 depletion 
in triple negative breast cancer cell lines (MDAMB436 and 468) had no impact on 
radiosensitization (Fig. 4.9E-F). Interestingly, a comparison of mRNA levels across 
multiple data sets from the TCGA shows lower HORMAD1 mRNA levels in breast 
cancer as compared with the lung cancer studies (Fig. 4.9G).  
 To examine the contribution of HORMAD1 to DNA repair following DSB induction in 
H1299, we measured rates of recombination and endjoining, indicative of HR and NHEJ 
activity, respectively. HORMAD1-depletion led to a 60% decrease in homologous 
recombination activity as measured by DR-GFP, however did not influence end joining 
in an analogous NHEJ reporter assay EJ2-5 (Fig. 4.10A-B).  
Under undamaged conditions, H1299 lung adenocarcinoma cells exhibit pan-nuclear 
staining of HORMAD1 that form foci upon exposure to ionizing radiation. HORMAD1 
irradiation induced foci (IRIF) also co-localized with gH2AX.  Additionally, abrogation of 
histone H2AX phosphorylation (γH2AX) through use of the ATM kinase inhibitor 
KU55933 prevented the IR-induced redistribution of HORMAD1 (Fig. 4.10C). 
Immunoprecipitation of HORMAD1 identified γH2AX as a novel binding partner (Fig. 
4.10D). Taken together these results suggest that HORMAD1 is directed to chromatin 
following formation of DSB. 
 132 
To determine whether HORMAD1 influences DNA repair proteins we examined the 
effect of HORMAD1 depletion on the recruitment of RAD51 (a key protein in HR) to 
IRIF. HORMAD1-depletion led to reduced numbers of RAD51-containing IRIF, 
indicating that HORMAD1 functions upstream of RAD51 in the HR pathway (Fig. 
4.10E).  In corresponding immunoblots we also found that HORMAD1-depletion 
diminished RAD51 chromatin-binding (Fig. 4.10F). Taken together these results suggest 
that HORMAD1 promotes recruitment of RAD51 to chromatin following the production of 
DSB.  
As a positive control in these experiments we also depleted BRCA1, a known HR 
protein. BRCA1-depletion attenuated chromatin-binding of RAD51, as expected, but 
also diminished the levels of chromatin-bound HORMAD, suggesting a new relationship 
between HORMAD1 and BRCA1 (Fig. 4.10F). Taken together these results suggest a 




MAGE-A members promote resistance to DSB-inducing therapeutics in NSCLC 
cells  
Resistance to traditional cancer therapies contributes to the high mortality rate seen 
in lung cancer. Recent reports have discovered links between MAGE-family CTAs, 
highly expressed in NSCLC (Fig. 4.3), and E3 ubiquitin ligases, suggesting that MAGEs 
may aberrantly reprogram ubiquitin signaling events in cancer cells 19, 26, 42-46. Ubiquitin 
signaling plays a key role in many DNA damage response pathways and thus MAGE 
 133 
proteins may contribute to or enhance the repair of DNA damage induced by cancer 
therapies, ultimately stimulating chemoresistance. Indeed, H1299 lung adenocarcinoma 
cells depleted of MAGEA4 exhibit increased sensitivity to ionizing radiation and a variety 
of chemotherapeutics (Camptothecin, Etoposide, Doxorubicin and Cisplatin) (Fig. 4.4A-
E). Notably, treatment with the pro-apoptotic mitotic spindle poison paclitaxel was 
unaffected by MAGEA4 status (Fig. 4.4F). Increased HR activity as measured by the 
DR-GFP assay in NSCLC cells depleted of MAGEA4 and MAGEA10 further support the 
notion of a role in DSB repair, potentially via pathways that antagonize HR (Fig. 4.8).  
 We recently identified MAGEA4 as a novel binding partner and stabilizer of 
RAD1826. RAD18 plays an important role in genome maintenance; in addition to 
activating the FA pathway and TLS, RAD18 is also thought to participate in DSB repair 
through homologous recombination (HR). We observed that H1299 RAD18-/- cells 
treated with agents that activate the Fanconi Anemia pathway (Camptothecin and 
Cisplatin) exhibit similar sensitivity to MAGEA4-depleted H1299 (Fig. 4.5A-B). MAGEA4 
depletion was also found to ablate recruitment of FANCD2 (a key regulator of Fanconi 
Anemia Pathway) following Camptothecin treatment. Interestingly, FANCD2 is also 
thought to participate in HR, downstream of the FA pathway through promotion of 
BRCA2 chromatin loading and subsequent modulation of RAD51 activity38, 47, 48. Thus 
Camptothecin/Cisplatin sensitivities from MAGEA4/RAD18 depletion could be due to 
defective DSB repair via HR or alternative end joining (alt-EJ/ TMEJ)- pathways that 
handle replication fork collapse49-51.  
 MAGEA proteins share considerable structural similarity, their expression is 
associated with poor patient outcomes, and family members can contribute to 
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resistance of DSB-inducing chemotherapeutics19, 52. MAGEA10 also sensitized lung 
adenocarcinoma cells to topoisomerase II inhibitors and ionizing radiation (Fig. 4.7A-C), 
but not Camptothecin or Cisplatin (data not shown). While the RAD18-MAGEA4 
complex may contribute to chemoresistance in a RAD18-independent manner, not all 
MAGEA4-mediated resistance to DSB cancer therapeutics is through RAD18, as 
indicated by the additive radiosensitivity in H1299 RAD18-/- cells depleted of MAGEA4 
(Fig. 4.6). Future studies should examine recruitment and survival epistasis with 
canonical DSB repair proteins (e.g. BRCA1, Ku, POLQ) to identify the exact 
mechanisms by with MAGE-A4 is contributing to DNA damage repair and therapeutic 
resistance. 
HORMAD1 promotes homologous recombination and radioresistance  
TCGA gene expression data revealed that HORMAD1 mRNA is highly expressed in 
lung tumors as compared to non-cancerous tissues, an observation not seen with genes 
that facilitate HORMAD1-mediated meiotic DSB processing (e.g. HORMAD2, SPO11, 
SYCE1, SYCP1-3) (Fig. 4.9A-B).  This suggests that HORMAD1 activities in cancer 
cells that are mechanistically distinct from its established role in meiosis.   
A previous report from Watkins et al. suggests that HORMAD1 expression 
suppresses RAD51-dependent HR and sensitizes triple negative breast cancer (TNBC) 
cells to chemotherapeutic treatment41. However, after depleting HORMAD1 in TNBC 
lines (MDAMB436 and 468) we saw no impact on radiosensitization (Fig. 4.9E-F). 
Survival experiments described by Watkins et al., however, compared cancer cell lines 
with contrasting ‘high’ or ‘low’ levels of HORMAD141. Thus, the direct impact of 
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HORMAD1 in these experiments was not investigated and it is possible that other 
cellular differences contributed to this correlation.  
HORMAD1 depletion sensitized H1299 and H38 NSCLC cells to radiotherapy and 
decreased homologous recombination by DR-GFP, the inverse of what was anticipated 
based on the findings in TNBC (Fig. 4.9C-D, 4.10A-B). Interestingly, a comparison of 
mRNA levels across multiple data sets from the TCGA shows lower HORMAD1 mRNA 
levels in breast cancer as compared with the lung cancer studies (Fig. 4.9G). It is 
possible that discrepancies in these observations could be the result of differential 
regulation of HORMAD1 in these cancers or cell lines. 
When attempting to uncover the mechanism for HORMAD1 in HR we found that 
HORMAD1 formed IRIF that co-localized with γH2AX (Fig. 4.10C) and that was 
abrogated following treatment with ATM kinase inhibitor, suggesting that HORMAD1 is 
directed sites of DSB on chromatin. HORMAD1-depletion also decreased RAD51 IRIF 
and chromatin binding (by immunoblot) (Fig. 4.10E-F). These results indicate that 
HORMAD1 promotes recruitment of RAD51 to chromatin following the production of 
DSB. Follow up studies should include structure-function analyses utilizing HORMAD1 
mutants to more precisely uncover the role of HORMAD1 in HR.   
Association between HORMAD1 and the HR-protein BRCA1 was detected in a 
screen for BRCA1-interactors53. We found that BRCA1 depletion unexpectedly 
diminishes the levels of chromatin-bound HORMAD, suggesting a new relationship 
between HORMAD1 and BRCA1 (Fig. 4.10F). Further studies should be done to 
determine whether HORMAD1 and BRCA1 participate epistatically in the DSB repair 
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response. This could potentially validate HORMAD1 as a key mediator in 
chemoresistance and as a new target for treatment of NSCLC. 
 










Figure 4.1: Role of DNA repair in chemorsistance
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Figure 4.3: Increased expression of MAGEA4 in lung adenocarcinoma cells
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Figure 4.4 MAGEA4 depletion sensitizes H1299 cells to DNA damaging cancer 
therapies 
(A) H1299 lung adenocarcinoma cells treated with control or MAGEA4 siRNA were 
subjected to mock or ionizing radiation. Survival data represent the mean +/- SEM 
(n=2). Relative survival of H1299 siControl was significantly higher than siMAGEA4 at 
the indicated dose (*p=0.0109). Significance was determined using ANOVA with 
Bonferroni’s multiple comparisons test. 
(B) H1299 lung adenocarcinoma cells treated with siRNA as in (A) were subjected to 
treatment with Camptothecin or vehicle. Survival data represent the mean +/- SEM 
(n=3). Relative survival of H1299 siControl was significantly higher than siMAGEA4 at 
the indicated doses (*p=0.0019, **p=0.0115). Significance was determined using 
ANOVA with Bonferroni’s multiple comparisons test. 
(C) H1299 lung adenocarcinoma cells treated with siRNA as in (A) were subjected to 
treatment with Etoposide or vehicle. Survival data represent the mean +/- SEM (n=3). 
Relative survival of H1299 siControl was significantly higher than siMAGEA4 at the 
indicated dose (****p<0.0001). Significance was determined using ANOVA with 
Bonferroni’s multiple comparisons test. 
(D) H1299 lung adenocarcinoma cells treated with siRNA as in (A) were subjected to 
treatment with cisplatin or vehicle. In this preliminary experiment, each survival data 
point represents the mean of triplicate determinations, and error bars represent the 
standard deviation.  
 
 






















































































































Figure 4.4: MAGEA4 depletion sensitizes lung adenocarcinoma cells cancer therapies
(A) H1299 lung adenocarcinoma cells treated with control or MAGEA10 siRNA were subjected to mock or 
ionizing radiation. Survival data  represent the mean + SEM (n=2).
(B)  H1299 lung adenocarcinoma cells treated with siRNA as in (A) were subjected to treatment with 
camptothecin or vehicle. Survival data  represent the mean + SEM (n=3).
(C) H1299 lung adenocarcinoma cells treated with siRNA as in (A) were subjected to treatment with 
etoposide or v hicle. Survival data  represent the mean + SEM (n=3).
(D) H1299 lung adenocarcinoma cells treated with siRNA as in (A) were subjected to treatment with 
cisplatin or vehicle. Each survival data point represents the mean of triplicate determinations, and error 
bars represent the range. 
(E) H1299 lung adenocarcinoma cells treated with siRNA as in (A) were subjected to treatment with doxo-
rubicin or vehicle. Each survival data point represents the mean of triplicate determinations, and error 
bars represent the range. 
(F) H1299 lung adenocarcinoma cells treated with siRNA as in (A) were subjected to treatment with 
pataxel or vehicle. Each survival data point represents the mean of triplicate determinations, and error 















Figure 4.4 MAGEA4 depletion sensitizes H1299 cells to DNA damaging cancer 
therapies 
 (E) H1299 lung adenocarcinoma cells treated with siRNA as in (A) were subjected to 
treatment with doxorubicin or vehicle. In this preliminary experiment, each survival data 
point represents the mean of triplicate determinations, and error bars represent the 
standard deviation.  
(F) H1299 lung adenocarcinoma cells treated with siRNA as in (A) were subjected to 
treatment with Paclitaxel or vehicle. In this preliminary experiment, each survival data 











Figure 4.5 MAGEA4/RAD18-dependent resistance to Fanconi Anemia pathway- 
activating chemotherapeutics 
(A), (B) H1299 WT and RAD18 -/- lung adenocarcinoma cells were subjected to 
treatment with Camptothecin, cisplatin, or vehicle. In these preliminary experiments, 
each survival data point represents the mean of triplicate determinations, and error bars 
represent the standard deviation.  
(C) H1299 lung adenocarcinoma cells treated with control or MAGEA4 siRNA were 
subjected to treatment with vehicle or 100 nM Camptothecin. After 24 hrs lysates were 
fractionated and processed for immunoblotting with the indicated antibodies.  


















































Figure 4.5: MAGEA4/RAD18-dependent resistance to Fanconi Anemia Pathway- activating chemo-
therapeutics
(A), (B) H1299 WT and RAD18 -/-  lung adenocarcinoma cells were subjected to treatment with camptoth-
ecin, cisplatin, or vehicle. Each survival data point represents the mean of triplicate determinations, and 
error bars represent the range. 
(C) H1299 lung adenoc rcinoma c lls treated with control or MAGEA4 siRNA were subjected to treatment 
with vehicle or 100 nM camptothecin. After 24 hr  lysates were fra tionated and processed for immuno-
blotting with the indicated antibodies. 
(D) Schematic of potential MAGEA4/RAD18 role in repair of cisplatin/ camptothecin lesions.
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Figure 4.6 MAGEA4 promotes radioresistance independent of RAD18 
H1299 WT and RAD18 -/- lung adenocarcinoma cells treated with control or MAGEA4 
siRNA were subjected ionization radiation (or mock). Survival data represent the mean 
+/- SEM (n=2). At all doses the relative survival of H1299 WT siControl was significantly 
higher than H1299 WT siMAGEA4 (p=0.0021), H1299 RAD18 -/- siControl (p=0.0016) 
and H1299 RAD18 -/- siMAGEA4 (p<0.0001). H1299 RAD18 -/- siMAGEA4 had 
significantly diminished relative survival as compared with H1299 WT siMAGEA4 
(p=0.0004) and H1299 RAD18-/- siControl (p=0.0006). In all cases significance was 












Figure 4.7 MAGEA10 promotes resistance to ionizing radiation and 
topoisomerase II inhibitors 
(A) H1299 lung adenocarcinoma cells treated with control or MAGEA10 siRNA were 
subjected to mock or ionizing radiation. Survival data represent the mean +/- SEM 
(n=2). Relative survival of H1299 siControl was significantly higher than siMAGEA10 at 
the indicated dose (*p=0.0760). Significance was determined using ANOVA with 
Bonferroni’s multiple comparisons test. 
(B) H1299 lung adenocarcinoma cells treated with siRNA as in (A) were subjected to 
treatment with Etoposide or vehicle. Survival data represent the mean +/- SEM (n=3). 
Relative survival of H1299 siControl was significantly higher than siMAGEA10 at the 
indicated doses (**p0.5nM=0.0020, **p1.0nM=0.0032). Significance was determined using 
ANOVA with Bonferroni’s multiple comparisons test. 
(C) H1299 lung adenocarcinoma cells treated with siRNA as in (A) were subjected to 
treatment with Etoposide or vehicle. . In this preliminary experiment, each survival data 












































































Figure 4.7: MAGEA10 promotes resistance to ionizing radiation and topoisomerase II i hibitors
(A) H1299 lung adenocarcinoma cells treated with control or MAGEA10 siRNA were subjected to mock or 
ionizing radiation. Survival data represent the mean + SEM (n=2).
(B) H1299 lung adenocarcinoma cells treated with siRNA as in (A) were subjected to treatment with 
etoposide or vehicle. Survival dat   repre ent the mean + SEM (n=3).
(C) H1299 lung adenocarcinoma cells treated with siRNA as in (A) were subjected to treatment with 
etoposide or vehicle. Each survival data point represents the mean of triplicate determinations, and error 






Figure 4.8 MAGEA4 and MAGEA10 depletion increase homologous recombination 
activity 
H1299 lung adenocarcinoma cells with stably integrated DR-GFP were treated with 
ISCE1 virus (or mock) to induce DSB and measure rates of recombination. In this 
preliminary experiment, each data point represents the mean of triplicate 





















































Figure 4.8: MAGEA4 and MAGEA10 depletion increase homologous recombination activity
H1299 lung adenocarcinoma cells with stably integrated DR-GFP were treated with ISCE1 virus (or mock) 
to induce DSB and measure rates of recombination. Each data point represents the mean of triplicate 









Figure 4.9 HORMAD1 promotes radioresistance in lung adenocarcinoma 
(A) The Cancer Genome Atlas (TCGA) HORMAD1 expression data for normal and 
NSCLC tissue. 
(B) Genes that cooperate with HORMAD1 in meiotic DSB processing (e.g. HORMAD2, 
SPO11, SYCE1, SYCP1-3) are not overexpressed in NSLC (TCGA).   
(C) H1299 lung adenocarcinoma cells treated with control or HORMAD1 siRNA were 
subjected to mock or ionizing radiation. Each survival data point represents the mean of 
triplicate determinations, and error bars represent the standard deviation (n=1).  
(D) H358 lung bronchoalveolar carcinoma cells treated with control or HORMAD1 
siRNA were subjected to treatment with Camptothecin or vehicle. Survival data 
represent the mean +/- SEM (n=3). At all doses the relative survival of H358 cells 
modified with siControl was significantly higher than those with siHORMAD1 
(**p=0.0023) and siBRCA2 (****p<0.0001). Significance was determined using ANOVA 
with Bonferroni’s multiple comparisons test. Lysates (right) were validated for efficient 
knockdown and probed with the indicated antibodies. Red arrow indicates specific top 
band. 
(E) MDAMB468 triple negative breast adenocarcinoma cells treated with control or 
HORMAD1 siRNA were subjected to mock or ionizing radiation. Survival data represent 
the mean +/- SEM (n=3). Lysates (right) were validated for efficient knockdown and 
probed with the indicated antibodies. Red arrow indicates specific top band. 
(F) MDAMB436 triple negative breast adenocarcinoma cells treated with control or 
HORMAD1 siRNA were subjected to mock or ionizing radiation. Survival data represent 
the mean +/- SEM (n=2). Lysates (right) were validated for efficient knockdown and 
probed with the indicated antibodies. Red arrow indicates specific top band. 















































































Figure 4.10 HORMAD1 promotes homologous recombination after ionizing 
radiation treatment  
(A), (B) H1299 cells containing a stably-integrated DR-GFP or EJ2-5 vector, were 
treated with control or HORMAD1 siRNA and harvest to determine homologous 
recombination (DR-GFP) or endjoining activity (EJ2-5). Data represents the mean and 
+/- the SEM (n=3).  
(C) H1299 cells were treated with mock or ionizing irradiation and DMSO or ATM 
(KU55933) inhibitor and immunostained with γH2AX and HORMAD1 antibodies. DNA 
was stained with DAPI.  
(D) H1299 cells treated with vector or HA-HORMAD1 were subjected to HA-
immunoprecipitation. Input lysates and immunoprecipitated HORMAD1 complexes were 
probed with the indicated antibodies.  
(E) H1299 cells treated with control or HORMAD1-targetting siRNA were subjected to 
mock or ionizing radiation and immunostained with γH2AX and RAD51 antibodies. DNA 
was stained with DAPI.  
(F) H1299 cells treated with control, BRCA1 or HORMAD1 siRNA were exposed to 































1. Stewart, B. W., et al. World cancer report 2014. 
2. "Cancer multidrug resistance." Nat Biotech. 
3. Swift, L. H. and R. M. Golsteyn (2014). "Genotoxic anti-cancer agents and their 
relationship to DNA damage, mitosis, and checkpoint adaptation in proliferating 
cancer cells." Int J Mol Sci 15(3): 3403-3431. 
4. Helleday, T., et al. (2008). "DNA repair pathways as targets for cancer therapy." 
Nat Rev Cancer 8(3): 193-204. 
5. Cheung-Ong, K., et al. (2013). "DNA-damaging agents in cancer chemotherapy: 
serendipity and chemical biology." Chem Biol 20(5): 648-659. 
6. Stansbury, K. H., et al. (2000). "Enzyme-mediated dialdehyde formation: an 
alternative pathway for benzo[a]pyrene 7,8-dihydrodiol bioactivation." Chem Res 
Toxicol 13(11): 1174-1180. 
7. Halliwell, B. (1991). "Reactive oxygen species in living systems: source, 
biochemistry, and role in human disease." Am J Med 91(3C): 14S-22S. 
8. Alt, A., et al. (2007). "Bypass of DNA lesions generated during anticancer 
treatment with cisplatin by DNA polymerase eta." Science 318(5852): 967-970. 
9. Santivasi, W. L. and F. Xia (2014). "Ionizing radiation-induced DNA damage, 
response, and repair." Antioxid Redox Signal 21(2): 251-259. 
10. Xu, Y. and C. Her (2015). "Inhibition of Topoisomerase (DNA) I (TOP1): DNA 
Damage Repair and Anticancer Therapy." Biomolecules 5(3): 1652-1670. 
11. Fan, Y., et al. (1998). "Molecular modeling studies of the DNA-topoisomerase I 
ternary cleavable complex with camptothecin." J Med Chem 41(13): 2216-2226. 
12. Raschle, M., et al. (2015). "DNA repair. Proteomics reveals dynamic assembly of 
repair complexes during bypass of DNA cross-links." Science 348(6234): 
1253671. 
13. O'Grady, S., et al. (2014). "The role of DNA repair pathways in cisplatin resistant 
lung cancer." Cancer Treat Rev 40(10): 1161-1170. 
14. Fuertes, M. A., et al. (2003). "Biochemical modulation of Cisplatin mechanisms of 
action: enhancement of antitumor activity and circumvention of drug resistance." 
Chem Rev 103(3): 645-662. 
 151 
15. Monte, M., et al. (2006). "MAGE-A tumor antigens target p53 transactivation 
function through histone deacetylase recruitment and confer resistance to 
chemotherapeutic agents." Proc Natl Acad Sci U S A 103(30): 11160-11165. 
16. Hartmann, S., et al. (2017). "MAGE-A11 expression contributes to cisplatin 
resistance in head and neck cancer." Clin Oral Investig. 
17. Duan, Z., et al. (2003). "Overexpression of MAGE/GAGE genes in 
paclitaxel/doxorubicin-resistant human cancer cell lines." Clin Cancer Res 9(7): 
2778-2785. 
18. Simpson, A. J., et al. (2005). "Cancer/testis antigens, gametogenesis and 
cancer." Nat Rev Cancer 5(8): 615-625. 
19. Doyle, J. M., et al. (2010). "MAGE-RING protein complexes comprise a family of 
E3 ubiquitin ligases." Mol Cell 39(6): 963-974. 
20. Chomez, P., et al. (2001). "An overview of the MAGE gene family with the 
identification of all human members of the family." Cancer Res 61(14): 5544-
5551. 
21. Forghanifard, M. M., et al. (2011). "Cancer-testis gene expression profiling in 
esophageal squamous cell carcinoma: identification of specific tumor marker and 
potential targets for immunotherapy." Cancer Biol Ther 12(3): 191-197. 
22. Daudi, S., et al. (2014). "Expression and immune responses to MAGE antigens 
predict survival in epithelial ovarian cancer." PLoS One 9(8): e104099. 
23. Li, X., et al. (2015). "Evaluation of melanoma antigen (MAGE) gene expression in 
human cancers using The Cancer Genome Atlas." Cancer Genet 208(1-2): 25-
34. 
24. Xie, C., et al. (2016). "Melanoma associated antigen (MAGE)-A3 promotes cell 
proliferation and chemotherapeutic drug resistance in gastric cancer." Cell Oncol 
(Dordr). 
25. Zou, C., et al. (2012). "Cancer-testis antigens expressed in osteosarcoma 
identified by gene microarray correlate with a poor patient prognosis." Cancer 
118(7): 1845-1855. 
26. Gao, Y., et al. (2016). "A neomorphic cancer cell-specific role of MAGE-A4 in 
trans-lesion synthesis." Nat Commun 7: 12105. 
27. Maxfield, K. E., et al. (2015). "Comprehensive functional characterization of 
cancer-testis antigens defines obligate participation in multiple hallmarks of 
cancer." Nat Commun 6: 8840. 
 152 
28. Fukuda, T., et al. (2012). "Phosphorylation of chromosome core components 
may serve as axis marks for the status of chromosomal events during 
mammalian meiosis." PLoS Genet 8(2): e1002485. 
29. Fukuda, T., et al. (2010). "A novel mammalian HORMA domain-containing 
protein, HORMAD1, preferentially associates with unsynapsed meiotic 
chromosomes." Exp Cell Res 316(2): 158-171. 
30. Pierce, A. J., et al. (1999). "XRCC3 promotes homology-directed repair of DNA 
damage in mammalian cells." Genes Dev 13(20): 2633-2638. 
31. Doil, C., et al. (2009). "RNF168 binds and amplifies ubiquitin conjugates on 
damaged chromosomes to allow accumulation of repair proteins." Cell 136(3): 
435-446. 
32. Franken, N. A., et al. (2006). "Clonogenic assay of cells in vitro." Nat Protoc 1(5): 
2315-2319. 
33. Guzman, C., et al. (2014). "ColonyArea: an ImageJ plugin to automatically 
quantify colony formation in clonogenic assays." PLoS One 9(3): e92444. 
34. Sinnott, R., et al. (2014). "Mechanisms promoting escape from mitotic stress-
induced tumor cell death." Cancer Res 74(14): 3857-3869. 
35. Hu, Q., et al. (2017). "Mechanisms of Ubiquitin-Nucleosome Recognition and 
Regulation of 53BP1 Chromatin Recruitment by RNF168/169 and RAD18." Mol 
Cell 66(4): 473-487 e479. 
36. Notenboom, V., et al. (2007). "Functional characterization of Rad18 domains for 
Rad6, ubiquitin, DNA binding and PCNA modification." Nucleic Acids Res 35(17): 
5819-5830. 
37. Saberi, A., et al. (2007). "RAD18 and poly(ADP-ribose) polymerase 
independently suppress the access of nonhomologous end joining to double-
strand breaks and facilitate homologous recombination-mediated repair." Mol 
Cell Biol 27(7): 2562-2571. 
38. Palle, K. and C. Vaziri (2011). "Rad18 E3 ubiquitin ligase activity mediates 
Fanconi anemia pathway activation and cell survival following DNA 
Topoisomerase 1 inhibition." Cell Cycle 10(10): 1625-1638. 
39. Weinstock, D. M., et al. (2006). "Modeling oncogenic translocations: distinct roles 
for double-strand break repair pathways in translocation formation in mammalian 
cells." DNA Repair (Amst) 5(9-10): 1065-1074. 
40. Weinstock, D. M., et al. (2006). "Assaying double-strand break repair pathway 
choice in mammalian cells using a targeted endonuclease or the RAG 
recombinase." Methods Enzymol 409: 524-540. 
 153 
41. Watkins, J., et al. (2015). "Genomic Complexity Profiling Reveals That 
HORMAD1 Overexpression Contributes to Homologous Recombination 
Deficiency in Triple-Negative Breast Cancers." Cancer Discov 5(5): 488-505. 
42. Yang, B., et al. (2007). "MAGE-A, mMage-b, and MAGE-C proteins form 
complexes with KAP1 and suppress p53-dependent apoptosis in MAGE-positive 
cell lines." Cancer Res 67(20): 9954-9962. 
43. Yang, B., et al. (2007). "Select cancer testes antigens of the MAGE-A, -B, and -C 
families are expressed in mast cell lines and promote cell viability in vitro and in 
vivo." J Invest Dermatol 127(2): 267-275. 
44. Sasaki, A., et al. (2002). "A RING finger protein Praja1 regulates Dlx5-dependent 
transcription through its ubiquitin ligase activity for the Dlx/Msx-interacting 
MAGE/Necdin family protein, Dlxin-1." J Biol Chem 277(25): 22541-22546. 
45. Marcar, L., et al. (2015). "MAGE-A Cancer/Testis Antigens Inhibit MDM2 
Ubiquitylation Function and Promote Increased Levels of MDM4." PLoS One 
10(5): e0127713. 
46. Espantman, K. C. and C. C. O'Shea (2010). "aMAGEing new players enter the 
RING to promote ubiquitylation." Mol Cell 39(6): 835-837. 
47. Wang, X., et al. (2004). "Functional interaction of monoubiquitinated FANCD2 
and BRCA2/FANCD1 in chromatin." Mol Cell Biol 24(13): 5850-5862. 
48. Song, I. Y., et al. (2010). "Rad18-mediated translesion synthesis of bulky DNA 
adducts is coupled to activation of the Fanconi anemia DNA repair pathway." J 
Biol Chem 285(41): 31525-31536. 
49. Yousefzadeh, M. J., et al. (2014). "Mechanism of suppression of chromosomal 
instability by DNA polymerase POLQ." PLoS Genet 10(10): e1004654. 
50. Wyatt, D. W., et al. (2016). "Essential Roles for Polymerase theta-Mediated End 
Joining in the Repair of Chromosome Breaks." Mol Cell 63(4): 662-673. 
51. Heyer, W. D., et al. (2010). "Regulation of homologous recombination in 
eukaryotes." Annu Rev Genet 44: 113-139. 
52. Weon, J. L. and P. R. Potts (2015). "The MAGE protein family and cancer." Curr 
Opin Cell Biol 37: 1-8. 
53. Hill, S. J., et al. (2014). "Systematic screening reveals a role for BRCA1 in the 




CHAPTER 5: DISCUSSION 
 
  Mutagenesis is a hallmark of cancer that not only incites carcinogenesis and 
promotes tumor progression, but can also lead to the development of chemotherapeutic 
resistance1-3. Mutations can occur when DNA damage (from endogenous, 
environmental or medicinal sources) interferes with DNA synthesis, causing replication 
errors. Cells undergoing multi-step tumorigenesis depend on DNA damage tolerance to 
survive intrinsic oncogenic stresses (e.g. reactive oxygen species) and environmental 
carcinogenic exposures (e.g. solar ultraviolet (UV) radiation)4, 5. Importantly, the DNA 
damage tolerance acquired during tumorigenesis also endows cancer cells with 
resistance to chemotherapeutic drugs (e.g. platinating agents)6 (Fig. 5.1). Elucidating 
mechanisms of DNA damage tolerance and mutagenesis will allow us to better 
understand tumor progression and develop superior treatments for the disease.  
We have identified several proteins that influence cancer cell survival through 
tolerance of genotoxic injury. Our first two discoveries uncover two novel regulators ( 
MAGEA4 and RNF168) of RAD18, a prominent activator of DNA damage tolerance via 
error-prone Trans-lesion Synthesis (TLS) and error-free Template Switching (TS). 
MAGEA4 belongs to a group of genes termed Cancer/Testis Antigens (CTA), that are 
absent from normal somatic cells but are abnormally expressed in many neoplastic 
cells7,while RNF168 is, canonically, a double strand break (DSB) repair signaling 
protein that is mutated in human RIDDLE syndrome, a genetic disease characterized by 
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severe immunodeficiency, developmental defects, radiosensitivity and a 
predisposition to cancer8. 
We show here that MAGEA4 is a stabilizing binding partner of RAD18 that is able to 
promote DNA damage tolerance through TLS9 and further identify a novel, DSB repair-
independent role for RNF168 in promoting replication-associated DNA damage 
tolerance through RAD18 in a manner that is consistent with TS. Interestingly, RNF168 
is also overexpressed in many cancers, emphasizing the importance of tightly controlled 
regulation of DNA damage tolerance pathways where both aberrant activation and 
deficiency contribute to mutagenesis. Together, these results provide a greater insight 
as to how aberrant RAD18 activation through MAGEA4 and RNF168 contribute to 
pathological DNA damage tolerance in cancer.  
CTAs were first discovered nearly three decades ago and immediately identified as 
a promising candidate for cancer cell-specific therapy10-12. Since their discovery, 
expression of CTAs has been correlated with increased tumor incidence and size, 
metastasis, and poor prognostic outcomes13-16. More recently, several publications have 
suggested that CTAs may promote resistance to DNA-damaging therapeutics, however 
information regarding the mechanistic contributions of CTAs to chemoresistance is 
severely lacking17-19.  
The third major contribution to carcinogenesis that we describe is that several 
additional CTAs (MAGEA4 as well as MAGEA10 and HORMAD1) directly promote 
resistance to DNA-damaging chemotherapeutics. This work may lead to novel 
treatments that specifically target damage tolerance mediators in cancer cells, thereby 
enhancing the efficacy and reducing the liabilities of current chemotherapeutics.  
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5.1 RNF168 promotes replication-associated DNA damage tolerance via RAD18 
Defects in proteins utilized for DNA repair and genome maintenance are associated 
with severe genetic diseases and cancer. Chromatin modification can significantly alter 
access of DNA damage response machinery to lesion sites and thus, defects in 
chromatin modifiers have been linked with a predisposition to cancer20. We have 
identified the RIDDLE syndrome and histone-modifier protein RNF168 as a novel 
mediator of DNA damage tolerance in response to replication-associated stress. 
Lesions encountered during DNA replication can be particularly problematic as they stall 
the replication fork and can lead to the development of unstable, mutagenesis-prone 
structures, or cell death. We discovered that RNF168 localizes to replication factories 
following treatment with fork-stalling agents.  RNF168 was also revealed as a unique 
component of the RAD18:RAD6 complex. RAD18 is a key mediator of several DNA 
damage tolerance pathways (e.g. TLS and TS) and was found to redistribute to 
replication forks following RNF168-dependent substrate ubiquitination. RNF168 was 
also found to promote poly-ubiquitination of the DNA polymerase processivity factor, 
PCNA, in an intrinsic ligase activity-independent manner when RAD18 is present. While 
RAD18 has been shown to promote HLTF/SHPRH-mediated poly ubiquitination to 
initiate template switching, RAD18 itself does not poly-ubiquitinate PCNA21. Depletion of 
RNF168 also reduced levels of HLTF on the chromatin and reduced the amount of 
RAD18-bound HLTF, suggesting a potential novel role for RNF168 in TS that should be 
further investigated in future studies.  
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RNF168-depletion was also found to reduce recruitment of TLS polymerase η to UV-
induced lesions - a high-fidelity substrate of Pol η and loss of RNF168 in UV-irradiated 
cells lead to prolonged replication fork stalling and the generation of vulnerable, single-
stranded DNA. Consistently, in a reciprocal experiment, RNF168 overexpression 
diminished UV-induced mutagenesis. These results support a potential role for RNF168 
in altering RAD18-mediated DNA damage tolerance via TS. Future work should explore 
whether blocking RNF168-mediated K63 linked poly-ubiquitin chain formation is able to 
increase UV-induced mutagenesis to determine if RNF168-mediated poly-ubiquitination 
of H2A/H2AX or a new substrate is contributing to UV tolerance22.  
It is now clear that initiation of template switching requires both PCNA poly-
ubiquitination and SUMOylation23, 24. Important next steps should include examining 
how other post-translational modifications (as well as negative regulators of post-
translational modifications) cooperate in regulating DNA damage tolerance 
mechanisms25-27.  
 
5.2 Novel role for MAGEA4 in trans-lesion DNA synthesis 
Trans-lesion synthesis is a low-fidelity DNA damage tolerance process that allows 
replication of damaged DNA (e.g. from environmental agents like solar radiation or 
chemotherapeutics such as Cisplatin) at the expense of increased mutagenesis. While 
TLS is postulated to mediate mutagenesis in neoplastic cells, the full contribution of TLS 
to carcinogenesis remains largely unexplored. We have identified a novel mechanism 
by which cancer cells utilize a germ cell protein to reprogram and enhance DNA 
damage tolerance and mutagenesis pathways. Several cancer cell lines rely on 
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MAGEA4 to stabilize the E3 ubiquitin ligase and DNA damage tolerance mediator, 
RAD18. By sustaining RAD18 levels, MAGEA4 promotes recruitment of Pol η to 
chromatin to resume DNA synthesis following UV irradiation, thus preventing the 
accumulation of DNA double stranded breaks. Further, MAGE-A4-depleted cells 
recapitulate many hallmarks observed in TLS-deficient cells  (e.g. delayed recovery 
from replication fork-stalling lesions), suggesting that MAGE-A4-RAD18 interactions 
promote trans-lesion synthesis in neoplastic cells. 
TLS polymerases are highly error prone and must be used sparingly to prevent 
mutagenesis. Previous results from our lab and others have identified lesion-specific 
roles of distinct TLS polymerases in conferring tolerance to different genotoxins28-30. In 
fact, the TLS polymerases also have distinct dependencies on ub-PCNA; e.g. Polη is 
less dependent than Polκ)31, 32. Thus, recruitment of certain TLS polymerases may be 
more affected by MAGEA4-induced ub-PCNA. Because excess TLS activity can 
produce mutations, any imbalance stemming from MAGEA4 expression will have 
profound implications for mechanisms of mutagenesis in response to different 
exposures. Future studies should determine the extent to which MAGEA4-RAD18 
drives inappropriate recruitment of TLS polymerases during a normal cell cycle cells 
and under conditions with extensive replication fork-stalling. The identification of specific 
damaging agents or inter-individual polymorphisms in MAGEA4, RAD18, or other DNA 
damage tolerance genes that influence propensity for mutagenesis will also greatly 
enhance our understanding of how to leverage these pathways for therapeutic benefit. 
Several studies have demonstrated a role for TLS in conferring chemoresistance in 
tumors. In defining MAGEA4-RAD18 as a mediator of DNA damage tolerance and 
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mutagenesis we also identify a new therapeutic target that is present only in cancer 
cells and thus its inhibition would be innocuous to normal tissue.  
 
5.3 The Cancer/Testis Antigens MAGEA4, MAGEA10, and HORMAD1 promote 
chemoresistance in cancer cells  
Owing to their tumor-specific expression, CTA proteins have received attention 
primarily because they represent potential targets for more specific cancer therapies. 
We have identified novel roles for CTAs in the promotion of resistance to traditional 
therapies used in the treatment of Non Small Cell Lung Cancer (NSCLC). 
We show here that MAGEA4 loss sensitized H1299 lung adenocarcinoma cells to 
treatment with agents used in the treatment of NSCLC (ionizing radiation (IR), 
Camptothecin, Cisplatin, Doxorubicin and Etoposide). All of these agents induce DNA 
lesions that are normally handled by homologous recombination (HR). Interestingly, 
MAGEA4 depletion did not sensitize H1299 cells to paclitaxel, a mitotic spindle poison 
that blocks normal progression through mitosis. MAGEA4 promotes both RAD18-
dependent and independent mechanisms of chemoresistance. Both MAGEA4 and 
RAD18 loss sensitize NSCLC cells to Cisplatin and Etoposide, pathways that employ 
the use of the Fanconi Anemia pathway. Indeed, MAGEA4 loss reduces recruitment of 
FANCD2 (a mediator of the Fanconi Anemia pathway). Following IR treatment, 
individual MAGEA4 and RAD18 depletion, sensitized H1299 levels to a similar extent, 
however, co-depletion exacerbated this effect, suggesting that the two proteins are not 
acting in the same pathway to mediate radioresistance. MAGEA10 loss sensitized 
NSCLC cells to DSB induced by ionizing radiation and topoisomerase II inhibitors, but 
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not to Cisplatin or Camptothecin (data not shown). Finally, both MAGEA4 and 
MAGEA10 loss increased rates of recombination seen by DR-GFP, suggesting that 
MAGEA4/10-mediated resistance to cancer therapies may be mediated through a DNA 
repair mechanism.  
The MAGE proteins lack any known enzymatic activity and are therefore presumed 
to function as adaptors or mediators. Thus, an important next step should employ 
affinity purification and mass spectrometry to define MAGE-dependent interaction 
networks both basally and following treatment with a DNA-damaging chemotherapeutic. 
An interesting control in these studies would be to include the MAGE-homology domain 
(MHD), ~170 amino acid region that is highly conserved amongst MAGE family 
members7. DNA damage tolerance mediators that are able to bind multiple full-length 
MAGE proteins (and isolated MHD) may substantiate utilizing the MHD in a small 
molecule inhibitor screen to more broadly target MAGEs in cancer. Future studies 
should also include the direct determination of the contribution of CTAs to repair of 
therapy-induced DNA lesions (e.g. via Comet Assay).  
 Hyperactive DNA repair is one of the mechanisms for acquired chemoresistance. A 
2013 study by the Jacks group found that chronic cisplatin treatment enhances DNA 
repair and tumor progression in a mouse model of lung cancer33. MAGE expression has 
been linked to poor outcomes in patients with NSCLC, thus an important next step is to 
examine the contribution of CTAs to chemoresistance in vivo34. Although some studies 
have suggested a link between CTA expression and chemoresistance, the direct effect 
of MAGEs on chemoresistance has not been investigated in vivo, nor have any CTA 
transgenic mice been reported to date. Our lab has developed the first known 
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transgenic MAGEA4 mouse that conditionally expresses MAGEA4 at the Rosa26 locus. 
We will use this mouse in a preclinical model to look at the contribution of MAGEA4 to 
chemoresistance in lung cancer. In a pilot experiment with a small cohort of mice we 
have confirmed MAGEA4 expression in tumors from Rosa26+/MAGEA4 LSL-Kris+/G12D 
mice35, 36 (Fig. 5.2). Using this model, we will be able to determine the impact of Cree-
induced MAGEA4 expression on resistance to chemotherapeutics used in the treatment 
of NSCLC in vivo. 
Our studies have also identified a role for the CTA HORMAD1 in promoting HR and 
radioresistance in NSCLC. Depletion of HORMAD1 sensitizes NSCLC cells, but not 
triple negative breast cancer cells, to ionizing radiation. However, relative expression 
levels may indicate reliance on HORMAD1 for radioresistance. HORMAD1 forms 
irradiation-induced foci that co-localize with γH2AX, which was also identified as a novel 
binding partner. HORMAD1 loss reduced rates of recombination by DR-GFP and 
abrogated recruitment of RAD51 to DSB. These findings are the first report of a cancer 
cell-specific mechanism for therapy resistance by HORMAD1 that might be exploitable 
for therapy. Future studies should further delineate the mechanistic roles between 
HORMAD1 and its known HR-affiliated binding partners (BRCA1) to generate an 
interaction network with and without IR treatment37.  
Arguably, the most important contribution of this research is the potential for 
development of new, cancer-cell specific therapies. To drive the discovery of small 
molecules that may interrupt CTA function, we have developed an AlphaScreen 
(Amplified Luminescent Proximity Homogeneous Assay Screen) for the MAGE:RAD18 
interaction (Fig. 5.3). The AlphaScreen is a high-throughput proximity assay that uses 
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anti-affinity tag beads to measure the binding interaction of tagged proteins and can be 
used as a platform for screening small molecules inhibitors of the MAGEA4:RAD18 
interaction. Importantly, this platform can be adapted to accommodate future CTA:DNA-
repair-factor protein:protein interactions. Due to the inherent cancer cell-specific 
expression of CTAs, these interactions represent untapped therapeutic targets whose 
inhibition would selectively sensitize cancer cells to therapy-induced DNA damage. 
Therefore, our work could eventually validate multiple CTA:DNA-repair-factor 
interactions as new therapeutic targets and facilitate the development of small molecule 
inhibitors to be used in a personalized medicine based treatment regimen that is 
informed by the CTA expression profile of the patient.  
 
5.4 Concluding remarks 
DNA damage tolerance is critical for multi-step carcinogenesis, allowing cancer cells 
to proliferate, adapt, invade and resist treatment. Determining how cancer cells adapt to 
tolerate environmental, endogenous, and therapy-induced DNA damage will expose 
molecular vulnerabilities that can be used to improve cancer prevention and treatment. 
We have identified several mediators of DNA damage tolerance (RNF168, MAGEA4, 
and HORMAD1) that will help us better understand how dysregulation of DNA repair in 
cancer cells can drive carcinogenesis, allowing cancer cells to proliferate, adapt, invade 
and resist chemotherapy. We have also identified multiple cancer cell-specific proteins 
that promote resistance to commonly used cancer therapies (MAGEA4, MAGEA10, and 
HORMAD1) offering exciting potential candidates for targeted therapies that may 
ultimately improve patient outcomes.  
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Figure 5.2 MAGEA4 as a mediator of chemoresistance in a pre-clinical mouse 
model of lung cancer 
 
H&E-staining (A) and MAGEA4 staining (brown) (B) in a representative lung tumor from 
a LSL-KrasG12D/+ Rosa26+/MAGEA4 mouse. (C) and (D) show automated analyses 










Figure 5.3 AlphaScreen platform to screen for small molecule inhibitors of 
CTA:DNA repair factor interactions 
 
(A) Schematic of AlphaScreen assay 


















































0 0.5 1 10 50 100 250
AlphaScreen Platform for High-Throughput Screening





1. Watson, I. R., et al. (2013). "Emerging patterns of somatic mutations in cancer." 
Nat Rev Genet 14(10): 703-718. 
2. Roach, J. C., et al. (2010). "Analysis of genetic inheritance in a family quartet by 
whole-genome sequencing." Science 328(5978): 636-639. 
3. Loeb, L. A. (2011). "Human cancers express mutator phenotypes: origin, 
consequences and targeting." Nat Rev Cancer 11(6): 450-457. 
4. Valko, M., et al. (2004). "Role of oxygen radicals in DNA damage and cancer 
incidence." Mol Cell Biochem 266(1-2): 37-56. 
5. Hendel, A., et al. (2008). "Reduced efficiency and increased mutagenicity of 
translesion DNA synthesis across a TT cyclobutane pyrimidine dimer, but not a 
TT 6-4 photoproduct, in human cells lacking DNA polymerase eta." DNA Repair 
(Amst) 7(10): 1636-1646. 
6. Alt, A., et al. (2007). "Bypass of DNA lesions generated during anticancer 
treatment with cisplatin by DNA polymerase eta." Science 318(5852): 967-970. 
7. Doyle, J. M., et al. (2010). "MAGE-RING protein complexes comprise a family of 
E3 ubiquitin ligases." Mol Cell 39(6): 963-974. 
8. Stewart, G. S., et al. (2009). "The RIDDLE syndrome protein mediates a 
ubiquitin-dependent signaling cascade at sites of DNA damage." Cell 136(3): 
420-434. 
9. Gao, Y., et al. (2016). "A neomorphic cancer cell-specific role of MAGE-A4 in 
trans-lesion synthesis." Nat Commun 7: 12105. 
10. van der Bruggen, P., et al. (1991). "A gene encoding an antigen recognized by 
cytolytic T lymphocytes on a human melanoma." Science 254(5038): 1643-1647. 
11. Traversari, C., et al. (1992). "Transfection and expression of a gene coding for a 
human melanoma antigen recognized by autologous cytolytic T lymphocytes." 
Immunogenetics 35(3): 145-152. 
12. Knuth, A., et al. (1989). "Cytolytic T-cell clones against an autologous human 
melanoma: specificity study and definition of three antigens by immunoselection." 
Proc Natl Acad Sci U S A 86(8): 2804-2808. 
13. Zou, C., et al. (2012). "Cancer-testis antigens expressed in osteosarcoma 
identified by gene microarray correlate with a poor patient prognosis." Cancer 
118(7): 1845-1855. 
 167 
14. Li, X., et al. (2015). "Evaluation of melanoma antigen (MAGE) gene expression in 
human cancers using The Cancer Genome Atlas." Cancer Genet 208(1-2): 25-
34. 
15. Forghanifard, M. M., et al. (2011). "Cancer-testis gene expression profiling in 
esophageal squamous cell carcinoma: identification of specific tumor marker and 
potential targets for immunotherapy." Cancer Biol Ther 12(3): 191-197. 
16. Daudi, S., et al. (2014). "Expression and immune responses to MAGE antigens 
predict survival in epithelial ovarian cancer." PLoS One 9(8): e104099. 
17. Monte, M., et al. (2006). "MAGE-A tumor antigens target p53 transactivation 
function through histone deacetylase recruitment and confer resistance to 
chemotherapeutic agents." Proc Natl Acad Sci U S A 103(30): 11160-11165. 
18. Hartmann, S., et al. (2017). "MAGE-A11 expression contributes to cisplatin 
resistance in head and neck cancer." Clin Oral Investig. 
19. Xie, C., et al. (2016). "Melanoma associated antigen (MAGE)-A3 promotes cell 
proliferation and chemotherapeutic drug resistance in gastric cancer." Cell Oncol 
(Dordr). 
20. Raschle, M., et al. (2015). "DNA repair. Proteomics reveals dynamic assembly of 
repair complexes during bypass of DNA cross-links." Science 348(6234): 
1253671. 
21. Hibbert, R. G., et al. (2011). "E3 ligase Rad18 promotes monoubiquitination 
rather than ubiquitin chain formation by E2 enzyme Rad6." Proc Natl Acad Sci U 
S A 108(14): 5590-5595. 
22. Chiu, R. K., et al. (2006). "Lysine 63-polyubiquitination guards against translesion 
synthesis-induced mutations." PLoS Genet 2(7): e116. 
23. Stelter, P. and H. D. Ulrich (2003). "Control of spontaneous and damage-induced 
mutagenesis by SUMO and ubiquitin conjugation." Nature 425(6954): 188-191. 
24. Hoege, C., et al. (2002). "RAD6-dependent DNA repair is linked to modification of 
PCNA by ubiquitin and SUMO." Nature 419(6903): 135-141. 
25. Kashiwaba, S., et al. (2015). "USP7 Is a Suppressor of PCNA Ubiquitination and 
Oxidative-Stress-Induced Mutagenesis in Human Cells." Cell Rep 13(10): 2072-
2080. 
26. Huang, T. T., et al. (2006). "Regulation of monoubiquitinated PCNA by DUB 
autocleavage." Nat Cell Biol 8(4): 339-347. 
27. Gallego-Sanchez, A., et al. (2012). "Reversal of PCNA ubiquitylation by Ubp10 in 
Saccharomyces cerevisiae." PLoS Genet 8(7): e1002826. 
 168 
28. Avkin, S., et al. (2004). "Quantitative analysis of translesion DNA synthesis 
across a benzo[a]pyrene-guanine adduct in mammalian cells: the role of DNA 
polymerase kappa." J Biol Chem 279(51): 53298-53305. 
29. Shachar, S., et al. (2009). "Two-polymerase mechanisms dictate error-free and 
error-prone translesion DNA synthesis in mammals." EMBO J 28(4): 383-393. 
30. Ziv, O., et al. (2009). "DNA polymerase zeta cooperates with polymerases kappa 
and iota in translesion DNA synthesis across pyrimidine photodimers in cells 
from XPV patients." Proc Natl Acad Sci U S A 106(28): 11552-11557. 
31. Bi, X., et al. (2005). "DNA polymerase kappa is specifically required for recovery 
from the benzo[a]pyrene-dihydrodiol epoxide (BPDE)-induced S-phase 
checkpoint." J Biol Chem 280(23): 22343-22355. 
32. Acharya, N., et al. (2008). "Roles of PCNA-binding and ubiquitin-binding domains 
in human DNA polymerase eta in translesion DNA synthesis." Proc Natl Acad Sci 
U S A 105(46): 17724-17729. 
33. Oliver, T. G., et al. (2010). "Chronic cisplatin treatment promotes enhanced 
damage repair and tumor progression in a mouse model of lung cancer." Genes 
Dev 24(8): 837-852. 
34. Gure, A. O., et al. (2005). "Cancer-testis genes are coordinately expressed and 
are markers of poor outcome in non-small cell lung cancer." Clin Cancer Res 
11(22): 8055-8062. 
35. Singh, M., et al. (2010). "Assessing therapeutic responses in Kras mutant 
cancers using genetically engineered mouse models." Nat Biotechnol 28(6): 585-
593. 
36. Jackson, E. L., et al. (2001). "Analysis of lung tumor initiation and progression 
using conditional expression of oncogenic K-ras." Genes Dev 15(24): 3243-3248. 
37. Hill, S. J., et al. (2014). "Systematic screening reveals a role for BRCA1 in the 
response to transcription-associated DNA damage." Genes Dev 28(17): 1957-
1975. 
 
 
